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vB. List of Figures
Figure 1: This figure demonstrates the sequence of events leading to colon cancer from
normal colon. In figure 1A, the sequence taking place in Familial adenomatous polyposis
syndrome and majority sporadic cases is shown. The sequence depicted in Figure 1B,
demonstrates the events in hereditary non-polyposis colorectal cancer syndrome and
remaining sporadic cases.
Figure 2: This figure demonstrates the canonical Wnt / -catenin signalling pathway.
Under normal circumstances, (Figure 2A) GSK3-phosphorylates -catenin, inducing
the later to undergo proteasomal degradation. However, if this phosphorylation is
inhibited (Figure 2B) by Wnt signalling pathway (via activated frizzled and dishevelled
respectively), -catenin translocates in the nucleus, replaces protein Groucho (from
Groucho-TCF4 complex) to form a complex with TCF-4. This molecular complex is an
active transcription factor and is responsible for inducing several proteins related to cell
proliferation.
Figure 3: This figure demonstrates the mechanisms by which K-ras activates several
transcription factors like AP1, elk1, c-jun – c-fos complex and c-myc to promote cell
proliferation through activation of Raf-Kinase and inhibits apoptosis, prevents
proteasomal degradation of -catenin and induces proteins related to cell proliferation
through activation of akt-kinase.
Figure 4: This figure demonstrates the anti-carcinogenic roles of TGF-in colon cancer
by promoting cell cycle arrest at G1 phase and apoptosis.
Figure 5: This figure demonstrates mechanisms related to the regulation of p53 and its
anti carcinogenic role by inhibiting anti- apoptotic factors (bcl-2, surviving and bcl-xn)
and promoting proteasomal degradation of -catenin.
Figure 6A: Mechanisms related to Non-steroidal anti-inflammatory drugs mediating 15-
lipoxygenase-1 induced apoptosis are demonstrated in this figure.
Figure 6B: This figure demonstrates the effects of PPAR and 15-LOX-1 in colon cancer.
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Figure 6C: This figure shows 15-lipoxygenase induced apoptosis dependent on p53,
p21 and NAG-1.
Figure 7: This figure demonstrates the toponome imaging system used for performing
these experiments with colon cancer and normal colon. Numbered arrows are used to
identify the important components:
1. Buffer tray covered by thin aluminium foil, to be pierced by the pipette tip.
2. Antibody tray, to be filled with antibody solutions of specified dilutions.
3. Pipette tip attached to the end of the robot arm.
4. Camera attached to the side port.
5. Microscope
6. Glass slide for the tissue section.
7. Touch panel control for microscope.
Figure 8: Figures showing results from optimisation runs. Figure 8a shows a section of
colon cancer where antibodies did not localise any proteins due to low concentration
during optimisation. Figure 8b shows complete white out image due to much higher
concentration of antibody Ki67 used on a colon cancer specimen. Figure 8c shows an
artefact with false fluorescence. Of note, these artefacts can result in false staining.
Figure 8d demonstrates unopened shutter, a problem encountered during TIS runs in
Warwick. Figure 8e shows a blurred phase image, possible causes being unco-
ordinated shutter opening or mal-positioned condenser of the microscope or moving
stage while imaging process in going on. Figure 8f shows artefact and blurring of phase
image due to auto-focussing on the artefact rather than on the tissue section
Figure 9: Phase (unstained) and OF (post fluorescent) images from the 21 tags used on
cancer tissue. The last image is of an adjacent section from the same cancer tissue
block stained with routine H&E to demonstrate cancer in the tissue.
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Figure Antibody/Tag/Description Figure Antibody/Tag/Description
a Phase image m Cyclin A
b PBS, post bleaching n CEA
c DAPI o CD166
d Laminin p PCNA
e CK-19 q CD44
f NCAM r Muc-2
g CD36 s Muc-1
h CK-20 t CD29
i Ki67 u CD57
j Bax v CD133
k Bcl-2 w EpCAM
l Cyclin D1 x H&E image of adjacent section
from same cancer colon tissue
block.
Figure 10: Phase and OF (post fluorescent) images of normal tissue. The last image is
of an adjacent section from the same normal tissue block stained with routine H&E to
demonstrate absence of cancer in the tissue.
Figure Antibody/Tag/Description Figure Antibody/Tag/Description
a Phase image m Cyclin A
b PBS, post bleaching n CEA
c DAPI o CD166
d Laminin p PCNA
e CK-19 q CD44
f NCAM r Muc-2
g CD36 s Muc-1
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h CK-20 t CD29
i Ki67 u CD57
j Bax v CD133
k Bcl-2 w EpCAM
l Cyclin D1 x H&E image of adjacent section
from same normal colon tissue
block.
Figure 11: Glandular structure in: colon cancer (figure a, phase contrast and b, DAPI)
and normal colon: (figure c, phase contrast and d, DAPI). The cell cytoskeleton, marked
by CK-19 and CK-20, is disrupted in colon cancer (figures a and b) and clumped in the
perinuclear area (figure b). In contrast, in normal colon the cell cytoskeleton is much
more evenly distributed (figure c and d).
Figure 12: Subset of colon cancer cells identified by CMPs. Cells marked by CMPs with
lead proteins; CD133, CD44, EpCAM and CD166 in the top row (a and b) and cells
marked by all the CMPs with CD166, CD44 and EpCAM as lead proteins in the middle
row (c and d) in cancer tissue. The CMPs in the top row have been shown by black
arrows and those in the middle row by white arrows. The bottom row (figure e, f and g)
shows magnified views of all CMPs from figure c. All the CMPs in the top and middle
sections have CD133 co-expressed along with CD166, CD44 and EpCAM, except the
single cell (CMP=colour purple) towards the centre of the middle row of images (c and
d). This cell is magnified in figure g in the bottom row.
Figure 13: Schematic diagram indicating CMP motifs specific for glandular cells and
stromal cells in colon cancer (in 13A) and normal colon (in 13B). The proteins are
indicated by numbers as in the table in the bottom right hand corner. The inner circle
shows proteins (highlighted in red) which are lead proteins. The outer circle shows the
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other proteins in the motif, the ones highlighted in yellow are anti-colocalised or absent
and the rest are variably present (wild card proteins).
Figure 14: Illustration of the 15 most frequent CMPs which are unique to normal
colon (not seen in the cancerous part of the same colon).
Figure 15: Illustration of the 15 most frequent CMPs which are unique to colon
cancer (not seen in the normal part of the same colon).
In Figures 14 and 15, each colour represents one specific CMP with subcellular
resolution. The left panel shows CMPs superimposed on the phase contrast image; the
right panel shows the same CMPs superimposed on the corresponding DAPI
fluorescence image showing the location of cellular nuclei (white). Note the CMP coding
list shown on the bottom of this figure with (i) specification of molecules co-mapped by
TIS (top line no.´s 1 – 21 of the list), (ii) colour specification of CMPs, in which every
CMP expresses a unique combinatorial binary code (1 bit information per
protein/molecule) corresponding to the colours in the phase- and DAPI- images; (iii)
CMP motifs (bottom line of the list). This CMP motif represents the higher order
organisation of the 15 different CMPs as a group with features common to all CMPs
described by a three symbol code1: L, lead protein/molecule (present in all CMPs); A
(proteins/molecules which are absent in all CMPs = anticolocated); W (wild card
proteins/molecules variably associated with the L and A molecules of CMPs). Bar: 10
µm.
Figure 16: 1st row; All 34 Cancer unique CMPs in phase (a) and DAPI (b) images, with
following lead proteins: CD133, CD166, EpCAM, CK-20 and Muc-1. Of note, these cells
also co-express Ki67, PCNA, Bax, Bcl-2 and Cyclin-A. 2nd row; CMPs in 1st row images
are magnified in phase (c) and DAPI (d) images.
xC. List of Tables
Table 1: List of all the antibodies with their locus link annotations, used in their order in
the original experiments.
Table 2: List of the 34 “unique” CMPs present in cancer with following lead proteins:
CD133, CD166, EpCAM, Muc-1, Laminin, CD57 and CK-20. The cells marked by these
CMPs also expressed Ki67, PCNA, Bax, Bcl-2 and Cyclin-A. Respective colour codes
are shown by the sides of each CMP. Of note, CD133, CD166 and EpCAM are putative
colon cancer stem cell markers.
Table 3: List of 25 most frequent CMPs found in stromal cells in colon cancer with
individual colour codes. Of note, the lead proteins (L) are CD57, Laminin and PCNA.
Proteins CD29, CD36, CEA, CK-19, Muc2, Muc1 and NCAM were found to be (A) anti-
co localised and rest of the proteins were wild cards (W) and hence variably expressed.
A schematic diagram is provided in Figure 13 to illustrate this.
Table 4: List of 29 most frequent CMPs found in neoplastic glandular cells in colon
cancer with individual colour codes. Of note, the lead proteins are CEA, EpCAM, CK20
and Ki67. Proteins CD36 and CD44 were found to be anti-co localised and rest of the
proteins were wild cards and hence variably expressed. A schematic diagram is
provided in Figure 13 to illustrate this.
Supplementary Tables:
Supplementary Table 1: Complete list of all CMPs in cancer colon. Each horizontal row
represents a CMP. The top row contains the names of the antibody tags used and the
last column on the right depicts the relative frequencies of the respective CMPs. Total
CMPs in this list = 6813
Supplementary Table 2: Complete list of all CMPs in normal colon. Each horizontal row
represents a CMP. The top row contains the names of the antibody tags used and the
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last column on the right depicts the relative frequencies of the respective CMPs. Total
CMPs in this list = 32009. Of note, the list is almost five times that of cancer.
Supplementary Table 3: Complete list of all CMPs unique in cancer. Each horizontal
row represents a CMP. The top row contains the names of the antibody tags used and
the last column on the right depicts the relative frequencies of the respective CMPs.
Total CMPs in this list = 5708.
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F. Summary
Introduction
In a proof of principle study, we have applied an automated fluorescence toponome
imaging system (TIS) in order to examine, whether TIS can find protein network
structures distinguishing cancerous from normal colon tissue from same patient.
Methods/Materials
Cancer specimen and corresponding normal tissue were harvested at colectomy from a
single patient. m sections were then prepared for TIS using a battery of different
antibodies, including a number of putative CSC markers. Expression of multiple protein
clusters was determined and Combinatorial Molecular Phenotypes (CMPs) were
analysed, using specific image-analysis tools.
Results
By using a three symbol code and a power of combinatorial molecular discrimination
(PCMD) of 221 per sub-cellular data point in one single tissue section, we demonstrate
an in situ protein network structure, visualized as a mosaic of 6,813 protein clusters
(Combinatorial molecular phenotype or CMPs) in the cancerous part of the colon. By
contrast, in the histologically normal colon, TIS identifies nearly 5 times the number of
protein clusters as compared to the cancerous part (32,009).
Discussion and Conclusion
By sub-cellular visualization procedures we found, that many cell surface membrane
molecules were closely associated with the cell cytoskeleton as unique CMPs in the
normal part of the colon, while the same molecules were disassembled in the cancerous
part, suggesting presence of dysfunctional cytoskeleton-membrane complexes. As
expected, glandular and stromal cell signatures were found, but interestingly also
potentially TIS signatures identifying a very restricted subset of cells expressing several
putative stem cell markers, all restricted to the cancerous tissue. The detection of these
signatures is based on the extreme searching depth, high degree of dimensionality, and
xvi
sub-cellular resolution capacity of TIS. These findings provide the technological rationale
for the feasibility of a complete colon cancer toponome to be established by massive
parallel high throughput/high content TIS mapping.
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H. Definitions:
Toponome: Toponome is derived from the Greek word Topos (Place) nomos (Law). It is
defined as the entirety of protein network in a cell, the final phase of protein interaction,
deciding cellular characteristics.
CMP: Combinatorial Molecular Phenotype, also referred as Combinatorial Protein
Pattern (CPP), is the smallest unit of Toponome. Each such CMP represents a
combination or cluster of proteins per data point in the visual field.
CMP motif: A combination of CMPs which share any unique character, for example
present or absent in a particular state (normal versus cancer) in a particular structure
(glandular structures versus stromal cells), forms a motif.
Lead protein: In a CMP motif, the protein(s) which are present in all the CMPs is / are
termed as Lead Protein(s).
Anticolocalised protein: In a CMP motif, the protein(s) which are absent in all the
CMPs is / are termed as Anti-colocalised Protein(s).
Wild Card protein: In a CMP motif, most of the proteins are present in some CMPs but
absent in others. These variably expressed proteins are termed as Wild Card Proteins.
Three symbol code: A three symbol code is a way to describe a CMP motif by its Lead
Protein(s), Anticolocalised Protein(s) and Wild Card proteins, thus represented by letters
L, A and W respectively.
1CHAPTER 1
1.1. INTRODUCTION
Colorectal cancer is responsible for a major proportion of cancer related mortality in the
western world (second commonest in England and Wales and third in US). Over 30,000
new cases of colon cancer are diagnosed each year, more than 25% of which are
Dukes’ C (advanced) at presentation1. Colon cancer originates from the colonic
epithelial cells undergoing sequential mutations. These putative mutations are
responsible for the transition of normal epithelial cells to adenomas with increasing
dysplasia, finally resulting in colorectal adenocarcinomas, as described by adenoma-
carcinoma sequence (shown in Figure 1). Such mutations could either be a result of
inborn genetic aberrations like Familial adenomatous polyposis (FAP) or could be due to
environmental carcinogens like tobacco smoke or chronic inflammatory states involving
the colon and rectum2.
Figure 1: This figure demonstrates the sequence of events leading to colon cancer from
normal colon. In figure 1A, the sequence taking place in Familial adenomatous polyposis
syndrome and majority sporadic cases is shown. The sequence depicted in Figure 1B,
2demonstrates the events in hereditary non-polyposis colorectal cancer syndrome and
remaining sporadic cases. (For further details please refer to Voutsadakis I.
Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the
ubiquitin-proteasome system and Cox-2 3.)
Origin of colorectal cancer is a hotly debated topic and is explained by two models:
 The stochastic or clonal evolution model
 The cancer stem cell model.
In the clonal evolution model, most of the cells in the tumour are thought to possess the
capacity of self-renewal and contribute to the growth of the tumour. The differentiation,
intra clonal genetic and epigenetic variations and other micro environmental influences
are responsible for the tumour heterogeneity in this model.
The cancer stem cell model rests on the hypothesis that, some special “stem cells” in
the colonic epithelium possess the unique capacity of differentiation and producing a
clone of cancer cells. These newly formed clone of cancer cells lack the potential for
self-renewal. Along with these cancer cells, the stem cells also produce new cancer
stem cells, which are responsible for further propagation of the cancer. According to this
theory, aberrant differentiation from stem cells contributes to the heterogeneous nature
of the tumour4.
1.1.1. Adult intestinal stem cells and cancer stem cells:
Adult Intestinal Stem cells:
Stem cells, by definition, are capable of reconstituting a tissue, autonomously in its
fundamental morphological and functional aspects. In adult human gut, epithelium
completely self renews itself within 5 days, producing more than 1010 differentiated cells
every day2. Upon activation, intestinal stem cells undergo a specific type of mitosis
called “asymmetric cell division”, to produce two cells of different developmental
potential: one daughter stem cell, capable of further stem cell activity and one non-stem
cell, which continue to replicate, migrate upwards in the crypt – villous axis and
3differentiate into mature cells5,6. These first generation non-stem daughter cells
produced by the stem cells are known as Transiently Amplifying cells (TA cells). Under
normal circumstances, TA cells divide actively for a fixed length of time, to produce a
cellular pool, which then differentiates to form a tissue7,8. The intestinal stem cells and
their TA cell progeny are located towards the base of the crypts of Lieuberkuhn of the
intestine. As these cells migrate towards the surface (except the Paneth cells, which
stay at the bottom of the crypts), they cease to proliferate and start differentiating into 5
major cell lineages9,10:
 Absorptive enterocytes
 Mucin producing goblets
 Peptide hormone producing neuroendocrine cells
 M cells involved with antigen transport from gut lumen to Peyer’s patches.
 Microbicidal Paneth cells.
A normal human crypt is usually quite small, contains multiple stem cells and composed
of nearly 2000 cells originating from different stem cells. The exact location of stem cells
in a crypt is still a matter of debate, the major obstacle being the absence of unique
molecular markers. Thus assumed functional properties like radio-sensitivity and label
retention were used for their identification. It has been proposed that in the intestine, the
stem cells reside in a protective “niche” or the “+4 position”, the niche playing an
important role in maintaining these cells in their immature state. If removed from their
niche, the respective stem cells are thought to lose their multi-potent nature. These +4
position cells were found to be both radiosensitive and label retaining, with elevated
expression of Bmi1 (mouse models), a gene thought to be needed for maintaining stem
cells11-13. Alternatively, mouse models were used by two scientific groups to identify
small epithelial cells interspersed in between Paneth cells in this niche, thought to have
stem cell properties. These cells were named Crypt Base Columnar (CBC) cells14,15.
Though the evidence is poor, a fenestrated sheath of intestinal sub-epithelial myo-
4fibroblasts, surrounding the crypts is thought to form this “protective niche” for the
intestinal stem cells. These myo-fibroblasts extend throughout the lamina propria and
merge with the layer of pericytes, surrounding the blood vessels16. Wnt pathway is one
of the main signalling pathways that direct stem cell proliferation. In presence of in vivo
Wnt signalling (please refer to Figure 2 and detailed discussion under morphogenetic
pathways section), -catenin phosphorylation is inhibited and intra nuclear active
transcription factor complex consisting of TCF-4 and -catenin results. The activity of the
Wnt pathway, in conjunction with other relevant pathways like BMP and Notch, is vital
for stem cell proliferation and the proper organisation of the intestinal epithelium. A Wnt
signalling gradient apparently exists along the intestinal crypt villous axis. The highest
level of influence of this signalling pathway is at the base of the crypts. As a proliferating
cell migrates away from the base, it progressively loses its proliferating nature and starts
differentiation. This explains why the stem cells are mostly found at the bottom of the
crypts. Likewise, the transcriptional target proteins of this pathway were expressed
abundantly in the crypts. Wnt signalling is also essential for the expression of cell
surface receptors and corresponding ligands involved in the organisation of the
epithelium, for example, EphB / EphrinB receptors and ligand system that dictates the
position of different cells along the crypt-villous axis17. Potten and colleagues found that
the upper and lower limits of cell proliferation in the colorectal mucosa are expressed by
the 95th and 5th percentiles at cell positions 43 and 4 respectively and the peak labelling
index was seen at cell position 1518. Musashi-1, a RNA-binding protein has been
considered as an intestinal stem cell marker in the past19. Cells expressing Musashi-1, in
their cytoplasm and nucleus, were demonstrated in abundance below position 10, with a
peak expression at positions 3-4, by Nishimura et al. Based on their findings, the authors
suggested that the location of intestinal stem cells in humans is between positions 1 –
10 in the crypt – villous axis20. Though the exact role of Musashi-1 in human intestinal
stem cells is not yet clearly understood, it has been shown to interact with Notch
5signalling pathway and contribute towards maintaining the stem cells in an immature
state in some mammalian tissues. Presumably, it plays a similar role in the human
intestine21. Among a small group of genes, whose presence was restricted mainly in the
crypt base, LGR5 (Leucine rich repeat containing G protein coupled receptor) encoded
for a G-protein coupled receptor and found mainly in CBC cells. Lineage trace in vivo
experiments with mouse models by Barker and colleagues confirmed the same.
Furthermore, it was also shown by the authors that these cells were able to divide
approximately once per day and thus generate all cell types of the intestine for the
lifetime of the mouse22. Recently, CBC cells were also found to express high levels of
CD133 as well, and lineage trace experiments with CD133 also indicated that CBC cells
are stem cells23. Beta-1 integrin subunit24, EphB receptors25 have also been considered
as markers for intestinal stem cell.
Cancer Stem cells:
A tumour can be considered as an “aberrant organ” that has its origin from a
transformed stem cell (monoclonal), producing a progeny of daughter cells, which
become heterogeneous due to subsequent differentiation. This heterogeneity is both in
terms of morphological and functional characteristics of the tumour cells. Functionally,
cells in a tumour have different proliferating potentials. Interestingly, in vivo and in vitro
experiments have shown that only a minority of the cells in a tumour mass are
tumorigenic and only a few of these possess high proliferating capacity26,27. As
previously discussed, origin of colon cancer has been explained by 2 models, the
stochastic or clonal evolution model and that of the cancer stem cell. Previously, tumour
origin was thought to result according to the principles of the stochastic model. In this
model, all cells in the tumour were considered to have equal ability to divide and sustain
the tumour. The morphological heterogeneity in tumours was explained in this model by
genetic instability of individual cells, causing them to follow different pathways of
aberrant differentiation. These changes were also held responsible for explaining the cell
6intrinsic and extrinsic processes associated with tumour development, such as
angiogenesis or Epithelial Mesenchymal Transitions (EMT). The therapeutic
consequence in this model was that, in order to successfully treat a tumour, all of its
cells needed to be removed or destroyed, as all of them were equally capable of
generating a new tumour and cause cancer relapse. Over the last two decades, with the
introduction of stem cell model, the tumour is studied applying the principles of stem cell
biology. This concept has been hugely supported by reports of small subsets of specific
cancer cells, named as cancer stem cells (CSC), having the capacity of self-renewal and
potential to proliferate for an indefinite time, when grafted in immuno-compromised
animal models. These cells might have originated from the normal stem cells of the
organ concerned or the transiently amplifying (TA) cells, as a result of putative mutations
in either of them28. There is also some suggestion that the cell of origin may also be a
late progenitor cell or even an early differentiated cell29. According to this “cancer stem
cell” concept, tumour cells are thought to maintain a hierarchical organization consisting
of a population of self renewing stem cells at the bottom of the hierarchy which undergo
atypical cell division to produce more stem cells on one hand, thus renewing its progeny
along with progenitor cells with limited proliferative capacity and differentiated cells with
no proliferative potential on the other hand. Quite interestingly, the clinical implication of
this model is that by removing the stem cell the tumour will no longer be capable of
growing and therefore can be downgraded. Henceforth, future therapeutic modulation
can be targeted against specific stem cells and not reducing or debulking the entire
tumour30. However, controversies still exist in this field as inability of most other colon
cancer cells in replicating in a xenograft model might reflect their limitations in making
the correct contacts, etc, in the ectopic new host or even the level of immune
suppression in the host animal (for example, mouse) model4,31. Mutations in Wnt
pathway, either inactivating tumour suppressor functions of APC or Axin2 or activating
oncogene -catenin are considered to be responsible for the vast majority of colon
7cancers. Under both circumstances, -catenin can be localized in the nucleus (Figure 2,
morphogenetic pathways) and Wnt target genes are found to be activated32. As shown
in Figure 1, after Wnt pathway, carcinogenic mutations in KRAS, SMAD4 and p53
pathways are responsible for conversion of a normal colonic cell to a cancerous cell
through “adenoma – carcinoma sequence” (Figure 1, please see above)33. Along with
these putative mutations in the process of carcinogenesis, additional genetic alterations
are also known to happen, like those leading to loss of positional clues of cancer cells,
leading to disorganized cellular arrangement. From our current understanding, un-
mutated Wnt pathway (Wnt gradient, discussed above) is responsible for establishing
the crypt – villous border. It is this same Wnt gradient which controls expression of
EphB/EphrinB receptor and ligands responsible for positional migration of the intestinal
cells, with proliferating cells at the bottom of the crypt and more differentiated cells
towards the top in the villous. A disruption of this system with mutations in Wnt pathway
is associated with EphB2 down regulation, a step found to be required for cells in an
adenoma to progress to carcinomatous cells, freeing themselves of their positional
constrains34. Studies using CRE inducible activation of Wnt pathway were used to
demonstrate that the cell of origin of adenomas was none other than the mutated
intestinal stem cell. In either of these studies CRE was expressed from the endogenous
LGR5 or CD133 locus of the stem cell marker genes and both LGR5 and CD133
proteins were found to be effective inducers of Wnt pathway leading to efficient tumour
formation23,35. However, not all cancer cells in an APC induced tumour had equal Wnt
pathway activity32,36. Again, loss of function mutation of APC in progenitors and
differentiated cells in mouse models rarely induced tumour formation35. Two scientific
groups reported that colon cancer cells expressing CD133 were uniquely capable of
initiating, proliferation and sustaining the tumour in NOD/SCID mice and therefore
claimed that CD133 is a marker for cancer stem cell in colon37,38. Later a subset of
human colon cancer cells expressing CD166, CD44 and EpCAM were also found to
have similar properties of producing tumours in mice models and hence these proteins
8were considered by the authors as additional markers for colon cancer stem cell39. In
both these cases, the new tumours generated in mice exactly phenocopied the human
colorectal cancers from which the parent cells were isolated. Additional support for stem
cell model came from the observation that these cancer stem cells were isolated from
metastases of human colon cancer. The considerable difference in frequency of stem
cells in between studies can be explained by different antibodies recognizing different
forms of marker proteins used (for example glycosylated CD133). Although, CD133 was
previously thought to be a specific marker of colon cancer stem cells23, it was later
shown to be expressed in many other intestinal cells including all normal stem cells and
progenitor cells40,41. Another interesting finding that has recently come to light is that the
stemness of a cancer stem cell is greatly controlled by the microenvironment
surrounding the cell. Furthermore, cells without previous stem cell property were
demonstrated to gain so when subjected to these specific set of extrinsic factors42.
These data, taken together suggests that human colon cancer consists of a subset of
cells with stem cell properties. These cells are most likely mutated normal intestinal cells
with activated Wnt signalling pathway, express certain protein markers (like CD133,
CD166, EpCAM, CD44) and their stem cell characters depend on certain external
factors or surrounding microenvironment. However, there still remains substantial doubt
as to which marker or combinations of which specific markers form the exact signature
for these stem cells.
1.1.2. Morphogenetic pathways related to colon cancer:
The investigation of the molecular pathways regulating intestinal morphogenesis was
hugely promoted by the studies related to the genetic background of familial syndromes,
associated with a high risk of colorectal cancer like Juvenile polyposis syndrome (JPS),
Familial adenomatous polyposis (FAP) and Cowden’s syndrome. Approximately, 80%
cases of FAP, present with mutations in APC (adenomatous polyposis coli) gene.
Mutations in the genes coding for SMAD-4 and Bone Morphogenetic Protein (BMP)
9receptor 1A are present in about 15-20% and 25-40% patients of JPS respectively.
Cowdens disease causes hamartomatous neoplasm of skin and mucosa along with
colonic polyps. PTEN (Phosphatase and tensin homologue) mutations are found in 80%
such patients2. The sequence of events occurring in between normal colon to its
progression to colon cancer is schematically shown in Figure1 (please see above).
1.1.2.1. Wnt pathway and APC:
Wnt glycoproteins (Wnt-1) are poorly soluble palmitoylated proteins mostly expressed
towards the bottom of the crypts of Lieuberkuhn. These proteins regulate the Wnt
signalling pathway (Figure 2) implicated in colorectal carcinogenesis43. The APC gene,
present on the chromosome 5q21, encodes protein APC. APC mutation is associated
with 63% cases of adenomas and 60% cases of colorectal carcinomas44. In a study of
53 familial adenomatous polyposis syndrome (FAP) patients, it was found that >80%
tumours had one mutation and in more than 60% patients there were at least 2
mutations in APC45. Most of the APC mutations occur at the mutation cluster region
(mcr), starting at codon 130046.
Figure 2: This figure demonstrates the canonical Wnt / -catenin signalling pathway.
Under normal circumstances, (Figure 2A) GSK3-phosphorylates -catenin, inducing
the later to undergo proteasomal degradation. However, if this phosphorylation is
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inhibited (Figure 2B) by Wnt signalling pathway (via activated frizzled and dishevelled
respectively), -catenin translocates in the nucleus, replaces protein Groucho (from
Groucho-TCF4 complex) to form a complex with TCF-4. This molecular complex is an
active transcription factor and is responsible for inducing several proteins related to cell
proliferation.(For further details please refer to Voutsadakis I. Pathogenesis of colorectal
carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system
and Cox-2 3.)
A relatively large protein, APC harbours several functional domains. One of its important
such domains consists of ten amino acid repeats, (three 15-amino acid repeats followed
by seven 20-amino acid repeats) that bind β-catenin. Three Serine-Alanine-Methionine-
Proline (SAMP) motifs are interspersed within the 20-amino acid repeats. These SAMP
motifs are essential for the ability of APC to bind to Axin molecule. These functional
domains play an important role in stabilizing APC as a part of a six protein complex (-
Catenin destruction complex) along with GSK3-(Glycogen synthase kinase 3 beta),
Axin, -Catenin, Conductin and CK-I (Caseine Kinase I)47-50. The middle domain of APC
is phosphorylated by GSK-3β. This phosphorylated segment and the SAMP motifs in the 
APC molecule have been found to be necessary for recruitment of β-catenin to the 
destruction complex49,51. Along with forming the -Catenin destruction complex, APC
also plays an active role in nuclear shuttling and sequestration of -Catenin52,53. GSK3-
under normal circumstances, phosphorylates -Catenin, both directly and indirectly
(through activating CK). Phosphorylated -Catenin undergoes ubiquitinization and
proteasomal degradation by the UP (Ubiquitin-Proteasomal) System. A potent inducer of
proliferation, Wnt-1 with co-receptor LRP-5 (Low density lipoprotein receptor related
protein) ligates and activates cell surface receptor “Frizzled”, forming a complex, which
in-turn activates protein “Dishevelled”. Activated “Dishevelled” along with GBP (GSK3-
binding protein) inhibits GSK3-from phosphorylating -Catenin. GSK3-is also
inhibited by other kinases like akt kinase (activated by K-ras), Protein Kinase-C(PKC)
and Integrin linked kinase (ILK) 54-56. This prolongs the life of -Catenin un-
phosphorylated form. -Catenin phosphorylation is also inhibited if the gene encoding for
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-Catenin  (S37A mutant or serine at position 37 is replaced by alanine) or protein APC, 
undergoes mutation. Un-phosphorylated -Catenin translocates into the nucleus and
forms a complex with TCF-4 (T-cell factor) by replacement of the inhibitory protein
“Groucho”. -Catenin-TCF-4 complex is an active transcription factor for several proteins
related to cell cycle, proliferation, apoptosis and metastasis, like Cyclin D1, c-myc,
CD44, IL-8 and Akt-13. Among the genes, which are down regulated by this complex,
are those coding for ZO-1 and Ephrin B57,58. Although the canonical view of APC/-
Catenin suggests that loss of function of APC results in nuclear translocation of -
Catenin, evidence suggests that specific post-translational modifications of -Catenin
molecule (example; tyrosine phosphorylation by activated c-kit) are necessary for its
nuclear localization in response to Wnt stimulation59,60.
-Catenin induces transcription of genes (like those coding for ARF or alternative
reading frame, which acts as a positive regulator of p53) in a TCF4 independent
manner, possibly with the help of other transcription factors like Fox O (Forkhead Box
O)61. -Catenin acts as a bridge between E-Cadherin and the Actin cytoskeleton and
thus maintains the integrity of the adherens-junction, the main inter-cellular adhesion
point62. The cytoplasmic tail of E-cadherin becomes structured only when bound to β-
catenin. This association begins in the endoplasmic reticulum and is found to be
essential for the effective transport of cadherin to the cell surface for the formation of
adherens junction (AJ, cell – cell adhesion complex, maintaining tissue homeostasis)
complex. At the plasma membrane, this cadherin–β-catenin complex recruits α-catenin. 
α-catenin physically links the cadherin – catenin complex to actin molecules and this is 
essential for AJ formation and function63. -Catenin also inhibits NF- (promotes
proliferation and angiogenesis) by direct interaction64. These actions of -Catenin are
anti-carcinogenic by inhibition of metastases, proliferation and angiogenesis and
stabilisation of inter-cellular interactions. APC can also promote cell apoptosis in a
Caspase-8 dependent manner, which is independent of -Catenin. This is impeded in
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truncating mutations of the APC gene and can contribute towards colon cancer
pathogenesis65. By using Dickkopf1 (Dkk1), a specific inhibitor of the Wnt-LRP5-
Frizzled complex, Pinto and colleagues66 reported that Wnt signalling pathway is also
essential in adult normal intestinal epithelium for the formation of normal crypt villus units
by maintaining a correct balance of cell positioning, proliferation and differentiation. The
Wnt pathway interacts with the Notch pathway and regulates proliferation and
differentiation of stem/progenitor cells in the crypts67.
1.1.2.2. K-ras and related pathways:
Activating mutation of K-RAS oncogene is found in about 50 % cases of colorectal
cancer68,69. K-ras is involved in 3 important pathways related to colorectal cancer (as
shown in Figure 3, below):
13
Figure 3: This figure demonstrates the mechanisms by which K-ras activates several
transcription factors like AP1, elk1, c-jun – c-fos complex and c-myc to promote cell
proliferation through activation of Raf-Kinase and inhibits apoptosis, prevents
proteasomal degradation of -catenin and induces proteins related to cell proliferation
through activation of akt-kinase. (For further details please refer to Voutsadakis I.
Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the
ubiquitin-proteasome system and Cox-2 3.)
 Raf/MAPK kinase pathway
 PI3-K/akt kinase pathway
 Ral nucleotide exchange factor and Phospholipase C.
i) Raf / MAPK kinase pathway
In this pathway, K-ras activated Raf kinase (a form of Mitogen Activated Protein Kinase
or MAPK) activates a cascade of kinases involving MEK-1 and 2, ERK 1 and 2
(extracellular signal regulated kinases 1 and 2), JNK 1 and 2 (c-jun N-terminal kinases 1
and 2) and finally activating transcription factors like AP-1, complex of c-jun and c-fos,
elk-1 and c-myc. Of note, AP-1 and the complex of c-jun and c-fos promote cell
proliferation70,71. MAPK activation by K-ras is also associated with up regulation of p-
glycoprotein, which plays active role in imparting multi-drug resistance to colon cancer
cells72. This pathway is also responsible for blocking TGF- induced cell cycle arrest by
inducing proteasomal degradation of p27, a cyclin dependent kinase (CDK) inhibitor73. In
a review article, published by our group, on the role of 15-lipoxygenase-1 (15-LOX-1) in
colon cancer, we have discussed that this may be a link between fatty acid metabolism
pathway and colon cancer and may explain a pro-carcinogenic effect of 15-LOX-174.
ii) PI3-K/akt kinase pathway
In this second pathway, PI3-Kinase (a serine threonine kinase) is activated by K-ras,
which in turn activates the kinase akt or PKB (Protein Kinase B). Downstream substrates
of akt kinase undergoing inhibitory phosphorylation are GSK-3, bad (pro-apoptotic
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family member of bcl-2), caspase 9 (caspase in mitochondria dependent pathway) and
transcription factors like FKHR and Fox O. This result into activation of - Catenin (which
may have anti-carcinogenic roles by inhibiting NF- promoting cell cycle arrest by
activating Fox-O and yet may be pro-carcinogenic by formation of a complex with TCF-
4), inhibition of apoptosis and inhibition of cell cycle arrest respectively. Kinase IKK,
another downstream substrate of kinase akt undergoes activation following
phosphorylation, which results into subsequent phosphorylation and proteasomal
degradation of I- (Inhibitor of NF-). As NF- is a potent pro-survival factor and
inhibitor of apoptosis, this mechanism of inhibiting I- is pro-carcinogenic75,76. Kinase
akt also phosphorylates mdm2, resulting to its translocation into the nucleus, which in
turn inhibits transcription of p53 target genes. Downstream substrates of kinase akt,
which are activated, are mTOR (mammalian target of rapamycin) and PTEN
(Phosphatase and Tensin at chromosome 10). Activated mTOR maintains elF4 in
activated state by inactivating 4E-BP. This leads to translation of proteins like cyclin D1
and Heat inducible factor (HIF), which have been linked to proliferation of cells and
colorectal carcinogenesis. PTEN is inhibitory to the PI3-K/akt pathway and therefore on
activation completes a negative feedback loop77-79.
Thus, interestingly both the Raf/MAPK and the PI3-K/akt pathways have pro and anti
carcinogenic roles in colorectal cancer3.
iii) Ral-nucleotide exchange factor and Phospholipase C (PLC)
Ral nucleotide exchange factor activation by K-ras promotes cytoskeleton re-modelling
and cell proliferation. PLC activates the receptors involved in calcium signalling80.
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1.1.2.3. Notch Pathway:
The notch receptors are trans-membrane proteins and concerned with positive and
negative regulation of proliferation and differentiation respectively, in the intestinal
stem/progenitor cells. Notch and Wnt signalling function together to co-ordinate bHLH
transcription factor dependent cell fate specification81. There are 4 types of notch
receptors in vertebrates, Notch 1 –4. The ligands for these receptors are Delta like (Dll
1, 3 and 4) and Jagged (1 and 2) family ligands. The reaction between ligand and
receptor is influenced by sugar transferases (from Fringe gene family) – Lfng, Mfng and
Rfng82-84. Ligand-receptor complex activates the Notch protein and Notch protein is
cleaved by TACE/ Kuzbanian proteases and secretase. This separates an intracellular
segment of the Notch protein called NotchIC, which translocates into the nucleus and
binds to DNA binding protein RBPJ/CBF-1 and to the transcriptional regulatory proteins
to control transcription85. Math-1 (Hath-1 in humans) is a bHLH transcription factor in
mice. It induces differentiation of enterocytes, goblet cells, entero-endocrine cells and
Paneth cells86. Notch pathway interruption by deletion of RBPJ/CBF-1or inhibition of
secretase causes a rise in Math-1 and premature conversion of crypt cells to goblet
cells (i.e increased differentiation). Notch has been found to activate Hes1 (bHLH
suppressor) which in-turn perturbs the transcription of Math-1 and two CDK inhibitors,
p27 (Kip1) and p57 (Kip2). This decreases differentiation and increases proliferation
respectively67,87. Colorectal cancer specimens from human patients have been found to
express increased levels of jagged ligands, Notch-1, Lfng, Hes1, low levels of Hath-1
(human orthologue for mouse Math-1) and no goblet cells. This proves that the Notch
system is activated in colorectal cancer and can be a possible target for therapeutics in
cancer management88,89,90.
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1.1.2.4. TGF - Pathway:
Transforming growth factor – beta (TGF-) is a protein molecule and is a part of the
TGF- superfamily, which also includes other proteins like inhibins, activins, bone
morphogenetic protein (BMP) and Vg-1. Three isoforms of TGF- have been identified:
TGF-1, TGF-2 and TGF-3. TGF- molecules are secreted as large protein
precursors, consisting of an N-terminal signal peptide (20-30 amino acids, required for
secretion from the cell), an intermediate latency associated peptide (LAP) and a C-
terminal segment comprising of 112-114 amino acids. The later becomes the mature
TGF- after proteolytic dissociation from the LAP segment. In the mature form, TGF-
exists as a dimer. A mature TGF- molecule has nine cysteine residues of which the first
eight forms a “cysteine knot”, a structure characteristic of the TGF- superfamily. The
ninth cysteine bonds with a similar cysteine residue from another TGF- to secure the
dimer. TGF- has anti-proliferative properties on normal epithelial cells. They are
secreted by a wide variety of normal cells, including cancer cells, where the production
of this protein factor is greatly exaggerated91-93.
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Figure 4A and 4B: This figure demonstrates the anti-carcinogenic roles of TGF-in
colon cancer by promoting cell cycle arrest at G1 phase (4A) and apoptosis (4B).(For
further details please refer to Voutsadakis I. Pathogenesis of colorectal carcinoma and
therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2 3)
TGF- manifests its properties through cell surface receptors called TGF- receptors
(R). Two types of such receptors are found on vertebrate cells, RI and RII94.
TGF- blocks the cells at G1 phase of cell cycle by three vital mechanisms95,96.
 Promoting production of p15 and p21, which blocks cyclin-CDK complex required
for Retinoblastoma (Rb) protein phosphorylation.
 Stabilizing cyclin dependent kinase inhibitor (CDK-inhibitor), p27 by inhibiting its
proteasomal degradation.
 Suppressing c-myc expression.
TGF- induces apoptosis in cells by Smad pathway97. Smads are transcripion factors
and are of the following types97,98.
 R-Smad (receptor regulated Smad) or Smad 1, 2, 3, 5 and 9. Mutations of Smad 2
are found in about 6% cases of human colorectal cancer99.
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 Co-Smad (common mediator Smad) or Smad 4, also known as DPC-4 (Deleted in
Pancreatic carcinoma-4). Mutations of Smad 4/ DPC-4 are found in 20% cases of
colorectal cancer100.
 I-Smad (inhibitor Smad) or Smad 6 and 7.
The above mechanisms are summarized in Figure 4. Binding of TGF- to its cell surface
receptors (RI and RII) initiates three main cascades of intracellular reactions. First,
R-Smads (Smad 2 and 3) are activated. The activated Smad 2 and 3 along with Smad 4
promotes transcription of some putative target genes like p15, p27, p21 (cyclin
dependent kinase inhibitors) and caspases (apoptosis promoting enzymes) and
represses transcription of c-myc. This mechanism is inhibited by TGIF (Smad Co-
repressor / TGF- inhibitory factor) and I-Smads (Smad 6 and 7). Second, activated
TRI and II promotes proteasomal inhibition3. Third, the K-ras and its related pathways
are activated directly or indirectly, the later via activation of PI3-K/akt kinase pathway101.
Thus, TGF- demonstrates both pro and anti-neoplastic effects in colon cancer, with the
cell fate being decided by the ratio of Smad 3 to akt-kinase102.
Interactions between pathways related to TGF- and K-ras
 K-ras activated MAPK/ERK pathway promotes proteasomal degradation of SMAD4,
which inhibits TGF- pathway103.
 K-ras stabilises TGIF (TGF- inhibitor) by inhibiting its degradation104.
 TGF- itself activates K-RAS directly or indirectly (via PI3-K/AKT-kinase pathway
activation) as discussed above.
Thus, with intact Smad signalling, anti-carcinogenic effects predominate. However,
debilitating mutations in Smads shift the balance towards K-ras pathway and are
therefore pro-neoplastic in colon cancer.
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Interactions between Wnt/-Catenin pathway and TGF-
 Axin, a component of -Catenin/APC/GSK- protein complex activates Smad 3
by direct interaction105.
 Some complex co-operation exists between transcription regulation of target genes
by Smads and -Catenin/TCF-4 complex106.
1.1.2.5. Bone Morphogenetic Protein (BMP):
These protein growth factors are related to the TGF-(Transforming growth factor 
beta)family and are concerned with embryonic development and different cellular 
functions. Till date, nearly 20 BMP family members have been identified107. BMP activity
was first described in 1965108. Purification and sequencing of Bovine BMP-3
(osteogenin) and cloning of human BMP-2 and 4 were reported subsequently109-111.
Apart from playing a central role in formation of bone and cartilage, BMPs are also
implicated in several non-osteogenic developmental processes like epidermal induction,
development of neural crest and induction of sympathetic adrenergic phenotype112-114.
BMP 2, 4 and 7 have been found to be absolutely essential for life through gene-
knockout experiments in mouse models107.
BMP signals through serine-threonine kinase receptors, which are composed of I and II
subtypes. Three type I subtypes (IA BMP/ALK-3, IB BMP/ALK-6, IA Activin/ALK-2) and
three type II subtypes (II BMP, II Activin and IIB Activin) have been discovered so far115-
120. Of these receptors, type IA, IB and II BMP receptors are specific for the BMP
ligands. After ligand binds to the receptor, a heterotetrameric receptor complex forms
(consisting of two type I and two type II receptors)121. This receptor complex
phosphorylates and activates Smad 1, 5 and 8. These phosphorylated Smad proteins
separate from the receptor and after forming a complex with Smad 4 in the cytoplasm,
translocates into the nucleus and act as a transcription factor107,122-124. Noggin and some
cystine containing molecules bind to BMP 2, 4 and 7 and block BMP signalling125. Smad
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6 acts as a negative regulator for the BMP signalling pathway by binding to type I BMP
receptors, inhibiting phosphorylation of the Smad 1 and 5 and formation of complex with
Smad 4126. Tob, a member of the anti-proliferative family of proteins, binds to BMP
activated Smad 1 and 5 and blocks the BMP signalling pathway127.
BMPs have been associated with the pathogenesis of some solid tumours. Up-
regulation of BMP receptors (IA and II) and BMP-2 mRNA levels along with bi-allelic loss
of Smad 4 (also called DPC-4 or deleted in pancreatic carcinoma-4) were associated
with pancreatic cancer.
The protein, BMP-2 was also found to enhance proliferation of pancreatic cells128-131.
Hardwick et al reported that BMP-2 has anti proliferative effects on normal colonic
epithelial cells (by promoting apoptosis and differentiation) and found that BMP-2,
pSmad1, Smad 4, BMP receptors IA, IB and II were predominantly expressed at the
epithelial surface of the normal adult colonic tissue132. The issue of BMP in colorectal
cancer becomes relevant when mutations in genes coding for Smad 4 and BMP
receptor IA were found to be associated with Juvenile polyposis syndrome, which is an
autosomal dominant condition presenting with multiple gastrointestinal hamatomatous
polyps, with a risk of developing colon cancer133-135(about 12 fold as compared to
normal).
Enhanced formation of new crypts and lesions in the intestine, similar to the
hamartomatous polyps in JPS, resulted from ectopic expression of Noggin136 (BMP
signalling inhibitor). Beck and colleagues used colon cancer cell lines (SW480 and
HCT116) and human colon cancer specimens to confirm the role of BMP signalling in
colon cancer and found that the signalling pathway is mostly intact and moderately
growth suppresive in human colon cancer specimens and cell lines137. The Wnt pathway
through activation of -Catenin acts as a positive regulator and the BMP signalling acts
as a negative regulator of the intestinal stem cell proliferation57,138-140. In a recent
scientific paper Lombardo and colleagues have reported that BMP4 (bone
morphogenetic protein 4) promotes differentiation and apoptosis in a colon cancer stem
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cells in a selective group of tumours where simultaneous mutation in Smad4 (mouse
model) or constitutive activation of PI3-K/ akt kinase pathway is absent. They have also
reported that BMP4 sensitises these tumours to chemotherapy with 5-fluorouracil and
oxaliplatin in mice141.
1.1.2.6. Pathways related to p53:
The transcription factor protein, p53 binds to DNA segments, which are comprised of
specific base sequence, RRRC(A/T)(T/A)GYYY, where Y is a pyrimidine and R
represents a purine. The carboxy-terminal of p53 has 3 lysine residues, which interacts
non-specifically with several DNA segments. Acetylation of these lysine residues by
p300 prevents such non-specific DNA binding and possibly regulates p53 interaction
with target genes. Poly-ubiquitinization of mono-ubiquitinated p53 (by mdm-2) is also
promoted by p300, which results ultimately into proteasomal degradation of p53.
Of the many important genes, transcriptions of following genes related to colon cancer
are influenced by p53:
 Inhibition of transcription of anti-apoptotic bcl-2, bcl-xn and survivin.
Activation of transcription of Siah-1. Siah-1 ubiquitinates -Catenin leading to its
proteasomal degradation and therefore prevents formation of -Catenin -TCF-4 complex
(functions of this has been discussed in the Wnt pathway and APC)142,143.
Thus p53 mainly results in increased apoptosis and cell cycle arrest. In nearly 50%
cases of colon cancer, some form of loss of function mutation of p53 is identified,
majority (95%) of which affects the DNA binding site of this protein144.
Regulation of p53 is an interesting topic in cancer research. The regulation may be:
1. Negative: Inhibition of p53 is caused by the following E3 ubiquitin ligases which
ubiquitinates p53 leading to its proteasomal degradation:
 Mdm-2 (mouse double minute 2, hdm-2 for humans)145.
 COP1146, Pirh2147, ARF-BP1/Mule148.
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Figure 5: This figure demonstrates mechanisms related to the regulation of p53 and its
anti carcinogenic role by inhibiting anti- apoptotic factors (bcl-2, surviving and bcl-xn)
and promoting proteasomal degradation of -catenin.(For further details please refer to
Voutsadakis I. Pathogenesis of colorectal carcinoma and therapeutic implications: the
roles of the ubiquitin-proteasome system and Cox-2 3.)
2. Positive: Following may cause positive regulation:
 p14ARF, which inhibits both mdm-2 (hdm-2) and ARF-BP1/Mule.
 Kinase ATM (Ataxia telangiectasia mutated) both directly and indirectly
phosphorylates and activates p53, the later by activation of chk1/2 kinases.
 GSK3- p38 and JNK145.
The above mechanisms are summarized in Figure 5.
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1.1.2.7. Colon cancer and its relationship with fatty acid metabolism:
Polyunsaturated fatty acids like arachidonic and linoleic acids (n-6 fatty acids) are pro-
carcinogenic unlike fish oils or n-3 polyunsaturated fatty acids, which may be protective1-
3. Oxidative metabolism of arachidonic and linoleic acids by the lipoxygenase (LOX) and
cycloxygenase (COX) enzymes generates metabolites, shown to contribute to the
pathogenesis and progression of various cancers, notably colorectal149. Moreover,
therapeutic targeting of n-6 fatty acid metabolism by agents, such as non-steroidal anti-
inflammatory drugs (NSAIDs), can inhibit tumour formation. Extensive research is on-
going in this area and several distinct new therapeutic targets are emerging in the 15-
lipoxygenase pathway for cancer chemo prevention in man150. Here we describe the role
of the15-lipoxygenase-1 (15-LOX-1) pathway of n-6 fatty acid metabolism in the patho-
etiology and progression of colorectal cancer and highlight recent progress in developing
novel therapeutics based on its manipulation.
Figure 6A: Mechanisms related to Non-steroidal anti-inflammatory drugs mediating 15-
lipoxygenase-1 induced apoptosis are demonstrated in this figure. (For further details
please refer to Bhattacharya S et al. 15-Lipoxygenase-1 in Colorectal Cancer: A
Review74.)
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Arachidonic acid metabolism by lipoxygenase in platelets was demonstrated in 1974151.
Rabbit reticulocyte lipoxygenase was described for the first time in 1975152. The
lipoxygenases are cytosolic dioxygenases, composed of a single polypeptide chain (mol
wt. 75-80 kDa) and react with polyunsaturated fatty acids to produce the corresponding
hydroperoxyderivatives. They have 2 domains, the smaller N-terminal beta barrel
domain and the larger C-terminal catalytic domain. A single non-heme iron is liganded to
the later domain by four histidines and the C-terminal isoleucine. In the active state of
this enzyme, the iron is in ferric form and reduced to ferrous form in the inactive state.
The beta barrel at the N-terminal has homology to a similar domain at the C-terminal of
the mammalian lipase, which is involved in substrate acquisition. This suggests a similar
role of this domain in the lipoxygenase153.
Although several inter-conflicting reports has been published, convincing recent
evidences from several in vitro and in vivo studies, especially the ones in the latter
category from Nixon et al154, Shureiqi et al155 and Wu et al156 makes us believe that the
overall effect of 15-LOX-1 and its 13-S-HODE metabolite is largely anti-carcinogenic in
colorectal cancer. Several of these reports also strengthen the view that up-regulation of
15-LOX-1 by specific targeted gene therapy has the potential to induce apoptosis and
decrease proliferation in colon cancer cells, which makes this molecule a potential
therapeutic target. The anti-carcinogenic role of 15-LOX-1 gains further support from the
reports supporting its inhibitory effects in angiogenesis, metastasis and facilitatory
effects on apoptosis and cell cycle arrest by increasing levels of p53.
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Figure 6B: This figure demonstrates the effects of PPAR and 15-LOX-1 in colon cancer.
Figure 6C: This figure shows 15-lipoxygenase induced apoptosis dependent on p53, p21
and NAG-1.(For further details please refer to Bhattacharya S et al. 15-Lipoxygenase-1
in Colorectal Cancer: A Review 74.)
However in vitro reports of suppression of p21 and inhibition of PPAR- by 13-S-HODE
by Yoshinaga et al157 and Hsi et al158 respectively might be contradictory to these
findings. Of note, both of these evidences were based upon in vitro studies and results
from animal experiments, confirming the relationship between 13-S-HODE with p21 and
MAPK are still lacking. Interestingly, in vivo studies by Shureiqi et al155 in nude mouse
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xenograft model has demonstrated that 13-S-HODE exerts inhibitory effects on PPAR-
, an effect which can explain the anti-carcinogenic effects of 13-S-HODE on PPAR-
and NSAID induced apoptosis in colorectal cancer cells. A detailed review on this
subject has been published by our group and are summarised in the Figures 6 A, B and
C74.
1.1.3. Biomarkers and colon cancer:
The term “biomarker” in cancer research refers to substances or processes indicating
tumour at primary or secondary (metastatic) sites159,160. This could either be molecules
secreted by cancer cells, also known as “cancer cell secretome” or a specific response
of the body to the presence of cancer160,161. The objectives behind cancer biomarker
research is therefore to invent simple, cost effective, non invasive or minimally invasive
investigations, preferably using easily accessible body fluids (blood, urine or saliva),
which would indicate the risk of cancer in asymptomatic healthy individuals, allow
detection of cancer at its early stages, provides us with simple tools to monitor disease
progression and guide us in its management, along with giving us information regarding
its prognosis162-164. Molecular biomarkers are classified under several broad classes
according to their role165,166.
1. Diagnostic markers, used for differentiating between cancer and non-cancer
cases.
2. Prognostic markers, predicting disease outcome.
3. Markers used to monitor therapeutic response, or response to certain treatment
(example chemotherapy).
4. Predictive markers, used to guide the clinician to choose the best treatment
modality, or the therapeutic intervention to which the cancer is most likely to
respond.
5. Screening marker, providing important information regarding disease risk in
general population aiming towards early detection of cancer160,167.
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Biomarkers can be further classified into,
1. Cancer specific markers, presence of which indicates the likelihood of presence
of a specific cancer. (example CEA, CA19-9, CA125, etc)168.
2. Tissue specific markers, which are secreted by a specific tissue (example
Prostate specific antigen, secreted by prostrate, not only raised in prostate
cancer, but also in other prostate related conditions and even with digital rectal
examination). However, its serial measurement is a very useful tool to identify
response of prostate cancer to treatment168,169.
Although, extensive literature exists on potential biomarkers, only a handful of them
have clinical application in diagnosing and monitoring cancers. Furthermore, several
shortcomings exist with the currently available biomarkers; for example, poor sensitivity
and specificity limits their clinical importance163. Assays used to detect over expressed
protein biomarkers from serum are techniques like immunoassays, with potential
drawbacks like necessity of specific antibodies and decrease in sensitivity when
molecules or cells of low abundance are detected in a medium (example, blood) where
other proteins or cells are present in abundance. RT-PCR used to detect mRNAs, are
based on the availability of special RNA isolation kits and RNA preservation techniques.
Although these are highly improved, mRNA instability poses a major problem.
Furthermore, carry-over contamination, detection of pseudogene-expressed mRNA,
illegitimate transcription and marker expression by normal cells affect the specificity of
this technology169-171.
Along with facing obstacles like relatively low abundance of target proteins in biological
fluids, association of target proteins with carrier proteins and labile nature of these
proteins, there are other biological variabilities and those associated with collecting
specimens and their preparation172,173. Although most easily accessible, plasma or
serum proteomics becomes challenging due to extreme complexity and dynamic
changes in structure and function of these proteins in response to physiological and
pathological changes. Blood contains numerous proteins, essential for maintaining body
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homeostasis159,170. Proteins from “cancer secretome” are also added to this pool.
Cleavage by proteases, alternative splicing of mRNA, single nucleotide polymorphisms
(SNPs), post translational modifications and other chromosomal genetic variations result
in many of these proteins existing in multiple forms. Complex disease processes like
cancers are likely to further increase this number of protein molecules due to mutations
and alterations in splicing and abnormal post translational mechanisms 174. Microarray
based exon profiling is used for studying alternative splicing. Post translational
modifications like acylation, phosphorylation, glycosylation, oxidation and cleavage are
studied by multiplexed panels of biomarkers or proteomic techniques based on mass
spectrometry or protein microarrays164,175,176. As already mentioned above, relatively low
abundance of potential biomarker proteins amidst other proteins in blood complicates
the processes involved in identifying and measuring them. Concentrations of known
plasma proteins range from 30 – 50 mg / ml (example, albumin). Less abundant proteins
have lower concentrations (1 ng/ml for some cytokines). Proteins related to cancer
secretome are expected to be of even lower concentration159,169. Modern advancements
in protein microarray and mass spectrometry (MS) have given us the capacity to detect
proteins at sub-nanogram level172. Conventional centrifugation, centrifugal ultra-filtration,
chromatographic techniques, utilizing nanoporous substrates, different immune-affinity
and precipitation methods are often used to deplete more abundant “unwanted” proteins
and for enriching low concentration biomarker “target” proteins177-180. An important
drawback in these approaches is the associated inadvertent loss of several low
abundance proteins or peptides, complexed to carrier proteins, such as albumin181.
Attempts to isolate these sequestered proteins by affinity harvesting of albumin from
blood samples and more recently developed, a “nano-particle technology”, revealed that
they could offer significant information182-186. The later used hydrogel nano-particles as
affinity bait to capture target proteins. Thus by using nano-porous core-shell enabled
size fractionation; proteins are protected against actions of endogenous and exogenous
proteinases. The main advantage in this technique is the ability to sequester target
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proteins (on affinity bait, in the centre of nano-particle) away from the carrier proteins like
albumin, thus enabling concentration of analytes174. In this technique, blood can be used
directly in vacutainers, containing nano-particle solutions, which is likely to solve the
problems related to short half life and lability of proteins187. All biological samples are
affected by variabilities related to sex, age, ethnicity, diet, exercise and physiological
states (for example; hormonal imbalance and fasting) along with changes imparted by
diseases188. These factors could be resolved by referencing databases from systematic
proteomic analyses of body fluids by projects such as HUPO (Human Proteome
Organization) Plasma Proteome Project174.
The data obtained from genomic and proteomic analyses are essential for
understanding underlying factors involved in human diseases, especially complex
processes involved in cancer biology. This data is also pivotal for the discovery of
diagnostic biomarkers, as well as for developing further insight into the metabolic effects
mediated by signalling molecules. “Omic” approaches, namely genomics,
transcriptomics, proteomics, metabonomics etc are used for analyzing all classes of
biological compounds, from genes through mRNA to proteins and metabolites, required
to develop a broader view of the complex biological system, including the pathology of
diseases. While the data obtained from genomics explain the disposition of diseases
(i.e., presence or absence of genes related to increased risk of acquiring a certain
disease), several other mechanisms that are not gene mediated may be involved in the
onset of disease as well. A single gene can be processed to result in several different
mRNAs and proteins, which directly determine different cellular functions. Variations in
metabolic effects and metabolic fluxes as the downstream result of changes in gene-
expression and protein translation, are expected to be amplified relative to changes in
the respective transcriptome and proteome. Interestingly, these changes are extremely
time dependent. Thus measurements and determinations of metabolite content at a
single time-point can be misleading as these fluxes vary quickly. Therefore, in order to
understand the complete disease process, the entire set of “omic” techniques are
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important. While genomics/transcriptomics enables assessments of all potential
information regarding genes and m-RNAs, proteomics enables us to assess the
programs that are actually executed by providing important information about the
proteins produced and metabonomics will display the results of such executions189.
Functional analysis of genes and their products in relation to health and disease,
constitutes a powerful and novel approach since the expression levels of multiple genes
and their resultant proteins can be analyzed simultaneously. Techniques related to
functional genomics like DNA microarrays and classical proteomic approaches
(extraction of different proteins from the tissue and identifying them separately) hold
great promise for the study of complex biological systems, along with having on-going
applications in molecular medicine. High throughput analysis of tissue is now possible
using these techniques, as being complementary to each other they lead to a better
understanding of the regulatory events involved both in physiological and disease
processes. Proteins are excellent targets for being prognostic, diagnostic and
therapeutic factors in diseases like cancers. Thus, proteomic approaches, such as mass
spectrometry (MS), two dimensional gel electrophoresis (2-DE) and two dimensional
liquid chromatography (2-DL), which allow simultaneous measurement of expression
levels of hundreds of proteins and comparing them in different subsets, represent
powerful tools for inventing novel therapeutic and prognostic targets and biomarkers and
in-depth studying of cellular metabolism and protein expressions190.
Screening techniques ideally applies to diseases with significant incidence, prevalence,
morbidity and mortality along with a natural history which can be timely intercepted and
influenced by medical or surgical interventions, thereby influencing the course of the
disease. Colorectal cancer fulfils most of the above criteria. In most cases, it has a long
precancerous stage through adenomas or polyps. In the present day, implemented
screening techniques play an important role in early detection of these precursors of
colon cancer, its primary prevention and reduction of cancer related mortality191. Yet,
nearly 70 percent of colon cancers present at advanced stages of disease (UICC III/IV)
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with five year disease free survival rates of 60 percent or even lower192. Therefore
introduction of more efficient screening tools is imperative for curative interventions.
Highly organized protein networks, both intracellular and cell-surface, are responsible for
determining their functionality. Thus the function of a cell is determined at following
levels:
 Genomic level, genetic codes deciding expression of a protein, chromosomal
abnormalities, mutations, etc.
 Transcriptional level, influencing protein synthesis at m-RNA level.
 Proteomic level and post translational modifications.
 Toponomic level, which determines the interaction between different proteins
which is highly organized quantitatively, timely and spatially193-195.
We will classify the biomarkers according to the levels of cellular function they arise
from.
1.1.3.1. Genomic level biomarkers:
A key mechanistic component for initiation and progression of colon cancer is instability
at genomic and epigenetic levels, increasing the rate of accumulation of such damaging
alterations, which permits the adaptations characteristic of a malignant tumour. An
important example in this field is the role of Microsatellite Instability (MSI) in the
pathogenesis of colon cancer196. Microsatellites are defined as repeated sequences of
DNA, the length of which are highly variable from person to person; each individual
having microsatellites of a set length. These repeated sequences are common, and
normally present. The appearance of abnormally long or short microsatellites in an
individual's DNA due to mutations in DNA repair genes is referred to as MSI197.
Microsatellites are also known as simple sequence repeats (SSRs). MSI is one of the
most promising molecular markers investigated to date, especially in relation to
biomarkers for colon cancer and also in relation to many other malignancies. It is
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estimated to be the cause for 15% of colon cancers. The remaining 85% of colorectal
cancers develop from the chromosomal instability (microsatellite-stable or MSS)
pathways, characterized by mechanisms like aneuploidy, allelic losses, amplifications,
and translocations. It has been demonstrated by several authors that tumours with high-
frequency MSI are characterised by high lymphocyte infiltration, tend to be more
proximally located in the colon, poorly differentiated, mucinous and retain their native
diploid state. In contrast, microsatellite stable tumours tend to be aneuploid and have no
site predilection198,199. A number of studies have investigated the relationship between
MSI status and prognosis in colon cancer patients. There is considerable difference in
opinion in between different reports. An extensive systematic review of the published
data by Popat and colleagues used standard techniques and estimated the prognostic
significance of this phenotype with relation to colorectal cancer. From their analyses, the
authors reported that tumours with MSI have a significantly improved prognosis.
However, these tumours were found to be slightly more resistant to chemotherapy by
Fluoro-pyrimidines, the later being the mainstay in colon cancer chemotherapy in the
present day. Although, these findings point towards a benefit in pre-selecting colon
cancer patients with or without MSI before making a treatment plan with adjuvant
chemotherapy in locally advanced stage III disease, the authors suggested the need for
further prospective randomised trials to validate this finding200. A more recent meta-
analysis specifically studied the role of MSI status in predicting the response to
chemotherapy in colorectal cancer patients. Interestingly, the authors showed that
although, MSI tumours had slightly better prognosis than MSS tumours, there was no
difference in “relapse-free survival” in patients with high MSI, whether or not they
received chemotherapy. In sharp contrast, MSS patients demonstrated a much better
response to chemotherapy, suggesting that MSI positivity in colon cancer predicts
chemo-resistance201.
Genome wide association studies (GWAS) may be considered as a significant approach
for high-throughput identification of common, low penetrance alleles modifying the risk
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for complex disease processes like colon cancer. These minor, yet common variations
detected in DNA sequences are referred to as single nucleotide polymorphisms or
SNPs. A small proportion (3-4%) of colon cancer results from familial syndromes caused
by rare mutations in genes of high penetrance. Important examples in this are APC
(adenomatous polyposis coli) syndrome, resulting in multiple colonic polyps, and the
genes related to DNA MMR (mismatch repair) that causes Lynch syndrome. The later is
an autosomal dominant disease causing early onset colon cancer along with a range of
extra colonic tumours, characterised by carcinogenic mutations in DNA MMR genes:
MLH1 (MutL homolog 1), MSH2 (MutS homolog 2), less frequently in MSH6 (MutS
homolog 6) and PMS2 (post meiotic segregation 2). Methylation of MLH1 can also result
in its deactivation resulting in sporadic colon cancer, not related to Lynch syndrome.
These methylated forms have been reported to be found in peripheral blood and
lymphocytes, along with tumour tissue202-204. Ligtenberg and colleagues identified a
relationship in between MSH2 methylation and colon cancer pathogenesis. The authors
reported that germline deletions at 3′-end of the epithelial cell adhesion molecule 
(EpCAM) gene, also known as tumor-associated calcium signal transducer 1 or
TACSTD1, located immediately upstream of MSH2 were the possible carcinogenic
changes, which abolished transcriptional termination of EpCAM and causing
transcriptional read-through into MSH2 resulting in over-expression of fusion transcripts
in epithelial tissues. The level of expression of these fusion transcripts correlated well
with the level of MSH2 methylation in these patients205,206.The human genome project
and extensive linkage analysis suggest that the high penetrance genes responsible for
such syndromes have essentially been identified. Many other familial clusters of colon
cancer are present, which are thought to arise from mutation in genes of low
penetrance. Through the GWAS technology, simultaneous linkage analysis of thousands
of SNPs has been made possible. Data from these linkage analysis studies thus help us
associate SNPs with certain disease processes207. These data have allowed us to better
understand the role of common genetic variants in the cause of cancer and other
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disease processes. In spite of its existence for last several years, it was in late 2007
when GWAS studies associated the first common low penetrance susceptibility variant
with the risk of colon cancer208. Since then, many other such variants have been linked
to this disease, as has been extensively reviewed by Goel and Boland209. Studies by two
independent research groups reported that one of these SNP variants 8q24 rs6983267
is present in nearly 50% of Europeans and almost 100% African population, thus being
quite common. Although, homozygosis of the G allele for this SNP raises the risk of
colon cancer in the population by only 1.5 times, it demonstrates relative copy number
increase during the actual process of development of tumour. Furthermore, this region
acts as a “transcriptional enhancer” for Wnt signalling pathway, a key mechanism
involved in colon cancer pathogenesis as discussed above210.
K-RAS is adhered to the inner layer of the cell membrane and is mutated early and most
frequently in colon cancer, among all the RAS family genes (K, H and N)211. As
discussed above, mutations in K-RAS plays a significant role in transformation of normal
colon cells to adenoma (Figure 1). The largest international study (RASCAL) in this
respect reports association of its mutation with increased incidences of recurrence and
death in colorectal cancer69. Poor outcome to chemotherapy has been reported with
mutated K-RAS212. Early and frequent mutation and its detection in stool samples from
colon cancer patients support its potential role as a biomarker. An assay based on
detection of mutated K-RAS has been developed but not yet been introduced for clinical
application213.
As discussed above, APC regulates cell proliferation and is known to be a tumour
suppressor gene in colon cancer. Mutations inactivating this gene are present in up to
70% sporadic cases of colorectal cancer (e.g. Familial adenomatous polyposis coli
syndrome). Though this mutation occurs in early stages of the disease, its use as a
diagnostic, screening or surveillance tool has not met much success214.
Mutations in genes related to DNA mismatch repair result into defective DNA repair,
causing genetic microsatellite instability. Halling and colleagues found an association
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between MSI and lower 5-year survival in colorectal cancer patients215. However its
independent role as a biomarker has not yet been established.
P53 is a tumour suppressor gene is involved with many important functions like cell
cycle control, inducing apoptosis and repairing DNA damage216. Mutations in this vital
gene are associated with transition of colorectal adenoma to carcinoma (Figure 1),
resulting in expression of the defective p53 protein in the nuclei of colonocytes,
detectable by immunohistochemistry3. Although p53 mutation has been shown to result
in shorter 5 year survival and worse prognosis by some studies217,218, conflicting results
have been reported in the literature219. Therefore its role as a biomarker is still under
question.
Hyper methylation of specific genes is a frequent event in colon cancer220. Restriction
enzyme-based qPCR, used to detect methylated forms of SEPT9 in serum samples
diagnosed colon cancer with a sensitivity of 52% and specificity of 95%221.
1.1.3.2. Transcriptomics:
The term “transcriptome” describes the entire set of RNA molecules produced in one or
a population of cells and includes mRNA, rRNA, tRNA, and other non-coding RNAs. The
term can also be applied to the total set of transcripts in a given organism, or in a
particular cell type. Unlike the genome, which is fixed for a given cell line (excepting
mutating cell lines) the transcriptome varies with external environmental conditions. As it
includes all mRNA transcripts, the transcriptome represents the genes that are being
actively expressed at any given time, with the exception of mRNA degradation (such as
transcriptional attenuation). The study of transcriptomics, also known as “gene
expression profiling” thus examines the expression level of mRNAs in a cell population,
often using high-throughput techniques based on DNA microarray techniques for
interpreting the functional elements of the genome, and also for understanding
development and disease. This technique enables us to catalogue all transcripts in a
defined subset of cells, determining the transcriptional structure of genes, splicing
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patterns and other post-transcriptional modifications222. Various technologies have so far
been developed to study the transcriptome, including hybridization or sequence-based
approaches. The former involves incubating fluorescently labelled cDNA with custom-
made or commercial microarrays. Specially designed microarrays with probes spanning
exon junctions are used to detect and quantify distinct spliced isoforms223.
In contrast to microarrays, sequence-based techniques directly determine the sequence
of cDNAs . Use of Sanger sequencing of cDNA or EST libraries was found to be
relatively low throughput, expensive and generally not quantitative224,225. To overcome
these above limitations, tag-based methods were developed, including serial analysis of
gene expression (SAGE), cap analysis of gene expression (CAGE) and massively
parallel signature sequencing (MPSS). Although these approaches were found to be
high throughput and provide precise, ‘digital’ gene expression levels, few disadvantages
were apparent. Most of these techniques were based on expensive Sanger sequencing
technology, and a significant portion of the short tags could not be uniquely mapped to
the reference genome. Moreover, only a portion of the transcript could be analysed and
isoforms were generally indistinguishable from each other. These disadvantages pose
potential limitations to the use of traditional sequencing technology in annotating the
structure of transcriptomes226-229. Recent development of novel high-throughput DNA
sequencing method, known as RNA-Seq (RNA sequencing) has provided a new
platform for mapping and quantifying transcriptome. Due to clear advantages of this
technique over existing approaches, it is expected to revolutionize the study of
transcriptomics, as apparent from its previous applications to Saccharomyces
cerevisiae, Schizosaccharomyces pombe, Arabidopsis thaliana, mouse and human
cells, including its application in transcriptome profiling of stem cells230-235. Although still
under constant development, RNA-Seq offers several key advantages over other
existing technologies. First, unlike hybridization-based approaches, RNA-Seq is not
limited to detecting transcripts that correspond to existing genomic sequence236. This
makes RNA-Seq particularly attractive for non-model organisms with genomic
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sequences that are yet to be determined. In addition, RNA-Seq can also reveal
sequence variations (for example, single nucleotide polymorphisms or SNPs) in the
transcribed regions235,237. A second advantage of RNA-Seq relative to DNA microarrays
is that RNA-Seq has very low, if any, background signal. As it does not have an upper
limit for quantification, correlating with the number of sequences obtained, it has a large
dynamic range of expression levels (very high sensitivity) over which transcripts can be
detected. In contrast, for genes expressed either at very high or extremely low levels,
DNA microarrays lack sensitivity and therefore have a much smaller dynamic range. The
results from RNA-Seq are highly reproducible and thus reliable, for both technical and
biological replicates. Finally, because there are no cloning steps, RNA-Seq requires less
RNA sample230,233,235.
In relation to human cancers, gene expression profiling has been successfully used in
breast cancer research. Specific subtypes of this disease (for example, tumours
expressing HER-2 or Human Epidermal growth factor Receptor - 2) are found to have
distinctive gene expression profiles and thus represent diverse biological entities
associated with clear differences in clinical outcome238,239. Gene expression profiles
have also been studied for different subgroups of breast cancer (with difference in
Estrogen receptor status or tumour metastases in lymph nodes, expressed as lymph
node status) with different clinical outcomes and responses to therapy, with clear
differences in between these subgroups with regards to prognosis240. In a case-control
study by van’t Veer and colleagues, from the Netherlands Cancer Institute, one such
profile, consisting of 70 genes, was developed using archived frozen tissue from a
cohort of 78 node-negative patients with breast cancer241. The authors demonstrated
that these rapidly relapsing tumours, following primary therapy had gene expression
profiles that were quite distinct from those who remained disease-free after treatment.
The authors further validated their results by applying these gene expression profiles to
a second set of 295 frozen tissue specimens, collected from a new cohort of patients
(including 61 patients from the previous group), yielding very similar results242. This 70-
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gene profile was thus found to predict outcome in breast cancer more efficiently than
traditional clinical criteria. These preliminary results thus suggested that transcriptomics
may be regarded as a very powerful tool for predicting outcome and may also be
considered as a guide to management.
Aneuploidy is associated with advanced colorectal cancer, increased incidence of
colonic dysplasia in ulcerative colitis and poor survival in colorectal cancer patients243-246.
Specific aneuploidies (example, trisomies) exert direct influence on the expression of
genes in affected chromosomes. These changes result in distinct levels of genetic and
protein expression, which correlate with the subsequent stages of colon cancer
progression247. Simultaneous analysis of thousands of genes in tumour genomes is
possible by microarray based gene expression profiling248. A search for possible
biomarkers for colorectal cancer has been performed by several researchers by this
technique249.
Expression profiling has also been used to investigate the role of miRNAs (micro RNAs)
in diagnosis of solid tumours, based on the expression signature of individual miRNAs.
Robust evidence shows that along with differentiating in between normal and cancer
tissue, expression profile of miRNAs can also distinguish between types and grades of
different individual tumours. A systematic analyses by Lu et al demonstrated successful
classification and diagnosis of different solid tumours based on specific mRNA
expression pattern with 70% accuracy250. Silencing of 32 miRNAs along with over
expression of 18 different miRNAs, with nearly 10 times over expression of 6 miRNAs
was reported in colon cancer as compared to normal colon tissue251. Monzo and
colleagues reported differential expression of 28 and 64 miRNAs in stage I and II colon
cancer when compared with corresponding normal colon252. Recent scientific studies
reported that miRNA-21 expression correlated with advanced colon cancer (Dukes’ C
and / or lymph node metastases). These results suggest that variable expression
profiles of different miRNA molecules may be a potentially reliable method of diagnosing
colon cancer and assessing its outcome. This is certainly a great advancement over
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standard clinical staging of colorectal cancer, based on which further management is
decided. Any human error on the part of the histo-pathologist in detecting micro
metastases in the lymph nodes is liable to under stage the disease, resulting in
inadequate treatment and poor outcome253,254.
1.1.3.3. Proteomic level biomarkers:
Ultimately all cellular functions are performed and regulated by proteins. Thus,
transcriptional profiling and genomics will never fully describe cell biology, even though
in many cases such information can be used to predict cell behaviours. The discrepancy
often noted however between these approaches and those which look directly at
proteins and protein modifications result from the following:
1. Levels of mRNA do not always directly correlate with levels of proteins, as these
can be influenced by many processes that may not be revealed by gene
expression studies.
a. Post transcriptional regulation, by various factors including, non coding
RNAs; regulation of translation and post-translational modification of
proteins
b. Regulation of protein stability, degradation etc
2. Protein modification, in particular by altering phosphorylation can switch proteins,
and therefore biological processes on or off, without any changes in mRNA or
protein synthesis.
3. Protein dynamics, translocation and complex formation.
Proteomics is a field of biology directed at addressing these issues255. The study of
proteomics is aimed towards identifying proteins within the organism. Application and
ongoing development of new techniques are aimed to identify temporal changes in
protein levels associated with normal tissue and tissue affected by tumorigenesis256.
These techniques are described below:
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 Two-dimensional denaturing poly-acrylamide gel electrophoresis (2D-
PAGE)
The initial description of this technique dates back to 1975257. In its initial stages of
development, separation and identification of target proteins in the first dimension, was
carried out by iso-electric focusing (IEF) according to their respective iso-electric points.
Thereafter, introduction of immobilized pH gradient (IPG) strips improved this technique
in terms of reproducibility and capacity258. In the second dimension, proteins are then
separated according to their molecular masses, mostly by (sodium dodecyl
sulfatepolyacrylamide) gel electrophoresis. After the gel is stained with silver or
Commassie blue the respective proteins are seen as spots or dots representing
differences between different samples. Special software is then used to study the gels,
in order to assess the differences in between proteomes. The potential of 2DE as a tool
for identifying biomarkers has been greatly augmented with the development of mass
spectrometry techniques (MS), where the later is used to identify the spots, representing
individual protein components166. Despite the fact that 2D-PAGE is currently an
important research tool in the study of proteomics, it has several limitations. Along with
being a time consuming and labour intensive technique, membrane bound proteins are
inadvertently under represented and poor solubility of a number of isolated protein
molecules can pose a problem259. Again, quantification of protein components is based
on respective staining signals, which can be inaccurate for proteins with very low
concentrations. Inter gel variability prevents superimposition of images, which is partly
solved by introducing difference-gel electrophoresis (DiGE), using highly sensitive
fluorescent dyes258,260. Protein molecules are covalently bound to two different
fluorescent dyes (Cy3 and Cy5), which are thereafter mixed and separated on 2D-
PAGE. The gels from individual samples are scanned by different wavelengths to
display the results, comparison of which, provides information on relative abundance of
proteins in these samples256. Ambiguities involved in “spot” matching can thus be
avoided, as one uses the same gel to separate spots. Many differentially expressed
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proteins have subsequently been detected by DiGE and functional phenotypes
identified, that might be an inducing factor for brain metastasis in breast cancer or nodal
metastases in oesophageal cancer261,262. Although, DiGE is associated with a low
throughput and limitations in analyzing insoluble proteins, perfect image super
imposition for image analysis, which may be a problem while dealing with large number
of samples in multistep 2DE, is less time consuming and relatively easier with
DiGE263,264.
 Mass spectrometry
Mass spectrometry (mass-to-charge ratio of gas-phase ions) is a valuable tool for
identifying and quantification of proteins, defining protein interactions, post-translational
modifications, N-terminal, C-terminal and de novo sequencing. In this technology,
electrical charge to the molecules is conferred by an ion source. A mass analyzer
thereafter separates these ions according to their m/z ratio, which are detected by a
detector265,266. Ionization of proteins is achieved either by matrix-assisted laser
desorption/ionization (MALDI) or electro spray ionization (ESI). MALDI uses a laser to
vaporize and ionize the sample protein molecules in a matrix. In ESI, ionization is
applied to a stream of liquid containing the sample, creating a stream of ions, which is
then analysed by the mass spectrometer173. Some analyzers used most commonly are
quadrupole (Q), ion-traps (for example, quadrupole ion trap or QIT; linear ion trap or
LIT), time of flight (TOF) and Fourier transform mass analyzer (ion cyclotron
resonance—FTICR). Several hybrid instruments combining capabilities of different
analyzers were also recently developed (example, dual-cell quadrupole linear ion trap-
orbitrap—dcQLT-orbitrap, LTQ-FTICR, etc.). MALDI is coupled with TOF mass analyzer,
which accelerates ions through an electrical field of known strength267,268. Both of these
techniques have been applied in identifying novel biomarkers. Metastatic cell lines were
compared by using 2D-PAGE and MALDI-TOF. Vimentin, a promoter of tumour cell
invasiveness, and diagnostic peptidome signatures from colorectal cancer were
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identified using this tool269,270. Protein patterns comparing and predicting survival of
patients with gliomas were detected Schwartz and colleagues271. Vydra et al reported
three differentially expressed proteins in patients with breast cancer with distant
metastases272. To reduce sample complexity and to deplete highly abundant more
unimportant plasma proteins, several approaches have been used. The most widely
used method is separating proteins by 2D-PAGE prior to MS. In addition, mass
analyzers are often directly coupled with other methods like liquid chromatography (LC)
and capillary electrophoresis (CE), which enables separation of protein molecules, such
as multi-dimensional protein identification technology or Mud-Pit, based upon affinity
columns enabling sequential cation exchange, and reverse-phase chromatography173,188.
 Surface-enhanced laser desorption/ionization (SELDI)
This technique, a variation of MALDI (discussed above), uses a chemically coated plate
(in place of a metal plate as in MALDI). The analyte solution is spotted onto this coated
plate. Some proteins in the mixture bind to this chemical on the plate. Subsequent
washing step removes the un-bound protein from the analyte. This works as a
separation step. The matrix is then spotted on the plate, allowed to crystallize along with
the bound peptide and irradiated with laser. Measurement of ionic mass is done in
similar lines as discussed in MALDI. Selective coating of the SELDI plate can be done
with antibodies to bind corresponding proteins273-275. Coupled to TOF spectrometers, this
method has the capacity of producing proteomic fingerprints from biological samples.
High throughput analyses are possible with this approach. However, its use in
biomarkers discovery is limited due to low-resolution 276,277. This approach has been
used by Smith et al to assess response to neoadjuvant radio–chemotherapy in rectal
cancer. They measured 14 differentially expressed proteins after 1 day and 2 days of
treatment in their cohort and demonstrated that pathologic response to treatment could
be predicted with 87.5% sensitivity and 80% specificity and also suggested that SELDI-
TOF-MS are capable of detecting biomarkers and predict therapeutic response at an
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individual level278. Other reports have used similar approaches in breast, ovarian, colon,
liver and gastric cancers with promising results164,170,279,280.
 Tandem mass spectrometry (MS)
Identification and sequencing of protein and / or peptide is possible by MS. It involves
multiple steps of separation in time (ion traps) or in space. Most widely used techniques
are collision-induced dissociation (CID), involving multiple collisions of protein ions with
rare gas atoms, electron-capture dissociation (ECD) and electron-transfer dissociation
(ETD), inducing fragmentation by transferring electrons to proteins, and infrared multi
photon dissociation (IRMPD) by infrared laser173,265. MS based technology has enabled
us to detect post translational modifications and dynamic changes of protein molecules.
Relative abundance of target proteins in disease versus healthy tissue can be detected
by labelling these respective proteins with stable isotopes. The differentially labelled
samples are then separated on affinity columns or LC, followed by which they undergo
analyses. Samples can be labelled chemically by several means; ICAT or Isotope coded
affinity tag, where isotopic labelling of amino acid side chain is achieved, isobaric mass
tags, such as tandem mass tags or TMT and isobaric tags for quantization (iTRAC and
new label mTRAC) based on incorporating reporter groups with the same mass. Stable
isotope labelling of amino acids in cell culture (SILAC) has been conducted in vivo and
in vitro models265,266,281,282. Label free quantification methods such as spectral counting
are applied to biological samples, where they are not combined, but measured
separately260.
 Protein microarrays
Protein microarrays enable global studies of protein expression, post translational
modifications, and interaction in between two protein molecules and protein–ligand and
protein–kinase interactions. Although high-throughput analyses is possible, there are
some technical obstacles in the way of robust protein assay, such as selecting
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appropriate methods for generating, purifying and immobilizing proteins, determining
specificity for different antibodies and solving high sample variability188,283,284. Variable
domains of single chain antibodies, in the form of “nano-bodies” were generated by
some researchers, as a simple and cost effective approach for immobilizing proteins on
microarray surface285,286. Reactive proteins are detected on chip by small molecule
probes being labelled with fluorescent, magnetic, affinity, photochemical or radioisotope
tags287,288. Label free detection method for protein interactions are being developed,
such as surface plasmon resonance (SPR) and high-speed oblique-incidence reflectivity
difference (OI-RD) microscope289. Laser-capture dissection or cell sorting techniques are
being used to isolate single cell populations as protein microarrays are not cell-
specific290-293. Assuring stability of immobilized proteins is a potential problem due to
rapid decrease of their activity. The protein in situ array (PISA) solves this problem and
seems to be promising for future development of protein microarrays. The method
generates protein arrays directly from (PCR amplified) c-DNA, generated by cell-free
synthesis of tagged proteins onto the tag-capturing surface294,295. Several types of
protein arrays, such as analytical protein microarrays, antibody, reverse phase,
functional and bead-based microarrays have been developed and extensively
reviewed283,284,288,296. Advanced stage ovarian cancer has been shown to over-express
phosphorylated extracellular-signal-regulated kinase unlike early stage disease, by the
application of reverse phase microarrays297. Protein ultra microarray was used for the
detection of IL-6 and PSA298. Important tumour marker antigens such as AFP, CEA, -
HCG, CA 125, CA 19-9 and CA 15-3 were detected by similar techniques299. In a study,
conducted by Gulmann and colleagues, laser-capture micro dissection was applied to
isolate tumour epithelium, stromal and normal cells from tissue samples obtained from
patients with colorectal cancer. Reverse-phase protein microarrays was used to
establish decreased levels of activated isoforms of proteins like p-ERK, p-p38 and p-
JNK, found to be involved in MAPK-kinase signaling pathway, as discussed above293.
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 Laser-capture micro-dissection (LCM):
This computerized technique uses laser energy to isolate different cells of interest
(normal, cancer, etc) from a tissue specimen, without denaturing them. However, given
the limitations like extremely specialized level of technology and relatively low protein
yield, its use for generalised cancer screening is not yet possible300.
 Bioinformatics in proteomic studies
Comparing and determining protein molecular composition has become easier with the
introduction of bio-informatic tools in proteomic research. Large data bases like Swiss–
Prot and BlastPro have been created and large heterogeneous data sets can be
compared against this database to gain information about new disease processes. New
algorithms for image analysis of 2D-PAGE gels, MS analyses or high density protein
microarrays have been developed within the last years283,301,302.
 Two dimensional difference gel electrophoresis (2-D DiGE):
In this form of gel electrophoresis, up to three different protein samples are labelled with
separate fluorescent dyes, the later differing in their respective excitation and emission
wavelengths. After 2-D gel electrophoresis, protein abundance is noted by repeated
scanning of the gel with excitation wavelength of one fluorescent dye after the other. In
this technique, proteins from different samples are run on the same gel; hence the inter-
gel variation as found with 2DE is substantially reduced.
A) Tissue Biomarkers:
The above mentioned techniques have been employed extensively by several
researchers and numerous tissue biomarkers have been reported from time to time.
Calgranulin B was found to be a prominent protein of uncertain functional significance in
colon cancer tissue and in pre cancerous lesions as compared to their normal
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counterparts by 2DE303. 2D-DiGE and MALDI was used to report differential expression
of nearly 52 different proteins in mucosal specimens of colorectal cancer as compared to
normal colonic mucosa304. Similar approach was used by another group to report
differential expression of vimentin, cytokeratin, –actin, heat shock protein 60, cathepsin
D, RSP4, calreticulin, relaxin, APC, metastasis associated protein, annexins IV and V in
colon cancer versus normal colon305. Locally advanced rectal tumour was investigated
using narrow pH range 2-DE and MALDI and increased expression of following proteins
were detected: tropomodulin, -tubulin, calsenilin, annexin V, heat shock protein 42,
DNA repair protein (RAD51L3), notch 2 protein homolog and keratin type I306. Nature
and progression of colon cancer through different stages (normal mucosa  adenoma
Dukes’ stages B to Dmetastatic colon cancer in liver) of the disease was studied by
2D-PAGE and cDNA (complementary DNA) microarray analysis by Kwong and
colleagues. Parallel assessment of the genes and resultant proteins was done in
different stages by the authors307. Colon and ovarian cancer cell lines were compared in
a report using multistep genomic and proteomic analyses. Villin and moesin were
identified as markers for colon and ovarian cancer cells respectively. The group used
techniques like cDNA microarray, affymetrix oligonucleotide chip analysis (corroborating
transcript levels), reverse phase protein micro-array (quantification of proteins) and
tissue micro-array308. Cancer therapeutics has also been influenced by these techniques
used for investigating cancer tissue. A pelvic mass of uncertain origin was analysed by
2-DE, compared against 2-DE analyses database of high grade colon and ovarian
malignancies, and was found to be of colonic origin and treated accordingly309.
Possibilities of recurrence in Dukes’ B colon cancer were predicted in a report with 78%
accuracy by using affymetrix U133a Gene Chip with nearly 22 thousand transcripts. If
similar studies could be validated in larger groups, published data with higher levels of
accuracy can be helpful in preventing cancer relapse through implementing adjuvant
therapy310.
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B) Serum Biomarkers:
An ideal biomarker is detected in a readily available body fluid such as serum,
differentiates healthy individuals from cancer cases and predicts the state and course of
the disease311. Although extensive research is ongoing in the field of serum biomarkers
for screening / detecting colon cancer and some progress has been made in serum
proteomics, results so far are largely disappointing312.
Carcino-embryonic antigen (CEA) is routinely used as a serum biomarker and an
independent prognostic measure for colorectal cancer in today’s clinical practice. It is a
highly glycosylated protein and has been described for the first time in 1965313,314.
Higher levels of serum CEA has been shown to correlate well with poorly differentiated
and advanced stage of tumour315. Preoperative CEA levels have also been shown to
predict post operative survival in patients with colorectal cancer316. However, based on
its diagnostic sensitivity (30-40%) and specificity (87%), Fletcher and colleagues
calculated that there would be 250 false positive cases for every cancer patient detected
by CEA estimation and 60% cancers will be missed317. Many metastatic cases of colon
cancer in livers (67%) and lungs (94%) have been missed when CEA was used as the
sole diagnostic tool318,319. Again, high CEA levels in response to non-malignant causes
like hepatitis, chronic obstructive pulmonary disease, pancreatitis and inflammatory
bowel disease, persistently high levels in smokers (19%) and high serum levels even
without any evidence of cancer recurrence puts its reliability and sensitivity under
question320-322. These values draw a limitation to its use as a diagnostic marker; however
its stand in colorectal cancer surveillance, after curative surgery is still widely
accepted315. Serum levels are expected to decrease following curative resection and
increase in recurrent cancer. Given its low sensitivity and specificity in Dukes’ A and B
colorectal cancer, the NIH (National Institute of Health) recommends that it should not
be used to screen for early colon cancer323. Macrophage migration inhibitory peptide
(MIF) is elevated in serum from colon cancer patients. Its sensitivity in early colon
cancer detection is higher than CEA (47.3% vs 29.5%)324. The sialylated Lewis-a
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antigen, CA 19-9 (Carbohydrate antigen 19-9) is currently used as a serum biomarker
for pancreatic carcinoma. Its role as serum biomarker in colon cancer has also been
tried, but the sensitivity is even lower as compared to that of CEA. Other similar antigens
like CA50, CA242, CA M26, CA72-4, CA195, CA M26 and CA M43 have also been
investigated from similar perspective in colon cancer, but sensitivities were found to be
very low325-327. Serum levels of Matrix metallo proteinases (MMPs 7 and 9)328,329,
prolactin330, G-CSF (granulocyte colony stimulating factor)331 and M-CSF (macrophage
colony stimulating factor) has been found to be elevated in colon cancer with varying
sensitivity and specificity. The later has also been reported to indicate lymph node
metastases in colon cancer332. Serum levels of MMP7 and laminin have been reported
to be independent prognostic markers for colon cancer328,333.
TIMP-1 (Tissue inhibitor of metalloproteinase type 1) is a glycoprotein, which is found to
be over expressed in serum from patients with colorectal cancer as compared to healthy
individuals and those with colonic adenoma, inflammatory bowel disease or primary
breast cancer334-336. Its role as an independent serological prognostic marker in
preoperative analysis has been reported337-339. However, its expression is not restricted
to colon cancer alone, but also present in other conditions like cancers of stomach340,
urinary bladder341, lung342 and ovary343.
An equal or better diagnostic accuracy for predicting colon cancer, as compared to that
of CEA, by serum levels of NNMT (nicotinamide N-methyl transferase) and PSME3
(proteasome activator complex subunit) has been reported by two studies 344,345. Wu and
colleagues reported that serum levels of CRMP-2 (collapsing response mediator protein)
have a better sensitivity but poorer specificity as compared to that of CEA in diagnosing
colorectal cancer346.
Albrethsen and colleagues used SELDI-TOF to demonstrate up-regulation of HNP
(human neutrophil peptide) – 1, 2 and 3 (alternatively called -defensin-1, 2 and 3
respectively), both in serum of colon cancer patients and mucosa from cancer
specimens as compared to healthy individuals347,348. One subsequent study reported
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that apo-lipoprotein C1, C3a-desArg, transferrin and 1-antitrypsin as markers of high
diagnostic potential in sera from colon cancer patients by using SELDI and ELISA
(enzyme linked immune sorbent assay)349. Habermann et al used ELISA (detecting C3a-
desArg levels in serum) to diagnose colon cancer with nearly 96 % specificity and 97 %
sensitivity. However, according to this later report, C3a-desArg levels were elevated in
86% serum samples only349,350. Using SELDI and highly sophisticated bioinformatics tool
on serum samples from colorectal cancer patients of different stages (Dukes’ A to D),
patients with colon adenomas and healthy individuals, Yu et al reported that patients
with adenomas and cancer can be differentiated from the rest of the cohort with 89%
sensitivity, 83% specificity and 89% predictive value351.
C) Stool Biomarkers:
Based on the recommendations by the American Gastroenterological Association, faecal
occult blood testing has been introduced as a widely accepted screening test for colon
cancer. It has been shown to reduce mortality in this disease by early detection352.
However, false negative cases may range up to 20-30% as reported in the literature due
to its poor sensitivity and due to the fact that all cancer may not bleed353. Again, false
positive cases may be substantially high if the diagnosis is based solely on FOBT, given
the numerous non-malignant causes of gastrointestinal bleed. Annual re-testing for
FOBT currently detects only 25-50% colon cancers and 10% adenomas354. Although
separating and amplifying abnormal mutated (cancer causing) DNAs from normal
human and bacterial DNAs possess a potential technical challenge and has been
compared with “finding a needle in the haystack”, higher integrity of DNA fragments in
the stool of colon cancer patients (as compared to normal patients), possibly due to
inhibition of apoptosis and auto digestion in cancer, is potentially advantageous355,356.
Colon cancers continuously exfoliate cells in the stool. Diagnosing cancer by detecting
mutated forms of DNAs from these colonocytes in a potential future non-invasive mode
of cancer screening and is still under investigation. The screening targets most
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commonly tried with stool are mutated k-ras, p53 and BAT-26213,357. Faecal DNA testing
was also found to yield better results, with diagnosing colon cancer, when compared
against FOBT in a large cohort of more than 4000 average risk adults of age more than
50 years. In this study by Imperiale et al, sensitivity of fecal DNA testing was far better
than FOBT (52% vs 13% respectively) for diagnosing invasive colon cancer and just
slightly better (15% vs 11%) in detecting adenomas with low or moderate grade
dysplasia. The specificity of faecal DNA testing and FOBT were almost found to be
same (94% vs 95% respectively)358. However, several questions put forward by Steven
Woolf in his editorial makes us think about the applicability of DNA analysis from faeces
as the sole screening test for colon cancer354. Faecal calprotectin has been reported to
be elevated in colon cancer and inflammatory bowel disease359,360. But a lower
specificity as compared to FOBT (63% vs 97%) makes it a poor biomarker for colon
cancer361.
1.1.3.4. Multiple markers in colon cancer:
From our previous discussion, it is apparent that the use of single proteins as
biomarkers for a certain cancer is often non-specific. Therefore the use of multiple
markers has been tried by several researchers. Serum levels of five protein panel:
TRAIL receptor-2 (TRAIL R-2), spondin-2, Reg IV, macrophage inhibitory cytokine 1
(MIC1) and tumour necrosis factor receptor superfamily member 6B (DcR3) has been
used as biomarker for colon cancer in conjunction and has been shown to have better
sensitivity and specificity than CEA used alone362. Similarly, serum levels of two protein
panel, CEA and CRMP-2, when used together, was found to have better sensitivity
(77%) and specificity (95%) than CEA (sensitivity and specificity of 43% and 87%
respectively)346. M2-pyruvate kinase alone has a sensitivity of 48-58% and specificity of
90-95% as a serum biomarker in colon cancer. However, its sensitivity increases when
used in conjunction with CEA, without a fall in its specificity363,364. Use of gene
microarray in diagnosing colon cancer, by detecting a panel of 5 differentially regulated
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genes, BANK1(B-cell scaffold protein with ankyrin repeats 1), BCNP1 (B-cell novel
protein 1), CDS( Cytidine deaminase), MGC20553(FERM domain containing 3) and
MS4A1 (membrane spanning 4-domains, subfamily A, member1), from the total
extracted pool of genes from peripheral white blood cells, was found to be very sensitive
(88-94%) but with lower specificity (64-77%) as compared to that of CEA365. Similar
combination strategies applied to stool biomarkers was found to be advantageous.
Although, presence of mutant k-ras in less than 50% cases of colon cancer is
responsible for its low sensitivity as a single stool based biomarker366, combination of the
other two targets (p53 and BAT-26) detected 71% colon cancer patients in a cohort357.
When mutated APC and long DNA (a marker for non-apoptosis) were combined with the
above, nearly 91% cases with colon cancer and 82% cases with adenomas (less than 1
cm) were detected. On removing k-ras from this 5-tag panel, the sensitivity dropped
slightly but the specificity rose to 100%367. As discussed before, faecal DNA testing has
better sensitivity and comparable specificity to FOBT in detecting colon cancer358.
Combination of FOBT and faecal DNA in large cohorts may be important in increasing
the sensitivity and specificity of screening for colon cancer.
In this context, Professor Zena Werb has rightly said, “As attractive as the concept of a
single marker is, it is now crucial to consider what such markers really mark. These
molecules, which often lack tumor-specific function, may help tumor cells maintain their
characteristics in a specific niche, or they may be expressed because of another gene
turned on in the tumor or because of altered adhesion. So it is not hard to imagine that
the markers may not be essential or constant, or that they may be expressed in normal
tissues. For understanding tumorigenesis and creating therapies, a spectrum of markers
may be the answer”368.
In a study with normal appearing colonic mucosa from patients with colonic
adenomatous polyps (and risk of colon cancer), higher expression of CD166, EpCAM
and CD44 was found to be associated with increased EGFR (Epidermal growth factor
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receptor, thought to promote proliferation in cancer cells), number of polyps found and
age of the patients 369.
As already mentioned, origin of colon cancer can be explained by 2 popular models,
stochastic model and cancer stem cell model. The first strong support for the stem cell
theory in colon cancer comes, from two recent studies by O’Brien et al 38 and Ricci-
Vitiani et al 37 . Based on their xeno-transplantation experiments, these two groups
reported that CD133 is a marker for colon CSCs 37,38. However, a more comprehensive
study performed in similar lines by Dalerba et al revealed that only the EpCAMRich /
CD44+ / CD166+ fraction of cells represents the proliferative segment of a colon cancer
mass, in contrast to the cells expressing only CD133, which was found to be a variable
indicator for CSCs by these authors. They also reported that CD49f was a more
consistent marker for most cells expressing CD44. However, the authors failed to
establish the specificity of this combinatorial protein expression to be a unique signature
of a colon cancer stem cell 39.
1.1.4. Toponome imaging system:
The different levels at which the functionality of a cell is determined are genomic,
transcriptional, and at proteomic levels. Protein networks within and on the surface of
cells are highly organized, both timely and spatially, determining specific cellular
functions at different time points. The living cell has been described as a “protein co-
compartmentalization machine”, where “each protein must be at the right time, at the
right location and at the right concentration in a cell to interact with other proteins”194 . If
we are to believe that every cellular function is represented by a specific in situ pattern
of protein network in a cell, detecting such pattern can be of pivotal importance in
understanding the cell’s physiological and / or pathological behaviour193.
The ultimate goal of cell biologists is to decipher the chain of life from molecules through
cells to tissues and finally to organisms. In order to clearly understand how cells work,
robust knowledge regarding identities, structures, functions of individual molecules and
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their interaction with each other is therefore imperative370. Although information on
molecular structure and function of individual proteins is steadily on the increase, our
knowledge regarding formation of protein clusters at sub cellular level, interaction of
these clusters as networks to generate functions and finally reassembling of protein
molecules to form new clusters over time, generating new functional networks, is still at
its infancy371.
Formation of protein networks is hugely determined by the cell and its interactions with
surrounding cells and inter cellular matrix. Homogenisation procedures notoriously
destroy the 3D information of cellular distribution of proteins in a toponome and also the
distribution of cells in its natural habitat. If we are to believe that in order to form a
functional protein cluster, each component protein must be present at the right time,
right place and in the right amount, a system which breaks down tissues before
analysing the components (homogenisation techniques) can only provide quantitative
information, but fails to confirm whether these proteins were at the right place or at the
right time to react with the right protein. Again, from our discussion above regarding
normal colonic stem cells, we know that when stem cells are removed from their
protective niche in the crypts, it affects their ‘stem-ness’. This may indicate that a
majority of cellular functions are also related to cell – cell and / or cell – matrix
interaction. Thus, a system which reads a part or whole of the protein network, yet
conserves the tissue architecture is essential to understand not only the protein network
pattern of the ‘cell of interest’, but also its relationship to the matrix and surrounding
cluster of cells in the tissue. Single cell 3D proteomics technology thus analyses
functional protein molecular networks, which are undetected by large scale expression
profiles based on tissue homogenates. Again, from our understanding of cell biology, we
know that even with similar expression levels, different molecular distribution patterns
are responsible for entirely different characters in the same cell.
For example, let us assume that ‘Protein A’ is responsible for cell adhesion. After being
formed in the cell, it is carried by a ‘carrier Protein B’ to the cell surface, which is an
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essential stage for Protein A to express its function. The inability of transporting protein
A from cytoplasm to the cell surface, due to non-formation of Protein B may thus be
responsible for increased deposition of this molecular component in the cytoplasm and
may explain a different character like decreased adhesion or increased mobility of this
cell resulting into its invasive behaviour (example in a malignant condition) as opposed
to the normal state where this protein is evenly distributed in the same quantity on cell
membrane. In this example, homogenization techniques would identify no difference
between diseased and normal cells as the relative molecular quantities are constant in
either cell. Only a technique which reads the protein network code in intact tissue
sections would explain this difference in cellular behaviour by localizing Protein A.
In the past, the human genome project had revealed the code for all proteins, among
other things. The next big challenge was to understand how these proteins interact in a
cell with other proteins in a timely and spatial manner. Development of new technologies
with the capacity to co-localize a huge number of proteins in one biologically intact
section in order to reveal these functional protein patterns (assemblies or clusters of
different proteins, in the form of a protein distribution map, also considered as the
protein code or the “biological code”) generating concrete cell functions. It is now being
possible to explore biological structures through developing techniques, allowing us to
study supra molecular aspects of protein network from the level of the tissue down to the
sub-cellular compartments of single cells.
A technology has recently been described by Schubert and colleagues, which enables
us to systematically address such issues in morphologically intact tissue sections by
using an automated immune-fluorescence imaging technology called TIS (Toponome
Imaging System) 372,373. TIS has the capacity to identify functional and hierarchical inter
relationships of proteins on a large scale in a single cell in intact tissue sections. This
level of protein organization or the entirety of protein network has been referred to as the
‘toponome’ (from the ancient greek words ‘topos’ = place, position; and ‘nomos’ =
law)193.
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In order to address the internal structure of such complex sub cellular in situ protein
networks, the huge number of protein molecules that needs to be co localized in a single
tissue section can significantly exceed the number of available wavelengths in traditional
fluorescence microscopy for their respective spectral isolation. This problem was solved
by demonstrating a basic fluorescence method, breaking this spectral limit, by
application of a cyclical one/two-dye imaging system374.
TIS was applied to solve the “Riddle of Myogenic Stem Cells” with a panel of 19 different
protein marker tags375. By using protein co-localization techniques, the authors reported
that endothelial cells from surrounding micro-vessels migrated to the damaged portion of
the muscle fibres and formed new myotubes. Furthermore, the authors identified unique
protein combinations (using their randomly selected panel of 19 marker tags), for
myogenic stem cells, newly formed myotubes, mature endothelial cells and muscle
fibres. These findings pointed towards the possibility of trans-differentiation of mature
endothelial cells into newly formed myotubes by selective protein switch on / off
mechanism on cell surface (CD36 switched off in endothelial cells to form myogenic
stem cells, with expression of CD56, the later being an isoform of NCAM and putative
marker for mononuclear myogenic stem cells). These findings were supported later by
alternative approaches by De Angelis et al (Cossu Group) 376.
In a subsequent report, TIS was used to investigate human muscle tissue, affected by
Polymyositis, an inflammatory condition. The researchers applied a panel of 20 different
cell surface receptor proteins, which were co-mapped simultaneously and were
obviously mismatched in sections of muscle tissue (from chronic Polymyositis) with T
lymphocytes invading the muscle cells. This experiment suggested that abnormal
combinatorial surface protein organization may be selective for pathological conditions,
for example inflammation in Polymyositis. It also demonstrated that the T cells through
their migration from peri-vascular space to the muscles fibres (different stages in this
migration were; a] peri vascular space, b] inside endomysium in contact to basal lamina
cylinder and c] pacemaker T cells inside basal lamina cylinder) had different protein
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combinations on their cell surface, which were interestingly specific for the micro
environment the T cells were subjected to 377. Based upon these initial findings, this
same principle was further used to develop a robot assisted automated immune
fluorescence technology which has the capacity of co-localizing a quasi random number
of different molecules in one tissue section, called TIS372,373.
In this method, dye-conjugated marker molecules (tags) are applied on a fixed biological
sample. As soon as the first molecular component is labelled with the respective tag
(post incubation stage), the corresponding fluorescence signal is registered as an
image. Following this the fluorescence is bleached (post bleaching stage) and the first
incubation–imaging–bleaching cycle is completed. Signals (fluorescence images) are
also recorded following the bleaching step, when the tissue is expected to have minimal
or no residual fluorescence signal. Phase contrast images are also recorded at the
respective post incubation and post bleaching stages. This cycle is repeated over and
over again with individual markers specific for other molecular components in respective
cycles, each of which ends with the corresponding bleaching step. It has been
demonstrated by the authors, using TIS experiments on sections from human skin, that
this system has the capacity to successfully complete at least 100 such repeated
incubation-imaging-bleaching cycles (RIIBC) on one biological sample leading to high-
dimensional structure associated, combinatorial molecular data sets, on every data point
of this sample, yielding a power of combinatorial molecular discrimination (PCMD) of at
least 2100 per data point372.
In practice, with traditional multi-channel fluorescence microscopy, at best signals from
four or lower number of different tags can be identified separately. This is grossly
insufficient to identify and explore large molecular networks in an entire biological
structure371. In contrast, by using TIS, multiple molecular components can be
simultaneously co-localized at a sub-cellular level. This enables us to study the
functional architecture of a tissue on a larger scale and also provides us with unique
57
information regarding which proteins are inter-related (“mapping togetherness”) and
which proteins are not in a given physiological or pathological condition of the tissue378.
In the protein co-localization experiments with TIS, images obtained from RIIBC, are
aligned and are processed by subtracting background (false) signals. Protein signal
combinations per pixel are identified in this data set. Thus every fluorescent image for
every visual field is a vectorial representation for the respective protein molecular
expression. Signal combinations or combination of these vectors per pixel are expressed
either as relative grey value profile or following introduction of a threshold for each
signal, as a combinatorial binary code. All these signal combinations (depicting protein
clusters) are assembled as a data set known as “Toponome map”. Such a data set can
be used to visualize the location of a given protein cluster (combinatorial molecular
phenotype or CMP) in groups of pixels or voxels, on the background of the section of
tissue studied195,373,379. This imaging can be in 2D or in 3D380. Furthermore, these data
sets can be archived for future reference and analyses. Needless to mention, thorough
calibration experiments with all these tags needs to precede any such protein co-
localization experiment to assure the specificity and selectivity of each individual tag
used371.
Co-mapping of a large number of different CMPs in one sample can be easily done by
introducing a threshold grey value for each fluorescent signal. This threshold grey value
is determined by the background fluorescence or tissue auto-fluorescence. In order to
achieve this, at the beginning of a TIS protein co-localization experiment, few
subsequent tags (number of such tags is determined by level of tissue auto-fluorescence
and optimisation steps) are replaced by PBS (phosphate buffer solution) and RIIB cycles
are allowed to run. In these cycles, the tissue is bleached without any new fluorescent
tag added to the tissue. The fluorescent signal (post incubation image) obtained with the
last PBS run is considered equivalent to the background fluorescence and can be used
as the threshold grey value for the same experiment.
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Location of each protein is detected by presence of signals within a CMP, mapped as
tag absent (=0) or present (=1), depending on whether the value for the fluorescence
signal is below or above the threshold signal, respectively (=1 bit information per protein
at a pixel / voxel). CMP motifs thus defined as a group of CMPs possessing unique
common features. These motifs are defined by the assembly’s lead proteins (L = 1),
absent proteins (A = anti-colocated, 0) and wild card proteins (W or variably expressed
i.e expressed in some CMPs and absent in others). This three symbol code (L, A and W)
can be used effectively to describe motifs of protein clusters unique to certain interesting
regions in a tissue section (example glandular cells versus stromal cells) or a section in
a certain disease state, (for example, present in cancer but not in normal condition for
the same tissue) 195,373,379. The use of photonic microscopy and use of increased number
of tags further refines this technology. TIS has been used by several other researchers
since its first publication374 in 1990 by Schubert and colleagues379-387.
In vitro TIS experiments using Rhabdomyosarcoma cells (from cell line TE671) with a
panel of 23 cell surface proteins, revealed the significance of identifying and inhibition of
lead proteins in functional clusters372. The authors described different stages of disease,
where a resting (spherical) cell transforms in invasive (exploratory) cell after developing
cell extensions. Interestingly, protein co-localization by TIS revealed identical
arrangement of 5 CMPs formed of only 6 proteins (from the above panel of 23 marker
tags) located on all these cell extensions with the lead protein being CD13
(Aminopeptidase N) in all of these combinations. By selectively inhibiting CD13, the
authors demonstrated that the exploratory cells lost their cell extensions and
transformed back to resting spherical cells. Spherical cells on the other hand, failed to
develop cell extensions; thus could not reach the invasive phase. This finding was
exciting, as it pointed towards the possibility of downgrading Rhabdomyosarcoma by
selective inhibition of lead proteins in functionally important protein clusters and its
potential applicability in other cancers. This experiment also revealed a new cell
polarization function (APOCON model; Aminopeptidase Polarization Control Network
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Model) for CD13, which was unknown through other scientific techniques. Similar
experiments with Amyotrophic Lateral Sclerosis cells lines revealed FCRIII
(FCReceptor III) protein as the lead protein in the defective nerve fibres372. Later on,
using FCknock-out mouse models, Mohamed and colleagues confirmed the
significance of blocking /inhibition of this target protein to control disease388.
In an ongoing research project, Berndt and colleagues389 investigated the role of T-cell
mediated immune response in colon cancer. They reported that T-cells (mostly CD8+ as
compared to CD4+) were grossly increased in lamina propria in colon cancer with
increased expression of NF and CD29 (increase proliferation and decrease
apoptosis) in these CD8+ cells. As an inference, the authors raised the possibility of up-
regulation of host mucosal auto-defence mechanism due to cancer, which can
potentially be exploited for cancer immunotherapy. Experiments with a single section of
prostate cancer by Schubert and colleagues demonstrated the capacity of TIS in
identifying motifs for cells demonstrating features of PIN (Progressive Intra epithelial
Neoplasia)379.
To summarize, TIS is a significant advancement towards this quest for reading the
“biological code” of a section of tissue from human body, cell aggregates from cultures
or body fluids. This system has the capacity to co-localize large number of molecular cell
components independently in the same cell, within a morphologically intact tissue
section, in the same experiment, under similar conditions, presenting the data as a
coloured mosaic, which can stored as a database and compared with different patterns
from other experiments in a systematic way, pixel by pixel195. This technology uses large
molecular libraries of antibodies, peptides, lectins or different ligands to tag and localise
corresponding molecular components in a specially fixed tissue section, by means of
photonic signals (fluorescence). This fully automated novel technique is based upon the
principle of diffusion kinetics within defined sub-cellular volumes. It detects and registers
each individual molecule in a cell as a spatial signal map and aligns them relative to
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other molecular signals from the same cellular compartment. The net result is expressed
as a toponomic map of the cell(s) of interest. Comparing toponomes from same cell
types in different pathological states of a tissue can give us disease specific molecular
configuration of the same protein molecules present in normal physiological conditions,
explaining their differential behaviour like invasion, metastases, etc 193.
61
CHAPTER 2
1.2. METHODS AND MATERIALS.
1.2.1. Specimen source:
Sections of colon cancer and corresponding normal colon tissue were collected from the
same patient, diagnosed with Dukes’ C1 non-mucinous adeno carcinoma (T4, N2, M0)
involving the descending colon, with macroscopic secondary spread to lymph nodes and
omentum, without any prior radio or chemotherapy, but had adjuvant treatment following
the surgery. The cancer and normal tissues were extracted from the colectomy
specimen, from the surface of tumour mass and normal looking colonic mucosa 10 cm
distant to the visible tumour margin respectively. Experimental procedures with these
tissues were performed on the basis of written consent from this patient.
1.2.2. Tissue preparation:
Tissues were immediately fixed in 4% para-formaldehyde (PBS) solution after collection.
Following overnight cryo protection in 20% sucrose solution at 40C, tissues were
embedded in OCT blocks and stored at -800C (minus 80 degrees) until preparation of
frozen sections.
1.2.3. Preparation of cover slips for experiments with TIS:
Following steps were followed to prepare coverslips in-house for the tissue sections for
our TIS experiments, in line with protocols described before373:
1) 5 millilitres of 3-aminopropyl-triethoxysilane (Fluka, cat no. 09324, kindly supplied
by Dr. Walter Shubert’s lab, Magdeburg, Germany) was mixed with 250 millilitres of
acetone to prepare “silane solution”.
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2) Coverslips (24 x 60 mm, thickness; 0.13 - 0.16 mm, vwr cat no. 16004-096) were
placed on a coverslip holder, placed in a glass chamber filled with freshly prepared
“silane solution” and incubated for 60 minutes at room temperature.
3) The coverslips is thereafter washed by placing the coverslip holder in two
separate glass chambers one after the other (each for 10 minutes) with clear distilled
water.
4) Coverslips are now baked at 600 C for 12 hours. Dried coverslips are stored at
40C for a maximum period of 4 months.
5) Defective coverslips: Some of the coverslips prepared in the above process
developed some dried water drops. These coverslips were discarded.
1.2.4. Preparation of tissue sections:
5 micrometre sections were cut from each block in a cryotome and every alternate
section were placed on special coverslips (numbered in sequence) preparation of which
has been discussed above. The temperature of the cryotome was set at minus 18
degree centigrade. These coverslips are attached to slides by OCT (tissue tech) and
stored in slide holders at minus 800 C freezer for future use. The other alternate set of
sections is collected on normal glass slides for Haematoxylin and Eosin stain. Thus for
every tissue section for TIS, we had two adjacent sections (one immediately before and
one immediately after) for H&E, numbered and stored in minus 800 C.
1.2.5. Antibody library:
We used a library of 20 different antibodies to identify the corresponding proteins in the
cancer, normal and omentum tissue sections. All the antibodies (except DAPI or 4,6’-
diamidino-2-phenylindole) were directly conjugated with FITC (fluoresceine-iso-thio-
cyanate). Of these, seven recognised nuclear markers, twelve recognised cell
membrane proteins and the remainder membrane and cytoplasmic markers. The list of
the tags used and their respective technical details are summarized below:
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Antibody (tag) Concentration Dilution Company Catalogue no.
DAPI 1.5µg/ml 1:150
Vector Lab.
Burlingame, USA H-1200
PCNA
Rabbit Polyclonal
IgG
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-7907 FITC
Bcl-2
Mouse, Monoclonal
IgG1
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-509 FITC
Bax
Mouse Monoclonal,
IgG2B
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-7480 FITC
Cyclin A
Rabbit Polyclonal
IgG
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-751 FITC
Cyclin D1
Mouse Monoclonal,
IgG2B
0.2mg/ml 6:100
Santa Cruz
Biotechnology,
USA
sc-8396 FITC
Ki67
Monoclonal
Antibody
0.1mg/ml 6:100 AbD Serotec , UK HCA006F
CEA
Mouse Monoclonal
IgG2B
0.2mg/ml 1:50
Santa Cruz
Biotechnology,
USA
sc-59875 FITC
CD44/HCAM
Mouse, Monoclonal
IgG1
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-7297 FITC
CK-19
Mouse, Monoclonal
IgG1
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-53003 FITC
CK-20
Goat Polyclonal,
IgG
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-17113 FITC
special custom
CD29
Mouse, Monoclonal
IgG1
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-9970 FITC
CD36
Mouse Monoclonal,
IgM
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-7309 FITC
CD57
Mouse Monoclonal,
IgM
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-6261 FITC
CD133
Mouse Monoclonal,
IgG1
0.1mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-130127
FITC, special
custom
Laminin -1
Rabbit Polyclonal
IgG
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-5582 FITC,
special custom
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CD166
Mouse, Monoclonal
IgG1
0.1mg/ml 1:5 AbD Serotec , UK MCA1926F
EpCAM
Mouse, Monoclonal
IgG1
0.1mg/ml 1:25 AbD Serotec , UK MCA1870F
NCAM/CD56
Mouse, Monoclonal
IgG1
0.2mg/ml 1:5
Santa Cruz
Biotechnology,
USA
sc-7326 FITC
Muc-1
Mouse Monoclonal,
IgG3
0.1mg/ml 1:5 AbD Serotec , UK MCA1742F
Muc-2
Mouse, Monoclonal
IgG1
0.1mg/ml 1:50 AbD Serotec , UK
MCA1743F,
special custom
1.2.6. Rationale behind using different antibodies:
We selected a random set of markers (Table 1 at the end of manuscript), related to
colon cancer for this initial optimising experiment. The rationale behind selecting cancer
stem cell related antibody targets like CD133, CD166, EpCAM and CD44 has already
been discussed in “introduction” above. A potential limitation in using more extensive
range of markers was unavailability of most antibodies in the conjugated form and
relative paucity of funds for this initial project. Here we would discuss the rationale
behind using the rest of the antibodies in our experiment.
 Nuclear markers: Proliferating cell nuclear antigen (PCNA), Cyclin A, Cyclin D1
and Ki67 are markers for cell proliferation and are thought to be associated with
metastasis and poor prognosis in colon cancer390,391. As previously discussed,
aneuploidy is commonly found in colon cancer. Cyclin A expression in nuclei has been
found to correlate well with colon cancers with aneuploidy245. The nuclear protein, Bax
(Bcl2-associated X protein), is a known inducer of cell death. Loss of this protein imparts
the cells with resistance to apoptosis392.
 CD29 (Integrin 1): It is a cell adhesion molecule, expressed in high
concentrations on the epithelial cell surfaces and is downregulated in advanced
colorectal cancer along with other adhesion molecules like E-Cadherin. DNAzymes
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targeting Integrin 1 have been shown to down regulate neovascularisation and several
other key tumourigenic processes in colon cancer both in vivo and in vitro393,394.
 CEA (Carcino-embryonic antigen): It is expressed in cytoplasm and cell
membrane of normal columnar epithelial cells and goblet cells in colon, but levels are
increased in many patients with colorectal cancer particularly those with hepatic
metastases; CEA is used to follow up colon cancer patients in clinical practice395-397. Its
importance has been discussed in the section of Biomarkers in “introduction”.
 Muc-1 and Muc-2. Mucins are epithelial glycoproteins and can either be of
transmembrane type (eg. Mucin-1 or Muc-1) or secreted gel forming type (eg. Mucin-2
or Muc-2). Muc-2 is over-expressed only in mucinous adenocarcinoma, but not in non-
mucinous types. Though still under debate, the current view regarding colon cancer is
that, up-regulation of Muc-1 and down regulation of Muc-2 correlate with advanced
disease and distant metastases398,399.
 Anatomical markers: We used DAPI400 to define the nuclei. Relevant tissue
anatomy was marked by Laminin401, CD36402, NCAM (neural cell adhesion molecule)403,
CD57 (HNK-1)404-406 and cytokeratins (CK-19 and CK-20). Along with anatomical
information about intracellular cytoskeleton, CK-20, a known marker of enterocyte
maturity407, is also known to be over-expressed in colon adenocarcinoma as compared
to normal colon408,409.
1.2.7. Toponome imaging system (TIS):
Detailed description of TISTM, purchased from ToposNomos Ltd. (Munich, Germany;
www.toposnomos.com), has been published previously195,372,373,379. Briefly, TIS is a
highly standardized robot imaging system for use, among other things, in the human
toponome project48. TIS comprises of an inverse epi-fluorescence microscope, a cooled
CCD camera, and a pipetting robot running many repetitive cycles ( up to > 100) of tag-
dye incubation, fluorescence imaging and bleaching on the microscope stage to
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generate a large number of protein location images of the same cell/tissue structure
(Figure 7).
The cover slip with respective tissue section was mounted on the stage of the inverted
wide-field (Zeiss) microscope implemented as part of the TISTM imaging robot. We used
fluorescence filter for FITC at position one (emission 520/35 BP, excitation 472/30 BP,
beam splitter 495LP), originally provided from AHF analysentechnik (Tübingen,
Germany, catalogue number F36-525) and installed DAPI filter (Filter set 49, catalogue
number 488049-9901-000, emission 445/50 BP, excitation G 365, beam splitter 395 FT)
to visualize the nuclei. For each tissue section, the experiment consisted of 25 repetitive-
incubation-imaging-bleaching (RIIB) cycles in line with the protocol previously
described372,373. The first four cycles consisted of PBS (described as PBS 1, 2, 3 and 4).
For ruling out false staining, we used a fifth cycle with PBS at an intermediate position in
the run. The temperature of the robotic system was maintained at 20°C. In each cycle,
phase contrast (at the beginning and end of the cycle, named IP and OP images
respectively) and fluorescence images (both before and after tag addition, called IF and
OF images respectively) were taken by a highly sensitive, cooled (- 20°C) CCD camera,
fitted to the side panel of the microscope. The magnification was adjusted to 63 times
and light intensity for the microscope bulb was set to 3.2 V. Shutter opening and closing
times were co-ordinated with the bleaching, end of incubation and washing times by the
TISTM software running the system. For all the antibodies, except DAPI, shutter opening
time was programmed to 600 ms for the phase image and 1000 ms for the fluorescent
image. For DAPI, these times were 2000 ms and 100 ms respectively. Almost all the
antibody tags used in our experiments have been used in diagnostic medicine and/or
cancer research in the past. Positive signals are therefore expected to mark the
positions of the target proteins.
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Figure 7: This figure demonstrates the toponome imaging system used for performing
these experiments with colon cancer and normal colon. Numbered arrows are used to
identify the important components:
1. Buffer tray covered by thin aluminium foil, to be pierced by the pipette tip.
2. Antibody tray, to be filled with antibody solutions of specified dilutions.
3. Pipette tip attached to the end of the robot arm.
4. Camera attached to the side port.
5. Microscope
6. Glass slide for the tissue section.
7. Touch panel control for microscope.
1.2.8. Optical parameters and magnification:
We used 63 times objective without any additional magnification from the microscope.
The CCD sensor has a nominal pixel number of 1024 x 1024. The pixel size is 13.0 x
13.0 micrometer. So the sensitive area is 13.3 x 13.3 millimetres. One pixel in the image
equates to 206 x 206 nanometres. When viewed through the eye-piece (10x
magnification) the net magnification with x63 objective will be 630 times. However, the
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camera attached to the side-port does not use the eye-piece. Hence magnification of the
images visualized on the computer screen is as follows:
Thus the images shown or are analyzed are approximately 740 times magnified. All
analyses are done on these images; hence the slight difference in magnification, when
visualized through the eye-piece has no implications on the final results.
1.2.9. Haematoxylin and Eosin (H&E) staining of slides:
Following protocol was followed for H&E staining of alternate sections (please refer to
preparation of sections) on glass slides (object slides 26mm x 76mm x 1mm, Marienfeld,
cat no.1000100). All steps were performed in room temperature:
1) Slides were mounted on a slide holder.
2) Slides incubated in Haematoxylin for 2.5 minutes.
3) Slides washed in distilled water for 45 seconds.
4) Slides incubated in acid alcohol for 45 seconds.
5) Repeat wash of slides in distilled water for 45 seconds.
6) Slides incubated in Scott’s solution for 1.5 minutes.
7) Repeat wash of slides in distilled water for 45 seconds.
8) Slides were thereafter incubated in eosin for 2.5 minutes.
9) Wash of slides in distilled water for 45 seconds.
10) The holder is then immersed and incubated in the following freshly prepared
solutions:
 50% Ethanol for 1 minute.
 70% Ethanol for 1 minute.
 80% Ethanol for 1 minute.
 90% Ethanol for 1 minute.
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 100% Ethanol for 1 minute.
 2 sets of Xylene solutions for 1 minute each.
11) Slides were immediately mounted in DPX and covered by a coverslip. They were
stored in a cool dry container for subsequent viewing.
1.2.10. Selection of appropriate sections for TIS runs:
Given the extremely heterogenous distribution of cancer cells in a tumour mass, we
selected the process of detecting them by studying the immediately adjacent sections
with protocol H&E staining. These H&E stained sections were studied by a trained
histologist and presence or absence of cancer was reported in them. The approximate
location of cancer cells in the H&E stained section was also pointed by a coloured
“pointer” by the Histologist. Based on these findings, we selected the appropriate
sections for TIS experiments. The “pointer” helped us in selecting the appropriate visual
fields, as will be discussed below.
1.2.11. Preparation of tissue for experiments with TIS:
Following steps were followed in preparing the tissue section immediately before starting
TIS run:
1) The sections were selected from the catalogue based on the results of H&E
staining.
2) Slides with attached coverslips were taken out of the freezer.
3) These were incubated in ice cold acetone at minus 200 C for 10 minutes.
4) Following this the section was air dried for 2 minutes and clean tissue paper was
used to wipe off the acetone around the section. Care should be taken not to disrupt the
tissue section.
5) A silicone ring (prepared in house from “Press-To-Seal silicone sheets, adhesive
on one side, Molecular Probes, cat no. P24725; rings with inner diameter: 10mm, outer
diameter: 20mm and height: 1.4mm) was attached to the coverslip surrounding the
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section, so that a watertight “well” was created and section lies at the bottom of it. The
area of the glass coverslip around the tissue section should be wiped absolutely dry to
facilitate the attachment of silicone ring.
6) The section was thereafter incubated with 200 l PBS by filling the well with it for
10 minutes.
7) At this stage, the coverslip was carefully separated from the slide and the other
side of the coverslip was wiped off all the embedding media by 70% ethanol solution.
This was a critical step, as this surface would be in direct contact with the lens of the
inverted microscope of TIS and in the light path of the microscope. Any excess
embedding material on this surface can therefore result in the following errors:
 Artefacts in images.
 Impaired movement of the slide over the lens and restricted shifting of one visual
field to another in between the run causing blurred images.
8) At this stage the PBS used in step 6 was removed and the tissue section
incubated with 200 l of goat serum solution (1.5 ml goat serum solution prepared by
mixing 50l of goat serum + 1450l of PBS) for 30 minutes to block non-specific
antigenic sites.
9) Following this the tissue section was washed with 100 l PBS for 20 times.
10) At the end of the washing step, the well was filled with 200 l PBS, rendering the
cover slip ready for the TIS run.
1.2.12. Setting up of TIS run, preparation of antibody and buffer trays:
At this stage, an appropriate programme is written in which the exact tag names,
incubation times, washing steps and the wells from which the robot collects the
respective antibody/buffer solutions are specified in detail. According to the data in this
programme, 96 well PCR plates (BrandTech, semi skirted 0.2 ml, 96 well PCR plate, cat.
no. 781400) were used to prepare antibody solutions. Buffer (PBS) used for intermediate
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washing steps was filled in the buffer trays (BrandTech 96 deep well plate, 2.2 ml, cat
no. 701354), placed in TIS. Both these trays were covered with aluminium foil which
would be pierced by robot disposable pipette tips (Eppendorf Combitips plus, 0.1ml,
Biopur, cat no. 0030 069.404) in TIS. Following these steps, the coverslip with the
prepared tissue section surrounded by the silicone ring is fixed (taped) to the platform
over the inverted lens of the TIS microscope. Low power of magnification (x10 and x20)
is used to select the appropriate area of the visual field initially. When an appropriate
area in the section is selected in low power, it is focused against the high power oil
immersion lens (x63). After manual selection of visual fields the TIS automated software
is allowed to run repeated incubation-imaging-bleaching-cycles on the same set of visual
fields (maximum of 5 visual fields), giving stacks of images as described before. The
images are automatically saved in preselected folders in the hard drive of the TIS
computer.
1.2.13. Construction of toponome maps:
As previously mentioned, for every antibody tag used (including each cycle of PBS), the
system stored 4 images for each visual field concerned. They were named as IF (initial
fluorescence), OF (post fluorescence), IP (Initial phase) and OP (post phase), as
mentioned before. Every fluorescent image is then corrected for inhomogeneous
illumination by using block based histogram-equalization algorithm, which is
programmed in interactive data language. By processing the phase contrast images (IP
and OP), relative misalignment in between images (due to shift between visual fields by
movement of the microscope stage in the run) are corrected using a block matching
algorithm with cross correlation as a maximum function. These corrections taken
together results in a stack of “shifted” (aligned) and “subtracted” (net fluorescence)
images. These images are then manually “binarised”, where an expert (chief researcher,
assisted by a histo-pathologist) sets thresholds for each given fluorescent signal,
revealing the most prominent binary signals, which are characteristic for any given
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antibody tag, as discussed in details by Schubert and colleagues373. Superimposition of
all these “shifted”, “subtracted” and “binarised” images for each visual fields by MoPPi
software gives us a toponome map for the corresponding visual field. This map is
presented as clusters of proteins and is viewed using the same software on the
background of a phase image (to compare relative locations of different CMPs in the
tissue) or over another fluorescent image (for example, DAPI, showing the relative
positions of the nuclei and CMPs).
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CHAPTER 3
1.3. RESULTS: OPTIMISATION OF TIS TO COLON CANCER RESEARCH.
Optimising first TIS unit at Warwick for colon cancer project:
In this section we will discuss the steps taken towards optimising the first TIS unit for a
future project with colon cancer. We will also highlight the obstacles faced and technical
errors for which several runs had to be abandoned. The aim of this section is therefore
to help future researchers in this unit. The approval for this research has been granted
on 26th October, 2006 by the Warwickshire Local Research Ethics Committee,
Warwickshire, UK. The research has been performed in Biological Sciences Laboratory,
University of Warwick, Coventry, UK. The human tissue has been collected from
operative samples at the George Eliot Hospital, Nuneaton, UK.
1.3.1. Finalising antibodies and their adequate concentrations for TIS:
A pre-requisite for TIS, as already mentioned in “Methods” section, is antibodies
primarily conjugated with FITC. Several antibodies like CD44, CEA, Cytokeratin-19,
Cyclin A, Cyclin D1, PCNA, Bax, CD29, CD36 (from Santa Cruz Biotechnology Inc,
Santa Cruz, USA), EpCAM, Muc-1, CD166 and Ki67 (from AbD Serotec, UK) were
purchased as primarily conjugated form which had been previously used in human
tissues and has been shown to work within a range of concentrations410-412. We started
our optimisation steps with these antibodies on our trial colon cancer sections on the TIS
using short 3 or 4 antibody programmes on one visual field. However, when we applied
these concentrations to the TIS, we found that most of these antibodies failed to stain
any tissue (Figure 8a, see below). Overnight staining of most of these antibodies in
separate experiments on colon cancer tissue (sectioned by similar specifications)
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revealed good staining. We implicated our failure to demonstrate adequate staining in
TIS on the short incubation time (60 mins) as compared to overnight staining (10 hours).
Longer incubation in TIS had the potential limitations of drying of tissue section being
stained (progressively increased risk of drying towards the end of the run) and usage of
fluorescence bulb time (maximum recommended length of use of one bulb = 300 hrs,
HBO 100 fluorescent bulb, Zeiss, cat.no. 380018-4060, $160.00). These limitations were
overcome by increasing the concentrations of these antibodies and finally reaching the
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Figure 8: Figures showing results from optimisation runs. Figure 8a shows a section of
colon cancer where antibodies did not localise any proteins due to low concentration
during optimisation. Figure 8b shows complete white out image due to much higher
concentration of antibody Ki67 used on a colon cancer specimen. Figure 8c shows an
artefact with false fluorescence. Of note, these artefacts can result in false staining.
Figure 8d demonstrates unopened shutter, a problem encountered during TIS runs in
Warwick. Figure 8e shows a blurred phase image, possible causes being un co-
ordinated shutter opening or mal-positioned condenser of the microscope or moving
stage while imaging process in going on. Figure 8f shows artefact and blurring of phase
image due to auto-focussing on the artefact rather than on the tissue section.
desired dilutions as mentioned in the “methods” section. On few occasions we also
accidentally used much higher dilutions (especially with antibodies like CEA and Ki67)
and these resulted in complete whiteout images (Figure 8b). The exposure time (camera
shutter opening time) for fluorescence image was fixed at 1000 ms for all antibody tags
(except DAPI, which was 100 ms). These fluorescent times were also titrated and
optimised with different exposure times and antibody concentrations to reach these
values to obtain the best images. Several antibodies like CD133, Cytokeratin-20,
Musashi-1 (from Santa Cruz Biotechnology Inc, Santa Cruz, USA), Muc-2 (from AbD
Serotec, UK) were not available in primary FITC conjugated form and had to be custom
made (specially conjugated by the respective companies). Of these antibodies, Musashi-
1 never worked in our tissues, a cause for which was never found. This tag was
therefore left out from our subsequent experiments. Again, some antibodies although
showed good staining initially, subsequent runs demonstrated huge artefacts (Figure 8f)
possibly from impurities present in the antibody itself. As we had no facility or expertise
of filtering antibodies in our unit, we had to dispose these antibodies as well.
1.3.2. Optimising TIS specifications:
The TIS programme that was responsible for running the automated repeated
incubation-imaging-bleaching cycles had to be written before hand. The variables like
shutter opening times (exposure time), light intensity, amount of PBS to be used in
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washing steps, number of washing steps to be used in-between two cycles, temperature
of the CCD camera and that of the TIS system were optimised one at a time depending
on our past experiences and with help from our German collaborators (Dr. Schubert’s
laboratory in Magdeburg). The shutter opening times was the most significant of the lot
as very short opening times (less than 100 ms) in a long run often resulted in one shutter
remaining closed in several images, resulting in partial blackout of the corresponding
segments of these images (Figure 8d). These short shutter opening times also resulted
in un-coordinated opening of two shutters, which also resulted in extreme blurring of few
images, rendering these images and therefore the whole run unusable. This problem
was also resolved by setting the CCD camera temperature to minus 20o C. The final
exposure times as mentioned in the “Methods” section were 600 ms for all phase
images (except that for DAPI which was 2000 ms) and 1000 ms for all fluorescent
images (except 100 ms for DAPI). The light intensity for the microscope was optimised
to 3.2 V. Intensities higher or lower than this value resulted in bright or dark phase
images respectively. Poor illumination was responsible for errors in auto-focussing steps
of the TIS microscope and resulted in blurred images (Figure 8e).
1.3.3. Optimising steps of tissue section preparation:
As already mentioned before, we have collected our colon tissue from (colectomy)
operative specimen. Although this patient had full bowel preparation before the
operation, in some cases faecal impurities were trapped. In some initial tissue sections
prepared, we found these foreign bodies presenting as bright spots in all the images.
However, by careful selection of visual field (avoiding solid particles in the visual field) in
the sections studied, decreased the incidence of such foreign bodies (Figure 8f) in
subsequent experiments. We believe that to reduce the incidence of foreign bodies in
sections, colon tissue needs to be rinsed in distilled water carefully. To reduce artefacts
in images resulting from impurities in PBS, we filtered the PBS (used for washing steps
in the TIS run, diluting antibodies and goat serum and preparing tissue section before
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TIS run) using cellulose filter paper (cat. no. CFP1-070, Sterlitech Corp. Kent, WA,
USA). However, we still get some occasional artefacts in our images, the cause of which
is currently being investigated.
1.3.4. Technical problems:
We encountered a few technical problems which are worth discussion. They were
responsible for disruption of several experiments and causing major delays in this
project. We started with a Micro Line ML-4710 camera with CCD sensor for imaging in
TIS, supplied by EHD imaging GmbH (EHD imaging GmbH, Damme, Germany,
originally supplied by Finger Lakes Instrumentation, Lima, New York, USA), which had 4
metallic shutter lamellas, fitted on a rubber ring. These shutters after several runs
underwent corrosion and this along with dirt particles caused increased inter-shutter
resistance causing un-coordinated opening of shutters on one or more occasions. The
consequences of such happening have already been discussed in the section under
“Optimising TIS specifications”. This problem needed repeated cleaning of the shutters
by a technical expert and abandoning the entire run. The technical support was un-
available in our unit (funding issues). Hence the use of this camera was found to be
unacceptable. This camera was replaced by a new camera (supplied by the same
company), a high quality product from Uniblitz, USA, which had 2 lamellas. It performed
much better, though extremely sensitive to the temperature. However when the
temperature was fixed to minus 20o C it worked better and posed no further problems
with respect to image quality after the shutter opening times were optimised.
In this period, we also found that the TIS suddenly stopped producing any fluorescent
images with the new CCD camera. This was found to have resulted from a cable fault
which co-ordinated the fluorescent imaging and shutter opening. This needed further
technical support from Germany.
The change of fluorescence bulb needed opening of the rear segment of the TIS cabinet
and on one occasion was associated with displacement of the robot arm by few
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centimetres. As a result of this, when we tried to start our next experiment, the TIS
programme could not identify the robot and flashed “Init COM4 error” message. Due to
lack of in house technical support, we had to wait for assistance from Germany and this
was resolved by simple manual re-placement of robot arm to the correct position.
The MoPPi software is German in house software (from Magdeburg) and is slow to
work on certain UK systems. It needs a bigger computer hard drive and does not work
on laptops. This prohibits reproducing the TIS analysis in other computers and therefore
restricts all the work on to one computer only. However, projects relating to its
development are ongoing in Germany.
The TIS present with any errors as “Init COM4 error” and it needs technical expertise
to know and solve the background problem, however small it may be. This causes major
delays in the experiments. In house technical support may be an answer to this problem.
An improvement in “notification of the type of error” (specifying exactly where the
error is and what is the easiest way to resolve it) can also help in resolving it faster and
resuming work on this system.
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1.4. RESULTS: TIS analysis of colon cancer and normal colon from the
same patient:
In this section, we demonstrate the potential of TIS in the investigation of colon cancer, a
complex disease, involving disordered cellular biology which can be readily observed
under the microscope. In this “proof of concept” section413, a colon cancer tissue (5 m
section) was compared with another tissue section (5 m) from adjacent area of normal
colon, sourced from the same colectomy specimen, 10 cm away from the cancer edge.
The tissues were respectively confirmed as cancer-containing and normal by an
independent pathologist, experienced in colorectal cancer. These sections were
prepared for TIS as previously described373. Serial sections were H&E stained and were
also examined by the pathologist to confirm that cancer was present or absent in each
tissue preparation (Figure 9x and 10x). Figure 9x, shows adenocarcinoma with
infiltrating, irregular, glandular, neoplastic elements and forming abnormal acinar
architectural structures. The carcinoma shows a moderately differentiated pattern, with
constituent cells demonstrating abnormal cytological features, including disrupted
cytoplasm with variable, enlarged, hyperchromatic nuclei showing some conspicuous
nucleoli. In addition, nuclei are disordered and instead of being in a regular orderly basal
arrangement are multilayered and stratified. Surrounding the glands a reactive fibro-
inflammatory stroma is also present. Conversely, Figure 10x, shows an entirely normal
colonic glandular structure, with no evidence of cancer and normal cellular architecture.
The visual fields (VF) for this study were selected by detailed analyses of the
histopathology in line with previous studies379.
The various individual TIS images resulting from 21 different protein location cycles,
following alignment and subtraction, are shown in Figures 9a - 9w and 10a – 10w. These
images were then used for subsequent MOPPI clustering and other analyses to
determine CMPs for normal and colon cancer tissues.
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Cancer CMPs:
Following features could be noted in the list of CMPs obtained from this cancer run:
 The total number of CMPs in colon cancer was found to be 6813 (supplementary
table).
 Most glandular epithelial cells in colon cancer were found to co-express Ki67 and
CK-20, a feature found slightly more prominently in cancer as compared to normal (data
not shown). However, when we looked at the co-expression of the cytokeratins (CK-19
and CK-20) in cancer (Figure 11), the motif showed marked decrease in cellular
expression. The CMPs representing the cytokeratins were found to be grossly
disorganized and clumped in the peri-nuclear area in cancer cells.
 Another feature of the colon cancer was a higher degree of expression of CEA
and CK-20 combination CMPs on the epithelial cell surfaces as compared to normal
(data not shown).
 In the cancer tissue, we found a motif of few busy CMPs, co-expressing CD133,
CD44, EpCAM and CD166 as the lead protein. These CMPs highlighted five cells in the
cancer tissue (Figures 12a and 12b, first row, marked by black arrows). Three (upper) of
these cells were found to be adjacent to the glandular epithelial cells and other (lower)
two, in the matrix. Interestingly, when CD133 was taken off this list of lead proteins, the
resultant CMP motif (Figures 12c and 12d, middle row, marked by white arrows)
highlighted only one more cell in the whole visual field in the matrix, apart from the
above five cells (centre of the visual field, CMP colour = purple). This clearly shows that
in most of the cells CD133 is co-expressed with the other three proteins in cancer.
 From the list of all CMPs in cancer (supplementary table), it has been found that
the cells marked by all the above protein clusters also co-express Ki67 and most nuclear
proliferative markers.
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Figure 9: Fluorescent images from cancer colon section used to create cancer CMPs.
 We have studied the CMPs that are specifically expressed in the stromal cells
(Table 3) and glandular cells in colon cancer (Table 4). We have obtained a motif of
CMPs which highlight the cells present in stroma in particular with very little expression
in the glandular epithelial cells. In this motif, the lead proteins were CD57, Laminin and
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PCNA. The proteins CD29, CD36, CEA, CK-19, Muc2, Muc1 and NCAM were absent
and hence “anti-co localised”. Rest of the proteins were variably expressed (wild cards).
In contrast to stromal cells, the glandular cells mostly co-expressed EpCAM, CK-20 and
CEA as lead proteins with anti-colocalisation of CD44 and CD36. The rest of the
proteins were found to be variably expressed. These findings are shown in a schematic
diagram in Figure 13.
CMPs in Normal:
Although, we primarily used normal colon to subtract the background normal features
from colon cancer, we found that many features in normal colon were totally different
from those in cancer tissue.
 The first striking feature was the number of total CMPs, found in normal colon
was nearly 5 times (32,009, please see supplementary table) as compared to cancer
tissue (6813, supplementary table).
 Among the 15 most frequent CMPs in normal colon, only a few CMPs were
found to be very interesting. The CMPs 1, 3, 4, 7, 8, 9 and 11 (table in figure 14), had 17
or more different proteins co-expressed. NCAM and CEA were anti-colocated. Muc-2
and EpCAM were found to be wild card proteins in this CMP motif. When looked on the
phase and DAPI images (Figure 14), interestingly most of these CMPs were localised in
glandular epithelial cells. Very few of these busy CMPs were found to be expressed in
the matrix. Another interesting finding was the total absence of these CMPs in colon
cancer tissue.
 All CMPs with CK-19 and CK-20 as lead proteins express many more glandular
cells in normal colon as compared to colon cancer (Figure 11c and 11d). When
visualized on respective phase and DAPI image backgrounds the motifs with these lead
proteins are extremely crowded on the glandular epithelial cell surfaces as compared to
the cancer cells.
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 In contrast to cancer tissue, only a few glandular epithelial cells showed CMPs
co-expressing CEA and CK-20 (data not shown).
Figure 10: Fluorescent images from normal colon section used to create normal CMPs.
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Cancer-unique CMPs:
By subtracting the CMPs found in normal from those in cancer (by Multicompare
software of MoPPi), we found 5708 CMPs (full list in supplementary table), which were
unique to cancer and will be referred as “cancer unique” motif. A list of 15 most
frequently appearing CMPs in “cancer unique” motif is shown on the cancer tissue in
figure 15.
In “cancer unique” data set, we found a motif of 34 CMPs (refer to Table 2 at the end of
manuscript, Figure 16a and 16b, magnified in 16c and 16d on phase and DAPI
backgrounds respectively). All these CMPs had the following lead proteins: CD133,
CD166, EpCAM, Muc-1, Laminin, CD57 and CK-20. The common findings about these
CMPs are as follows:
 Cells marked by these CMPs also expressed Ki-67, PCNA, Bax, Bcl-2 and
Cyclin-A.
 CD44 was found to be a wild card protein and was seen to be co-existent with
the rest of the lead proteins in only 5 CMPs (range of frequency 28 – 1).
 The cells marked by these 34 CMPs were mostly present adjacent to the
glandular epithelial cells (table 5).
 All the CMPs described by those lead protein were found to be peri-nuclear or
slightly overlapping the respective nuclei. This proves that the CMPs are marking
specific cells and are unlikely to be spurious.
 A magnified view of these cells is given in figures 16c and 16d. In order to get a
full list of proteins and CMPs present in these few cells of interest, we looked at them in
the raw CMP data from cancer and found that, all these cells also co-express CD44,
along with the above proteins. However, most of these CMPs with CD44 were found to
be present in normal colon as well as cancer. Surprisingly only few CMPs (with very low
frequency) in these cells had CEA, which was contrary to our expectations.
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MoPPI analyses of Cancer and Normal CMPs:
The first level of analyses involves a comparison of the 15 most frequent CMPs unique
to either cancerous or normal colon (Figures 15 and 14, respectively). In each of figures
14 and 15, the left panel shows CMPs superimposed on the phase contrast image; the
right panel shows the same CMPs superimposed on the corresponding DAPI
Figure 11: Glandular structure in: colon cancer (figure a, phase contrast and b, DAPI)
and normal colon: (figure c, phase contrast and d, DAPI). The cell cytoskeleton, marked
by CK-19 and CK-20, is disrupted in colon cancer (figures a and b) and clumped in the
perinuclear area (figure b). In contrast, in normal colon the cell cytoskeleton is much
more evenly distributed (figure c and d).
fluorescence image showing the location of cellular nuclei (white). CMP coding lists are
shown on the bottom of the figures with (i) specification of molecules co-mapped by TIS
(top line no.´s 1 – 21 of the list), (ii) specification of coloured CMPs, in which every CMP
expresses a unique combinatorial binary code (1 bit information per protein/molecule)
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corresponding to the colours in the phase- and DAPI- images; (iii) CMP motifs (bottom
line of the list). For this study we chose to concentrate on the 15 highest frequency
CMPs, based on previous studies in other systems.
Figure 12: Subset of colon cancer cells identified by CMPs. Cells marked by CMPs with
lead proteins; CD133, CD44, EpCAM and CD166 in the top row (a and b) and cells
marked by all the CMPs with CD166, CD44 and EpCAM as lead proteins in the middle
row (c and d) in cancer tissue. The CMPs in the top row have been shown by black
arrows and those in the middle row by white arrows. The bottom row (figure e, f and g)
shows magnified views of all CMPs from figure c. All the CMPs in the top and middle
sections have CD133 co-expressed along with CD166, CD44 and EpCAM, except the
single cell (CMP=colour purple) towards the centre of the middle row of images (c and
d). This cell is magnified in figure g in the bottom row.
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Figure 13: Schematic diagram indicating CMP motifs specific for glandular cells and
stromal cells in colon cancer (in 13A) and normal colon (in 13B). The proteins are
indicated by numbers as in the table in the bottom right hand corner. The inner circle
shows proteins (highlighted in red) which are lead proteins. The outer circle shows the
other proteins in the motif, the ones highlighted in yellow are anti-colocalised or absent
and the rest are variably present (wild card proteins).
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Figure 14: Fifteen most frequent CMPs in normal colon. In this figure, each colour
represents one specific CMP with sub-cellular resolution. The left panel shows CMPs
superimposed on the phase contrast image; the right panel shows the same CMPs
superimposed on the corresponding DAPI fluorescence image showing the location of
cellular nuclei (white). Note the CMP coding list shown on the bottom of this figure with
(i) specification of molecules co-mapped by TIS (top line no.´s 1 – 21 of the list), (ii)
colour specification of CMPs, in which every CMP expresses a unique combinatorial
binary code (1 bit information per protein/molecule) corresponding to the colours in the
phase- and DAPI- images; (iii) CMP motifs (bottom line of the list). This CMP motif
represents the higher order organisation of the 15 different CMPs as a group with
features common to all CMPs described by a three symbol code. L, lead
protein/molecule (present in all CMPs); A (proteins/molecules which are absent in all
CMPs = anti-colocated); W (wild card proteins/molecules variably associated with the L
and A molecules of CMPs). Bar: 10 µm.
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Figure 15: Fifteen most frequent CMPs in colon cancer. In this figure, each colour
represents one specific CMP with sub-cellular resolution. The left panel shows CMPs
superimposed on the phase contrast image; the right panel shows the same CMPs
superimposed on the corresponding DAPI fluorescence image showing the location of
cellular nuclei (white). Note the CMP coding list shown on the bottom of this figure with
(i) specification of molecules co-mapped by TIS (top line no.´s 1 – 21 of the list), (ii)
colour specification of CMPs, in which every CMP expresses a unique combinatorial
binary code (1 bit information per protein/molecule) corresponding to the colours in the
phase- and DAPI- images; (iii) CMP motifs (bottom line of the list). This CMP motif
represents the higher order organisation of the 15 different CMPs as a group with
features common to all CMPs described by a three symbol code. L, lead
protein/molecule (present in all CMPs); A (proteins/molecules which are absent in all
CMPs = anti-colocated); W (wild card proteins/molecules variably associated with the L
and A molecules of CMPs). Bar: 10 µm.
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Illustration of the 15 most frequent CMPs which are unique to colon cancer-
Figure 15 (not seen in the normal part of the same colon Figure 14; please see
above):
Interestingly, the majority of these abnormal CMPs are located near to the apical part of
the colonic epithelial cells and in the stroma of the colon tissue (in clear contrast to the
normal-unique CMPs, which are primarily located at the basolateral structures of the
colonic epithelium: see Figure 14). Note the extreme reduction of the number of
molecules combined per CMP as compared to the normal colon (Figure 15 and 14,
respectively). There is a cancer unique CMP motif with Ki 67 as lead protein, and a clear
indication of a disruption of cytoskeleton/membrane molecule-expressing CMPs, as
shown by the variably associated molecules 7-14 (W) in the motif, which is in striking
contrast to the normal CMP motif (from Figure 14).
Illustration of the 15 most frequent CMPs which are unique to normal colon in
Figure 14 (not seen in the cancerous part of the same colon in Figure 15):
In contrast to cancerous colon, the majority of the normal CMPs are located on the
basolateral part of the colonic epithelial cells, whereas the cancer-unique CMPs, are
largely located at the apical structures of the colonic epithelium (Figure 15). There is a
normal - unique CMP motif with 7 lead proteins (PCNA/ CD57/ CD166/ CK19/ CK20/
CyclinA/ Laminin). The presence of these putative cytoskeleton/membrane molecule
expressing CMPs, strongly supports the intact topology of cytoskeleton-membrane
molecule assemblies. Note striking contrast to the cancerous part of the colon (Figure
15).
Total number of “Cancer-unique”CMPs:
When all CMPs found in normal were subtracted from all of those found in cancer using
MoPPi, a total of 5708 cancer unique CMPs were identified and will be referred to as the
“cancer unique” motif in this paper (The full list is given in supplementary table 1). The
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15 most frequently appearing CMPs amongst the cancer unique group have already
been shown in Figure 15. In the cancer unique data set, we found a motif of 34 CMPs
(Shown in Figure 16 and tabulated in Table 2). All of these CMPs have the following
lead proteins: CD133, CD166, EpCAM, Muc-1, Laminin, CD57 and CK-20. Cells marked
by these CMPs also expressed Ki-67, PCNA, Bax, Bcl-2 and Cyclin-A, suggesting that
these might be proliferative. The cells marked by these 34 CMPs were mostly located
adjacent to the glandular epithelial cells. All the CMPs described by those lead proteins
were found to be peri-nuclear or slightly overlapping the respective nuclei. CD44 was
found to be a wild card protein and was seen to be co-existent with the rest of the lead
proteins in only 5 CMPs (range of frequency 28 – 1).
Figure 16 : 1st row; All 34 Cancer unique CMPs in phase (a) and DAPI (b) images, with
following lead proteins: CD133, CD166, EpCAM, CK-20 and Muc-1. Of note, these cells
also co-express Ki67, PCNA, Bax, Bcl-2 and Cyclin-A. 2nd row; CMPs in 1st row images
are magnified in phase (c) and DAPI (d) images.
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Normal unique CMPs:
Strikingly, the total number of CMPs, found in normal colon was nearly 5 times that
(32,009) present in cancer tissue (6813), (supplementary tables 2 and 3, included in
supplementary files only).The CMPs 1, 3, 4, 7, 8, 9 and 11 (table in figure 14), had 17 or
more different proteins co-expressed.
CMPs may identify specific subsets of cells:
All the CMPs with CD133, CD44, EpCAM and CD166 as the lead protein highlighted five
cells in the cancer tissue (Cells marked by black arrows in Figures 12, top row). The
uppermost three of these cells were found to be adjacent to the glandular epithelial cells
and the remainder were in the matrix. Removing CD133 from the CMP motifs (Figures
12c and 12d, middle row, marked by white arrows) results in the highlighting of only one
more cell (CMP colour = purple), suggesting that in most of these cells CD133 is co-
expressed with the other three proteins in cancer.
From the list of all CMPs in cancer (see supplementary table 3, in supplementary files
only), it was found that the cells marked by all the above protein clusters also co-express
Ki67.
Most glandular epithelial cells in colon cancer were found to co-express Ki67 and CK-20
(data not shown). However, when we looked at the co-expression of the cytokeratins
(CK-19 and CK-20) in cancer (Figures 11a and 11b), the motif showed a marked
decrease in cellular expression. The CMPs representing the cytokeratins were found to
be grossly disorganized and clumped in the peri-nuclear area in cancer cells.
Many more glandular cells in normal colon as compared to colon cancer express CMPs
with CK-19 and CK-20 as lead proteins. Moreover, when visualized on respective phase
and DAPI image (Figures 11c and 11d) backgrounds, the motifs with these lead proteins
are extremely crowded on the glandular epithelial cell surfaces as compared to the
cancer cells.
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In contrast to cancer tissue, only a few glandular epithelial cells showed CMPs co-
expressing CEA and CK-20 (data not shown). We have also examined CMPs that are
specifically expressed in stromal cells (Table 3 at the end of manuscript) and glandular
cells in colon cancer (Table 4 at the end of manuscript). We have found a motif of CMPs
which highlight the cells present in stroma in particular with very little expression in the
glandular epithelial cells. In this motif, the lead proteins were CD57, Laminin and PCNA.
The proteins CD29, CD36, CEA, CK-19, Muc2, Muc1 and NCAM were absent and
hence anti-co localised. Rest of the proteins were variably expressed (wild cards). In
contrast to stromal cells, the glandular cells mostly co-expressed EpCAM, CK-20 and
CEA as lead proteins with anti-co-localisation of CD44 and CD36. The rest of the
proteins were found to be variably expressed. We have also shown the expression of
these same proteins in normal colon in the form of three symbol code (Figure 13B).
Please note that in contrast to cancer tissue, proteins Ki67 and CK20 are variably
expressed (wild cards) in glandular cell motif in normal colon. The anti-colocalised
proteins are the same in both cases. These findings are shown in a schematic diagram
in Figure 13 above.
94
CHAPTER 4
1.5. GENERAL DISCUSSION AND FUTURE PROSPECTS
Colorectal cancer is characterised by uncontrolled growth of colorectal epithelial cells.
According to the theory of multistep carcinogenesis, colorectal epithelial cells
accumulate a number of molecular changes and eventually become fully malignant cells
through steps that has been discussed above. Genetic and epigenetic events during the
carcinogenesis process differ considerably from tumour to tumour. Thus, colorectal
cancer may be considered to be a conglomeration of heterogenous complex of diseases
with different sets of genetic and epigenetic alterations. Essentially, each tumour arises
and behaves in a unique fashion that is unlikely to be exactly recapitulated by any other
tumour. Therefore level of expression of different proteins in colon cancer varies widely
and has been extensively studied by different authors. Below we have discussed some
of these proteins which we have used in our study with Toponome Imaging System.
1.5.1. Colon cancer and related proteins:
CD133 (prominin-1) is a trans-membrane glycoprotein (120kDa, 865 amino acids),
encoded by a gene on chromosome 4 in humans (4p15.33). It has an N-terminal
extracellular domain and a intracellular segment composed of 59 amino acids, the two
connected by five trans-membrane domains with two extracellular loops414,415. It is
thought to play a role in organizing and maintaining the lipid composition of plasma
membrane of intestinal epithelial cells416. The significance of CD133 in the field of colon
cancer stem cell can broadly be in three fields.
 Its potential role in identifying stem cells from a group of several colon cancer cells,
which may be a step towards discovering a new stem cell bio-marker.
 Its functional significance in colon cancer, which is currently under much debate.
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 Its potential prognostic significance in colorectal cancer patients.
Reports from Marzesco and colleagues suggested that expression of CD133 in a cell
sustains its stem cell phenotype. As CD133 containing vesicles are released, the cell
becomes committed and starts differentiating417. Yin and colleagues produced a
monoclonal antibody, AC133, which identified a specific glycosylation-dependent
epitope of CD133418. Though, many human cell lines and differentiated cells express
CD133, its AC133 epitope is only expressed in stem or progenitor cells and not in
mature cells as the glycosylation status of a cell changes on maturation or malignant
transformation. Thus AC133 epitope may be a more specific marker for stem cells419.
According to the stem cell theory, cancers originate from normal stem cells or from cells,
which are their immediate descendants420. Independent reports published by two
research groups have confirmed the presence of such cancer initiating cells in human
colon expressing CD13337,38. Subcutaneous injection of immuno-deficient mice with
freshly isolated, CD133+, human colon cancer cells readily reproduced the original
tumour from which the cells were extracted. Interestingly, serial transplantation of these
CD133+ cells produced tumours which had similar phenotype but were much more
aggressive than their parent tumours. Floating undifferentiated CD133 + cell aggregates
called colon spheres resulted when colon cancer cells were cultivated in a proliferative
serum-free medium. Upon differentiation, these cells expressed high levels of colon
cancer specific marker, CDX2 and cytokeratin-20 (CK-20, a protein expressed in
differentiated gastric and intestinal epithelial cells) along with progressive down-
regulation of CD133 expression. Similar attempts with CD133- cells failed to induce
tumorigenesis in immuno-deficient mice. These experiments indicated that only
undifferentiated CD133+ cells (colon cancer stem cells) are capable of tumorigenesis37.
Reports from in vivo limiting dilution experiments by O’Brien and colleagues indicated
that on an average one cancer stem cell exists in every 262 CD133+ cells in a colorectal
tumour and in every 5.7 x 104 un-fractionated colon cancer cells38. Interestingly, these
cells retaining tumorigenicity in vitro were resistant to many chemotherapeutic
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drugs37,421. However, conflicting results have been published which shows that CD133 is
not only exclusive to colon cancer stem cells but also expressed in other colon cancer
cells (unable to replicate in xenograft host) along with a range of normal adult human
tissues like colonocytes, pancreatic ducts, proximal tubules in kidneys and lactiferous
ducts of mammary glands40,422.
Nikolova et al reported that proliferation of cord blood derived CD133+ cells are
exaggerated in culture media containing Wnt signalling factors (Wnt 1, Wnt 3a, Wnt 4,
Wnt 5a and Wnt 11) and is associated with increased expression of neural stem cell
marker nestin and endothelial cell surface markers (CD31 and von Willebrand factor).
Furthermore, cells grown in Wnt 3a containing media demonstrated a more
undifferentiated phenotype. This paper also reported that Wnt 5a induced expressions of
nuclear and cytoplasmic -catenin m-RNA and protein423. This evidence supports a
direct link between Wnt-catenin pathway and proliferation in cells expressing CD133.
Similar reports have established links between Hedgehog, Notch and BMP signalling
pathways with CD133 expressing cancer stem cells in human brain tumours424-426. The
significance of these morphogenetic signalling pathways in colon cancer has already
been discussed. These evidences point towards a functional basis for the expression of
CD133 in colon cancer stem cell.
Increased expression of CD133 in colon cancer tissue correlates well with low patient
survival 427,428. This has been supported by a recent publication showing increased
incidences of liver metastases in patients with high expression of CD133, both in the
primary cancer and the corresponding liver secondary. By gene knock-out studies the
authors demonstrated that CD133 has got no significant functional contribution to the
aggressiveness of colon cancer cells in vitro429. However, they failed to demonstrate the
expression of CD133 in normal colon, which differs from those of a previous report40.
Cell adhesion molecules (CAMs) are known to play significant roles in cell cycle, cell
migration, cell signalling, tissue regeneration and interaction between cell and the
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matrix. Thus they maintain tissue homeostasis. They are also involved in the
pathogenesis of cancers, inflammations and auto-immune diseases. The CAMs are
divided into 4 super-families: Cadherins, Selectins, Integrins and Immunoglobulin-CAM
(IgCAM). Apart from these four super-families there are also some other CAMs, which
do not share the characters of any specific family (eg. EpCAM)430. The first example
from CAMs playing active role in cancer metastasis came from the family of CD44.
Invasive cancer phenotype is often associated with loss of E-Cadherin431.
The cloning of CD166/ALCAM was described for the first time in 1995 (432). CD166 is a
trans-membrane glycoprotein (65kDa, 583 amino acids) and a member of IgCAM
superfamily. It has an intracellular cytoplasmic chain (of variable length), a
transmembrane domain and an extracellular component consisting of 2 distal variable
and 3 proximal constant Ig domains. The main functions of this protein are ligand
binding, cellular avidity and development. Ligand binding is related to the extracellular
domains and it is responsible for both homo and heterophilic cell-cell adhesion (ALCAM-
ALCAM and ALCAM-CD6 respectively). Developmental studies have revealed that
CD166 is mostly expressed in proliferating cells. Its normal tissue distribution in selected
epithelial cells, lymphoid and myeloid cells, bone marrow mesenchymal cells,
hepatocytes, pancreatic islets and acinar cells, cells of para-aortic mesoderm in
developing embryo supports this function. This protein has also been expressed in
several cancers like colorectal, breast, lung, prostrate and melanomas. Though its
function is somewhat similar to cadherins in terms of cell adhesion, interestingly, in
contrast to the later group, CD166 is found to be present and often induced in several
cancers, especially colorectal. This degree of induction may also co-relate with the
invasiveness of the respective cancers concerned433. Weichert et al established
connection between membranous expression of CD166 and shortened survival in
colonic adenocarcinoma434.
CD326/EpCAM is a type 1, glycoprotein (40kDa). Like other CAMs, it has extra cellular,
trans-membrane and intra cellular domains (ICD). Its distribution in fertilized egg,
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morula, embryonic stem cells and cells undergoing differentiation with concomitant
absence in terminally differentiated cells supports its role in embryogenesis and
differentiation. It promotes cellular proliferation, which is dependent on minimal growth
factors and in an anchorage independent manner. In keeping with this property, it is
over-expressed in carcinomas (except malignancies of mesodermal or ectodermal
origin). Its over-expression in pancreatic and colorectal cancer is associated with poor
prognosis and invasive/metastatic disease 435. It is a homotypic adhesion molecule and
antagonizes cadherin mediated cell-cell adhesion 436. The ICD fragment of EpCAM has
been implicated in well recognized cell membrane to nucleus signalling pathways,
however exact mechanisms are still un-clear. Munz et al demonstrated that inducible
expression of EpCAM can provoke expression of C-MYC and its target genes like Cyclin
E and Cyclin A437. Of note, products of both these genes are well recognized
proliferating factors. Therefore, induction of c-myc and its target genes may explain the
observation that, EpCAM expressing cells demonstrate rapid proliferation in an
anchorage independent manner and with a reduced requirement for growth factors437,438.
Maetzel and colleagues have demonstrated that ADAM17 (metalloprotease) and
secretase sequentially cleave EpCAM to produce its 5kDa ICD fragment. From these
in vitro experiments, the authors reported the presence of EpCAM–ICD fragment in
cytoplasm and nucleus of the experimental proliferating cells, which could be prevented
by using specific protease inhibitors in cell culture. They also found the existence of
these EpCAM–ICDs in nuclei of colon cancer cells in contrast to normal colonic cells439.
In a short review published in 2009 by Carpenter and Brewer440, EpCAM has been aptly
referred to as a “Surface to Nucleus Missile”. The mechanism by which EpCAM–ICD
induces proliferation of cells is thought to involve protein FLH-2 (four and half LIM
domain protein 2). Reports confirm the presence of EpCAM–ICD as an intranuclear (650
kDa) complex, which also includes FLH2, -Catenin and Left1/TCF. Exogenous addition
of EpCAM–ICD without EpCAM, also results in formation of this intranuclear complex
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with induction of c-myc and its target genes441. As discussed under the section of-
Catenin, Left1/TCF is a major regulator of c-myc expression. Based on these findings,
related to the significance of EpCAM–ICD and cleavage of membranous EpCAM by
proteases like (ADAM17 and secretase), EpCAM is being considered as a therapeutic
target in several cancers and currently several anti EpCAM agents are being used in
clinical trials442.
CD44/HCAM is a trans-membrane glycoprotein and is expressed as several iso-forms,
of which the commonest is the standard or haematopoietic form. All the isoforms
belonging to this family are encoded by a single gene on chromosome 11 in humans
and chromosome 2 in mice. CD44 isoform proteins are mostly expressed in cells of
neuro-ectodermal origin and are characterised by a constant region comprised of large
extracellular domain composed of 270 amino acids, trans-membrane region formed of
23 amino acids and an intra-cellular domain with 72 amino acids. These regions are
encoded by the first and the last 5 exons and account for the smallest but most
commonly expressed isoform, CD44s. A variable region, close to the transmembrane
region, is encoded by various combinations of exons 6–15 (v1–v10), giving rise to CD44
variant isoforms (CD44v). The N-terminal of the ectodomain in all isoforms is
characterised by a hyaluronic acid binding site. The ectodomain is extensively modified
by N- and O-glycosylations, which affect the HA binding ability of CD44 isoforms443.
Function of the HA binding domain in these protein molecules is dependent on the cells
concerned, for example, hyaluronic acid turnover by mesenchymal cells and “homing” of
leukocytes during inflammation444. The ectodomain of CD44v3 (an isoform of CD44) is
decorated with heparin sulphate, which enables it to bind growth factors like VEGF445.
The intracellular domain (ICD) of CD44 has a binding site for Ankyrin. and Ezrin-Radixin-
Moesin (ERM) proteins. Both of these interactions provide a link between CD44 and the
cell cytoskeleton. The ankyrin binding site is close to the domain of amino acids that
anchors ERM proteins to CD44. Phosphorylation of a serine residue at position 291,
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close to the ERM binding site, inhibits binding of ICD to ERM and thus influences CD44-
mediated directional cell motility446,447. CD44 proteins are known to play active role in cell
proliferation, differentiation, survival and motility. A CD44 protein isoform, containing the
exons v4–v7 was identified in a highly metastasizing rat pancreatic carcinoma cell line,
BSp73ASML. Interestingly, these specific variants of CD44, when transfected into
related BSp73AS cells with no metastatic potential, were found to confer the metastatic
potential to the later upon injection into syngeneic rats. Furthermore, CD44 exon v6-
specific antibody also blocked the metastasis in these cells. Animals treated with
metastatic cells BSpASv4–v7 with the CD44v6 antibody blocked lymph node and lung
metastases in them. This was the first major finding pointing towards an active role of
CD44 isoforms in cancer metastasis448,449. In human colon, expression of CD44s as well
as other variants is reported to be enhanced in adenomas and carcinomas. Expression
of CD44s, CD44v3, CD44v6 and CD44v8–v10 also correlates with bad prognosis and
advanced disease in patients450. In an in vivo murine breast cancer model, the HA
binding capacity of CD44 ectodomain was shown to promote metastasis and inhibit
apoptosis. CD44 – HA molecular aggregates were essential for binding MMP9 (Matrix
metalloprotease 9) to the cancer cell surface and induce the activity of MMP9. This in
turn, induced collagen IV degradation and subsequent invasion of these cancer cells.
Activated MMP9 on cancer cells also activated TGF leading to angiogenesis of cancer
tissue451,452. In an in vitro model, invasion of colon carcinoma cells was also found to be
dependent on CD44 binding to HA and on accumulation of HA in the matrix in peri-
cellular region. Invasion of these cells in matrigel was prevented by CD44 antibodies,
preventing CD44 – HA interaction and also by introducing an antisense construct
against 2 of the 3 human enzymes (HAS2 and 3) responsible for HA synthesis453.
CD44v6 and CD44v5 are up-regulated in gastric cancer and CD44v5 expression is
preferentially found in poorly differentiated carcinomas and metastatic lymph nodes.
Presence of CD44v3, v6, v7/8 in breast cancer correlates with more aggressive stages
of the disease454,455. Interestingly, CD44 has also been shown to interact with collagen,
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laminin, fibrinogen, chondoitin sulphate, fibronectin, serglycin / gp600, MHC Class II
(major histocompatibility complex class II) invariant chain, selectins (N-Selectin and E-
Selectin) and osteopontin (OPN). Osteopontin is a cytokine and is found to contribute to
metastasis in various cancers. OPN specifically binds to CD44v6, which leads to
enhanced cell motility and chemotaxis. In in vitro experimental model of hepatocellular
carcinoma, CD44 blocking antibody inhibited invasion of cancer cells, which was
induced by osteopontin456-458. CD44v6 has been tried as a target for anti-cancer therapy
in squamous cell carcinoma (SCC) in humans, where frequent and homogeneous
expression of this isoform was detected. A humanised version of an anti-CD44v6
antibody labelled with rhenium-186 was tested in patients suffering from head and neck
squamous cell carcinoma (HNSCC). Based upon the initial promising results,
bivatuzumab coupled with a non-radioactive cytotoxic drug, bivatuzumab mertansine,
was developed. Thirty patients were treated with this compound. This trial demonstrated
disease stabilisation and regression of tumour in 10% cases. Although an unfortunate
mortality in a patient in this cohort due to toxic epidermal necrolysis terminated this
project prematurely, CD44v6 and other isoforms still continue to be molecules of
potential interest for therapeutic modulation of different cancers431,459,460.
Cytoskeletal filaments are formed of Intermediate filament (IF) proteins, acting as their
building blocks. Depending on the amino acid sequence and structure of protein, IF
proteins are subdivided into 5 major types. Types I–IV IFs are cytoplasmic in location.
Cytokeratins (CK) are the largest subgroup of IF proteins and are included under type I
and type II or the acidic and basic CKs, respectively. They are functionally important in
maintaining normal epithelial architecture and physiology in cells. Desmin in muscle
tissue and Vimentin in mesenchymal cells are examples of type III IF. Type IV IFs
include neurofilament proteins in neuronal cells. Type V IF, the lamins, are nuclear in
location in contrast to the rest of the IFs. Several features distinguish cytokeratins from
other IF proteins461,462. First, cytokeratins are preferentially expressed in epithelial cells;
and second, they are obligate non-covalent hetero-polymers that include at least one of
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each type I and type II keratin462,463. However, the cytokeratins possess a similar
structural organization as compared to all other IF proteins. This includes a central
domain formed of coiled alpha-helix, flanked by non–alpha-helical head and tail
domains. These later non-alpha-helical domains contain most of the motifs that are
responsible for regulatory modifications like glycosylation and phosphorylation, resulting
in structural heterogeneity of the CKs462,464. The CKs which are predominantly
expressed in simple (single-layered) epithelial cells or simple epithelial keratins (SEKs)
consist of CK7, CK8, CK18, CK19, CK20, and CK23. Of these, types 7, 8, 18, 19 and 20
are expressed in normal gastrointestinal tract epithelial cells465. Simple epithelial cells
are commonly found in glands and organs involved in secretion and absorption. These
individual cells are often polarized, which suggests that the unique expression of SEKs
in these cells is likely to have significant functional significance in these cells466,467.
Among the cytokeratins, the most studied SEKs are CK8 and CK18468. Variable levels of
cytokeratin 7, 19 and 20 are also expressed in many simple epithelial cells. Adult
hepatocytes and proximal renal tubular cells express cytokeratin 8 and 18 exclusively, in
contrast to enterocytes, which manifest a complex distribution that depending upon the
stage of differentiation and specific cell type469,470. More recently identified, CK23 is
found to be expressed in pancreatic and colonic tumours471-473. CK8 and CK18 are found
in pseudo-stratified and urothelial epithelium, mostly in luminal cells. CK7 and CK19
serve as markers for ductal epithelial cells and are also found in gastrointestinal
epithelium. CK20 is expressed primarily in terminally differentiated enterocytes, gastric
epithelium, urothelial cells and neuroendocrine cells469. Under-expression of all four
isoforms of CK-19 and over expression of CK-20 has previously been shown to be a
feature of colon cancer474. Some cell types exhibit a polarized distribution of SEKs within
distinct sub cellular compartments. For example, cytokeratins 8 and 18 localize
preferentially within cytoplasmic filaments, whereas CK7 and CK19 are primarily found
in the apicolateral compartment in close proximity to the cell membrane475.Interestingly,
CK19 and CK20 were reported to be up regulated in pancreatic injury and incorporated
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into cytoplasmic filaments. This localization reverts to the typical apicolateral distribution
upon healing476. Stress conditions and different pathological changes can affect not only
keratin expression profiles, but also their expression levels and post translational
modification. For example, increased keratin phosphorylation is a marker of tissue injury
and disease progression in intestinal goblet cells in mouse and hepatocytes in human
and mouse models470,477. Multiple SEKs are generally expressed in an epithelial cell–
specific manner. This and the fact that cytokeratin expression profiles (but not their
levels) remain relatively stable even during neoplastic transformation explain why
cytokeratins are commonly used tumour markers. For distinguishing between tumours of
epithelial and non-epithelial cell origin, staining with a pan keratin–specific antibody has
been used widely. Metastases of specific tumours express certain specific cytokeratins.
Secondary hepato-cellular carcinomas typically express the variants 8 and 18, and
cholangio carcinomas express CK7 in addition to these above two cytokeratins. In
contrast, metastases of colorectal carcinomas are mostly found to express CK20, but
not CK7469,478,479. The expression pattern of different cytokeratins can also be useful in
predicting the prognosis in certain tumours. In colorectal carcinoma for instance, low
CK20 expression is encountered in carcinomas with high microsatellite instability, which
constitute a distinct 15% entity of these cancers and are associated with improved
survival compared with carcinomas with low microsatellite instability480. In breast cancer,
expression of cytokeratin 8 and 18 is associated with favourable prognosis, whereas in
breast cancers with CK5, CK14, and K17 the prognosis is relatively poor469,478. In the
normal bladder, expression of CK20 is confined to the superficial umbrella cells, and
also in non invasive transitional cell carcinoma. The persistence of this expression
pattern predicts that the tumour is unlikely to recur469. Several reports suggest a direct
beneficial impact of CK18 expression in breast cancers. For example, when this specific
variant of cytokeratin is experimentally down regulated in advanced and high-grade
tumours, its suppression directly correlates with shorter patient survival481. Similarly, in
vitro studies revealed that CK18 over expression in a breast cancer cell line led to
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reduced invasiveness of cancer cells and reduced tumorigenicity in nude mice models in
vivo482. Although additional evidence is needed in this field, it appears that SEK
expression levels may positively correlate with lower tumour invasiveness and SEKs
may be a potential therapeutic target for modulating cancers in near future483.
Mucins are high molecular weight glycoproteins, produced by epithelial cells. Mucin
molecules include an oligosaccharide motif attached to the threonine or serine residue of
its core protein backbone by O-glycosidic linkages. Mucins are classified into the
following484,485:
 Membrane-associated mucins (MUC1, MUC3, MUC4, MUC12, MUC16, and
MUC17),
 Gel forming secreted mucins (MUC2, MUC5AC, MUC5B, and MUC6), and
 Soluble secreted mucin (MUC7).
The epithelial membrane bound mucins are quite distinct from the classic extracellular
complex mucins secreted by goblet cells forming the mucous layers of the
gastrointestinal and respiratory tracts. These membrane associated mucins are in
reality, trans-membrane (TM) molecules, expressed by most of the glandular and ductal
epithelial cells486. They are characterised by an extensive extracellular domain, single
trans-membrane segment and a cytoplasmic tail. The extracellular portion of these
mucin molecules are composed of variable number of the tandem-repeat domain (TR
domain), sperm-protein, enterokinase and agrin domain (SEA domain) and epidermal
growth factor like domain (EGF-like domain). These TR domains are unique to mucins
and differentiate the mucins from all other membrane bound glycoprotein molecules.
The specific biochemical and biophysical properties of mucin molecules depends on the
extent and nature of glycosylation of the TR domains484,485,487. Mucins have been studied
extensively in relation to human cancers. Mucins have been reported to have complex
associations with various cellular pathways related to proliferation, and apoptosis488.
Transformation of fibroblasts and influencing tumorigenicity and metastatic potentials in
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various cancer cell lines by experimentally modulating up regulation and suppression of
MUC1 and 4 in vitro established this link in various scientific reports489-493. MUC1
undergoes aberrant glycosylation, is over expressed in 90% cases of breast cancer and
is frequently expressed in other human cancers like colorectal, pancreatic, hepato-
biliary, lung and ovarian494. In 1993 invasive ductal carcinoma of pancreas was reported
to express MUC1 (pan-epithelial type membrane-associated mucin) in contrast to MUC2
(intestinal type secreted mucin), the later being predominantly expressed in intraductal
papillary mucinous pancreatic neoplasm with indolent biological behaviour495. This and
several other subsequent reports from other human solid tumours (mainly pancreatic
and hepato-biliary) led to the conclusion that expressions of MUC1 and MUC4
independently correlated with more invasive forms of tumours with worse prognosis, in
sharp contrast to MUC2, which was mainly found in tumours which were primarily non-
invasive and had a better outcome496-506. MUC4 expression has been found to carry a
poor prognosis for lung adenocarcinoma507. MUC16, also known as CA-125 is used as a
tumour marker for ovarian cancer. It is the largest membrane bound mucin508. In a
patient comparison study of mucin expression profiles, in between invasive intra-hepatic
cholangio-carcinoma (ICC) with poor prognosis and non invasive mucin producing bile
duct tumour (MPBDT) with a favourable outcome, MUC1 was predominantly found at
the cell apex, lateral cell membrane, cytoplasm, and in luminal contents of the ICC cells.
On long term follow up, these cancers demonstrated aggressive lymphatic permeation
and peri-neural invasion. In sharp contrast to these findings, MUC2 was located in the
cytoplasm of MPBDT cells only. All these cancers were characterised by less aggressive
lymphatic metastases and no peri-neural invasion509. A similar study studying mucin
expression in 136 gastric cancer patients, reported that MUC1 and MUC2 expressions
were independently related to worse and favourable outcomes respectively500. MUC1
has been reported to serve as a natural ligand for galectin-3 in human cancer cells.
Interaction in between cancer cell associated MUC1 and circulating galectin-3 enhances
adhesion between endothelial surface and cancer cells, thereby promoting
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metastasis510.The cytoplasmic tail of MUC1 consists of 69 amino acids and includes
several serine, tyrosine and threonine phosphorylation sites which are potential regions
for interaction and activation of proteins associated with proliferation and suppression of
apoptosis508,511,512. Previously we have discussed the significance of MEK / ERK kinases
and -catenin in the morphogenetic pathways associated in colon cancer. Through
interacting with and subsequently activating ErbB1 growth factor, MUC1 activates ERK 1
and 2513,514. MUC1 has also been found to regulate ERK signalling by modulating the
transcription of genes encoding for MEK-1, c-jun and Raf-1, by an ErbB-independent
pathway515. Interaction of MUC1 with FGFR3 (Fibroblast growth factor receptor 3)
induces tyrosin phosphorylation of the cytoplasmic tail of MUC1. This in turn, enhances
binding between MUC1 and -catenin and the transportation of the later in the nucleus.
MUC1 also inhibits GSK3β-mediated phosphorylation and degradation of β-catenin and 
thus increases its cytoplasmic and nuclear levels. As previously stated, nuclear β-
catenin acts as a transcriptional co-activator and increases the expression of genes
related to proliferation like, cyclin-D1 and c-myc516,517. MUC1 promotes cell proliferation
in breast cancer cell lines (in vitro) by interacting with and stabilizing estrogen receptor α 
(ERα) and also stimulating ERα mediated transcription of growth factors and apoptosis 
inhibitors. This interaction and stabilization is induced by estrogen515,518. Recent reports
suggest that MUC1 confers protection against oxidative stress induced cell death. This it
does by regulating p53-responsive genes. As previously discussed, activation of p53
target genes promotes induction of apoptosis or a growth arrest and repair response.
MUC1 selectively down regulates transcription of genes responsible for apoptosis by
directly binding to the p53 regulatory domain519. In addition, MUC1 also induces anti-
apoptotic Bcl-XL and PI3K/Akt pathways520. FGF1 induces tyrosine phosphorylation of
the cytoplasmic tail of MUC1 and facilitates the binding of MUC1 to the heat shock
protein (HSP) 90, finally targeting the cytoplasmic tail fragment of MUC1 to the
mitochondria516. This interaction between MUC1 cytoplasmic tail and mitochondria is
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associated with the attenuation of stress-induced release of mitochondrial pro-apoptotic
factors, activation of caspase-3, and finally leading to cell death521. This suggests that by
interacting with HSP90, MUC1-cytoplasmic tail transduces signals from the cell
membrane to mitochondria, activating the intrinsic apoptotic pathway in response to
stress516. Activated cytoplasmic c-Abl binds to cytosolic 14-3-3 proteins and translocates
into the nucleus, where it activates MEK kinase-1 and thereby activates the pro-
apoptotic c-Jun N-terminal kinase (JNK) pathway522,523. Raina and colleagues have
shown that MUC1 blocks this nuclear transfer of c-Abl and thus the apoptotic response
to genotoxic anticancer agents is blocked524. Ahmad et al reported that MUC1 interacts
with the IκB kinase complex, increasing the phosphorylation and degradation of IκBα, 
thus promoting the activation of nuclear factor-κB (NF- κB)525. The role of pro-
carcinogenic role of NF- κB has already been discussed before. MUC1 also binds 
directly to caspase-8 and FADD, blocks recruitment of caspase-8 to the death-inducing
signaling complex and thereby directly prevents activation of the extrinsic apoptotic
pathway526. The functional significance of this interaction in normal epithelial cells is a
protective mechanism, inhibiting unnecessary caspase-8 activation. However, malignant
cells exploit this phenomenon for survival under adverse conditions by over-expressing
MUC1527.
1.5.2. TIS analysis of single section of colon cancer and its comparison to
corresponding normal colon.
In the “proof of concept section” we aimed to confirm, for the first time, that the novel TIS
platform could be successfully employed to investigate the architecture of a complex
protein system in colon cancer in situ. Our first specific goal was to confirm that unique
CMP patterns could be identified using TIS that correlate with and may illustrate certain
key cellular biological features, as has been previously suggested for prostate cancer379.
Ultimately, we hope that this preliminary study will act as a foundation for a full scale
toponome study of colon cancer. The protocols, techniques and initial observations
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presented here can readily be exploited now in larger scale validation and functional
studies in vivo and in vitro. Here we have developed and optimised the TIS platform and
then have presented the results of comparing a colon cancer tissue section with a
matched control normal tissue taken from the same patient (some 10 cm away from the
cancer), in order to minimise any inter- individual variation in protein expression.
Absence of cancer in the control sample was confirmed by examining of H&E stained
sections and further confirmed by a pathologist experienced in colorectal cancer.
Following TIS imaging, protein co-localisation patterns (Combinatorial molecular
phenotypes- CMPs) were identified in both cancer and normal sections and then
compared by proprietary image-analysis software (MoPPi). CMPs are groups of pixels or
voxels, signifying the localization of given protein clusters in a tissue section195,373. It is
important to note that unlike regions of expression of a single protein epitope, CMPs
represent areas of individual cells or structures, in which more than 1 protein is
expressed, in very close proximity (within 1-2 pixels) to one another. Although, this does
not prove that such proteins are physically interacting, the repeated finding of CMPs
comprising particular proteins, when combined with anatomical observations of the
cells/sub cellular compartments involved, can allow such a hypothesis to be generated.
This provides a further new way for unravelling functional protein networks in systems
biology approaches, because unlike most existing ‘Omics’ techniques, anatomical and
spatial data are not lost as a consequence of the analysis. In a given combination of
CMPs, proteins which exist or are entirely absent in all the clusters are termed as “lead
proteins” (L) and “anti-colocalised” (A) proteins respectively. The rest of the proteins are
variably expressed (present in some and absent in others) and are termed as “wild card”
(W) proteins. A combination of CMPs thus can have one or more lead proteins or anti
colocalised proteins and several wild card proteins, depending upon the number of
protein tags used in the experiment. Such a combination of CMPs expressing a common
feature is a “CMP motif”. Most importantly, the grouping of CMPs into motifs with lead
proteins reveals, for the first time, the functional structure of protein systems in situ, in
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which the interaction of proteins within and between different CMPs is hierarchically
controlled by the lead protein(s), as demonstrated for Rhabdomyosarcoma cells371,372.
Blockade of a cell surface lead protein leads to disassembly of the corresponding
network of interlocked protein clusters and loss of function (transition of the spherical cell
to the exploratory state preceding migration / metastasis, APOCON model).
One of the key findings in this study has been the identification of multiple high
frequency unique CMPs for both ‘cancer’ and ‘normal’. The top 15 unique CMPs for
each are shown in figures 15 and 14 respectively. Importantly, these CMPs correlate not
only with normal and cancer but also seem to illustrate cellular biological differences
apparent visually between the conditions, namely the different localisation sub-cellularly
of the CMPs and also the link with cytoskeletal disruption in the cancer (see also Figure
11). This lends weight to the application of methodologies like TIS to pathological states
where protein expression changes can be powerfully linked to histo-pathological
/cytological behaviours/changes visible under light microscopy. This is inherently very
different to the situation pertaining to many ‘omics’ techniques where
disruption/destruction of the tissue of origin precludes any such simultaneous combined
analyses of anatomy and molecular phenotype.
Our data clearly shows that in cancer, as compared to normal colon, the cell
cytoskeleton system (marked by combination of CK19 and CK20) is grossly disrupted
(Figure 11, see above in results section). Intermediate filaments are seen mostly
clumped around the respective nuclei. In comparison to cancer, normal glandular cells
show a more evenly distributed cell cytoskeleton system. Though cells in both the
cancer and normal tissue expressed CEA (mostly at the apical cell surfaces) and CK-20,
we found a higher number of CMP motifs containing both CEA and CK-20 in the
glandular epithelium of colon cancer as compared to normal colon. This is important, as
our results are consistent with those of other researchers408,528. As discussed above,
cytokeratins are intermediate filaments and are important in maintaining normal
epithelial architecture and physiology in cells. Few specific cytokeratins (types 7, 8, 18,
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19 and 20) are expressed in normal gastrointestinal tract epithelial cells465. Under-
expression of all four isoforms of CK-19 and over expression of CK-20 has previously
been shown in colon cancer474, and supports our own observations that CK20-CEA
combination motifs are more and CK19-CK20 less frequent in colon cancer CMPs. We
have also identified motifs that appear to distinguish neoplastic glandular and stromal
cells (Figure 13, see above in results section). In this figure, the proteins indicated by
numbers highlighted by red in the centre are lead proteins, those in the outer circle
highlighted by yellow are absent from the CMPs and the rest are variably expressed
(expressed in some and absent in other CMPs or wild card proteins).
Overall, 5708 unique CMPs were identified in cancer from patient A (complete CMP list
is shown in supplementary table), and which were absent in normal colon. The degree of
combinatorics per data point was found to be much higher for normal colon from the
same patient as compared to cancer. Thus, a far greater number of CMPs were found in
normal and this is exemplified by seven busy CMPs from the most frequent in normal
colon (CMPs 1, 3, 4, 7, 8, 9 and 11 shown in the table in figure 14), which show that
nearly 17 different proteins were co-expressed in different combinations in all of them.
However, as these CMPs are largely localised to normal glandular epithelial cells and
are totally absent from cancer glandular epithelium, it is possible that these CMPs are in
some way inhibited by the process of carcinogenesis.
Although, still contentious, a large body of evidence suggests that colon cancer may be
driven by a side population of putative colon cancer stem cells (CCSC). CCSC represent
a small number of cells within the cancer, but are held to be essential for proliferation
and maintaining the cancer mass529,530. In the last decade, numerous potential protein
markers for CCSCs have been described. However, despite progress, none of these
markers, individually or in low level combinations, have proved to be cancer-specific and
are found, though maybe with reduced frequency, also in normal colon 38-39. Thus, to
date, no unique cancer stem cell protein signature has been described. However, some
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very important predictions can be made, based on the wealth of important existing
studies in this area. Thus, CCSCs are predicted to:
 Be located adjacent to epithelial cells.
 Express, amongst others, combinations of CD133, CD166, EpCAM, and CD44
on the cell surface.
 Express replication markers.
 Express additional markers essential for their unambiguous recognition and
characterisation.
With this in mind, in this study, we have identified a small subset of colon cancer cells
(five cells in total in the entire visual field), by use of specific CMP motifs with CD133,
CD44, EpCAM and CD166 as lead proteins (figures 12a and 12b, please refer to results
section). A further single cell was identified by presence of CD44, EpCAM and CD166
as lead proteins without CD133 (figure 12c and 12d, results section). Given, that these
cells also express replication markers and are completely absent from the normal colon,
these findings are entirely consistent with the predictions about putative CCSCs. There
are some interesting points to emphasise here and which strengthen the likely relevance
of the results, in particular the confirmation of previous observations from the literature.
In brief, of all cancer unique CMPs: 2317 CMPs contained CD133, 1103 contained
CD133 plus CD166 and 262 contained CD133 with CD44 as lead proteins and only 100,
with all 3. Moreover, a higher degree of correlation exists between expressions of
CD133 together with CD166 as compared to CD44. Interestingly, much of this is
consistent with the existing literature, which suggests that CD133 is not always co-
expressed with other stem cell markers39, and that expression of both CD133 and
CD166 is poorly correlated with expression of CD44 in colon cancer patients531. Many of
the cells identified by stem cell marker protein containing CMPs in this study, also carry
CMPs containing replication markers such as Ki67, PCNA, and Cyclin A, suggesting that
they might be actively proliferating cells. This is also consistent with findings of previous
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studies37,39,529,532. Our current findings also support the view that the search for stem
cells may best be undertaken by employing a battery of markers, because single
markers (for example CD133)2, 40 or even a low level combination of markers39.
However, lack of functional studies makes it difficult to confirm the same. These
intriguing findings are subject of further studies by our team at Warwick. First, we will
have to test the hypotheses generated here in a large cohort of colon cancer patients
and second we will aim to exploit cell surface TIS signatures described here to isolate
such cells by FACS or other allied techniques for functional study in future.
Our findings in this study also revealed that if a search for stem cells is performed by a
single marker (for example CD133) or even by a group of few markers, this is likely to
locate many nonspecific cells both in cancer and normal (data not shown). This finding
supports the results of Shmelkov et al, who clearly demonstrated that CD133 is
expressed not only by cancer stem cells but also by other cancer cells not possessing
any stem cell property40.
TIS analysis of colon cancer is a potential way to unearth huge data in stem cell
research. Though lack of functional studies is a potential drawback with TIS, this system
allows us to investigate intact tissue sections and identify the presence or absence of
thousands of protein clusters in a single cell, implications of which are numerous. There
are several future possibilities, aside from application of increasing numbers of different
antibody libraries to allow ever more detailed molecular phenotyping of colon cancer
cells. By combining the unique strengths of both TIS and of mass spectrometry based
proteomics will be a very powerful one. The strength of TIS is the higher resolution, the
ability to examine combinatorial protein expression at the cell surface and also the
complete preservation of anatomical information. The strength of MS-based techniques,
amongst others, lies in the ability to discover relevant new or previously unsuspected
proteins in a given system.
Many more sections are being studied and extensive Toponomic database is being
created. This is of extreme significance as any future work in this line can be compared
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against this data set. Although, most of the experiments performed in last 2 years failed
due to reasons of problems associated with imaging (in at least one or more visual fields
of the entire data set), malfunctioning antibodies supplied by companies (may be related
to the conditions to which they were subject while transfer from these companies to our
lab), artefacts in tissue sections and custom made antibodies (discussed in optimisation
section), extensive work is under way at Warwick to overcome these hurdles. A probable
solution may be to create an in house system of FITC conjugation and generating
antibodies for these experiments. Metastatic colon cancer in other sources (example
omentum, liver, lymph nodes, lung, etc) can also be analysed by TIS. Colocalisation of
similar motifs in cancer and metastases in omentum or other secondary sites from same
patients and their absence in respective normal colon tissue may further strengthen the
stem cell theory of cancer origin. This project however would need further ethics
committee approval and funding. Colon cancer has been shown to arise in colon
affected by ulcerative colitis533. Therefore projects comparing colon with ulcerative colitis
and cancer can contribute significant information to the scientific community in this
respect.
We have the potential to increase our antibody library. Our project involved optimisation
of several antibodies used for the first time in TIS for human colon. Most of these
antibodies were custom made for this purpose. The resulting cost implication was a
potential limitation to the size of antibody library in our current project. This can be
addressed by entering into industrial collaborations with companies to increase the
supply of primarily conjugated antibodies. A relatively inexpensive alternative exists in
setting up an in house conjugation unit as mentioned above, which can substantially
reduce the expenditure and can ensure a ready supply of antibodies. However, this
involves funding and employing full time technicians for this pupose.
Project involving software modification is currently underway in Magdeburg, where
MoPPi software is being improved to work faster and automatically generate toponome
maps as soon as the TIS runs are over. Automated binarising of net fluorescence
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images is also a potential project in this field. An important hindrance in this aspect is the
luminal micro particles and foreign bodies in colon which often result in false fluorescent
signals and needs to be excluded from the final data sets. A similar in house project at
Warwick University is currently under way. In this project the data images undergo
registration and segmentation, followed by which the DAPI images are primarily used to
generate the data. The aim of this project is to assess the TIS results with improved
software which will provide quantitative information on the proteins expressed (shown as
a graph) based on the level of fluorescence signals from the respective tags. However,
this method will only be applicable when the antibodies and their concentrations used
are fixed for every run being compared and thus needs further optimisation for
respective tissue sections.
In-vivo and in-vitro experiments, functional studies: TIS project in cancer research can
be taken a step further by introducing in-vivo and in-vitro experiments along with. The
clusters thought to be significant in sections of cancer or diseased tissue (for example
CMPs signifying stem cell subset) can be blocked in-vivo or in-vitro. The results from
such blocking action can be further assessed by TIS analysis of cells from cultures (in-
vitro) or biopsy material from animal models (in-vivo). It goes without saying that these
results have serious implications in future therapeutic modulation.
To conclude, TIS is a novel technique which can reveal several important facts about the
cellular biology of colon cancer and potentially also about different subsets of cancer
cells, including potentially the elusive CCSC. It may help reveal much about protein
interactions, identification of lead proteins, and most importantly TIS is a technique that
can optically resolve the structure of cancer specific protein systems with direct
implications for the hierarchical functions/dysfunctions of proteins. A fixed section can
withstand a TIS run for at least 2 weeks and hence experiments using vast numbers of
antibody tags are technically possible and would provide us with tens of thousands of
CMPs372. These findings provide the rationale for a colon cancer toponome project on a
proteome wide scale.
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2. Published data and Ethics approval
A major portion of this thesis has been published in 2010 as a scientific publication by
our group in Journal of Proteome Research. This publication is cited in Pubmed as
follows:
Toponome imaging system: in situ protein network mapping in normal and cancerous colon from
the same patient reveals more than five-thousand cancer specific protein clusters and their
subcellular annotation by using a three symbol code.
Bhattacharya S, Mathew G, Ruban E, Epstein DB, Krusche A, Hillert R, Schubert W, Khan M.J
Proteome Res. 2010 Dec 3;9(12):6112-25. Epub 2010 Oct 28.PMID:20822185
A portion of the introduction section on relationship in between fatty acid metabolism and
colon cancer has also been published as an independent review article by our group and
cited in pubmed as follows:
15-lipoxygenase-1 in colorectal cancer: a review.
Bhattacharya S, Mathew G, Jayne DG, Pelengaris S, Khan M.
Tumour Biol. 2009;30(4):185-99. Epub 2009 Sep 10. Review.PMID:19752603
Ethics committee approval for research
The approval for this research has been granted by the Warwickshire Local Research
Ethics Committee, Warwickshire, UK. The research has been performed in Biological
Sciences Laboratory, University of Warwick, Coventry, UK. The human tissue has been
collected from operative samples at the George Eliot Hospital, Nuneaton, UK.
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Molecule/ Moiety
recognised
Official
symbol Cellular expression / Known Function
Position
in TIS
CD44 CD44
CD44 or HCAM (Homing cell adhesion molecule) is a cell-surface glycoprotein
involved in cell-cell interactions, cell adhesion and migration. This protein
participates in a wide variety of cellular functions including lymphocyte activation,
recirculation and homing, hematopoiesis, and tumor metastasis. [Homo sapiens ]
4
Cyclin D1 CCND1
This cyclin forms a complex with and functions as a regulatory subunit of CDK4
or CDK6 (CDK Kinase), whose activity is required for cell cycle G1/S transition.
Mutations, amplification and overexpression of this gene, which alters cell cycle
progression, are observed frequently in a variety of tumors and may contribute to
tumorigenesis. [Homo sapiens ]
5
Cytokeratin-20 KRT20
The keratins are intermediate filament proteins responsible for the structural
integrity of epithelial cells. This cytokeratin is a major cellular protein of mature
enterocytes and goblet cells and is specifically expressed in the gastric and
intestinal mucosa. It is known to be over-expressed in colon adenocarcinoma as
compared to normal colon. [Homo sapiens ]
6
EpCAM EpCAM
Epithelial cell adhesion molecule is expressed on most normal epithelial cells and
gastrointestinal carcinomas and functions as a homotypic calcium-independent cell
adhesion molecule. The antigen is being used as a target for immunotherapy
treatment of human carcinomas.[Homo sapiens ]
7
Cyclin A CCNA2
This cyclin is expressed in all tissues tested. It binds and activates CDC2 or CDK2
kinases, and thus promotes both cell cycle G1/S and G2/M transitions. [Homo
sapiens ]
8
Table 1: MELK/TIS tag library.
CD166 ALCAM
Activated leukocyte cell adhesion molecule is a trans-membrane glycoprotein. The
main functions of this protein are ligand binding, cellular avidity and development.
It is found in selected epithelial cells, lymphoid and myeloid cells, bone marrow
mesenchymal cells, hepatocytes, pancreatic islets and acinar cells, developing
embryo, several cancers like colorectal, breast, lung, prostrate and melanomas. Its
degree of induction co-relates with the invasiveness of the respective cancers.
[Homo sapiens ]
9
Cytokeratin-19 KRT19
This smallest known acidic cytokeratin is not paired with a basic cytokeratin in
epithelial cells. It is specifically expressed in the periderm, the transiently
superficial layer that envelopes the developing epidermis. [Homo sapiens ]
10
Ki-67 MKI67 It is a nuclear protein that is associated with and may be necessary for cellularproliferation. [Homo sapiens ]
11
Mucin-1 MUC3A
It is an epithelial glycoprotein, which is secreted and some of it is membrane
bound. Each of its genes contain at least one large domain of tandemly repeated
sequence that encodes the peptide sequence rich in serine and/or threonine
residues, which carries most of the O-linked glycosylation. [Homo sapiens ]
12
Carcino
Embryonic
Antigen
CEA
This is a glycoprotein, with a series of Ig like domains. Its normal tissue
distribution includes columnar epithelial cells and goblet cells in colon, mucous
cells in stomach, squamous epithelium of tongue, esophagus and cervix and
prostate. It is used clinically as a tumour marker for colorectal cancer. It is also
elevated in cirrhosis, biliary obstruction and hepatitis. Highest levels are
encountered in hepatic metastases from colon cancer. [Homo sapiens ]
13
CD133 PROM1
Prominin-1 is a pentaspan transmembrane glycoprotein. The protein localizes to
membrane protrusions and is often expressed on adult stem cells, where it is
thought to function in maintaining stem cell properties by suppressing
differentiation. [Homo sapiens ]
14
Mucin-2 MUC2
It forms an insoluble mucous barrier that protects the gut lumen. The protein
polymerizes into a gel of which 80% is composed of oligosaccharide side chains by
weight. The protein features a central domain containing tandem repeats rich in
threonine and proline that varies between 50 and 115 copies in different
individuals. [Homo sapiens ]
15
Laminin LAMB1
It is an extracellular matrix glycoprotein and the major noncollagenous constituent
of basement membranes. It is implicated in wide variety of biological processes
including cell adhesion, differentiation, migration, signaling, neurite outgrowth and
metastasis. [Homo sapiens ]
17
PCNA PCNA
Proliferating cell nuclear antigen is found in the nucleus and is a cofactor of DNA
polymerase delta. It acts as a homotrimer and promotes DNA replication. In
response to DNA damage, this protein is ubiquitinated and is involved in the
RAD6-dependent DNA repair pathway. [Homo sapiens ]
18
Bcl-2 BCL2
It is an integral outer mitochondrial membrane protein that blocks the apoptotic
death of some cells such as lymphocytes. It is over expressed in various cancers.
[Homo sapiens ]
19
NCAM NCAM1
Neural cell adhesion molecule is a major cell adhesion molecule found in several
differentiated cells. It mediates adhesion between neurones and also between
neurones and muscles. [Homo sapiens ]
20
Bax BAX
This protein functions as an apoptotic activator. It interacts with, and increases the
opening of, the mitochondrial voltage-dependent anion channel (VDAC), which
leads to the release of cytochrome c. The expression of this gene is regulated by the
tumor suppressor P53 and has been shown to be involved in P53-mediated
apoptosis. [Homo sapiens ]
21
CD29 ITGB1
Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes
MDF2, MSK12) is expressed by all leukocytes and forms heterodimers with many
integrin R subunits which mediate cell-cell and cell-matrix adhesion. [Homo
sapiens ]
22
CD36 CD36
It is a major glycoprotein on the platelet surface and serves as a receptor for
thrombospondin in platelets and various cell lines. It binds to collagen,
thrombospondin, anionic phospholipids and oxidized LDL. [Homo sapiens ]
23
CD57 CD57
This glycoprotein is expressed normally in haematopoietic cells (Natural killer
cells or NK cells and CD8 positive T lymphocytes), neuro-ectodermal cells, neuro
endocrine cells, striated muscles and epithelium of prostate. It is possibly related to
cell-cell interaction. Laminin, P-selectin and N-selectin are its natural ligands.
Binding to the last two initiates rolling of leucocytes on endothelium and activated
platelets. [Homo sapiens ]
24
4,6’-diamidino-2-
phenylindole DAPI
4,6’-diamidino-2-phenylindole (DAPI) is an intercalating agent. It is a fluorescent
molecule and has been used to stain DNA nucleic acids.
25
List of molecular cell components labelled in this study (column 1) together with their locus link annotations (column 2 and 3)
and their respective positions in the cycle (column 4). Column 3 describes the known cellular expressions and functions of the
corresponding protein markers, illustrating the rationale behind their selection in this study. Note that all the protein tags were
conjugated to FITC in our experiments. DAPI was used on its own at the end of the experiment to tag the nuclei.
Table 2 PCNA Bax Bcl2 CD29 CD36 CD44 CD57 CD133 CD166 CEA CK19 CK20 CyclinA CyclinD1 DAPI EpCAM Ki67 Laminin Muc2 Muc1 NCAM Freq. Colour codes
1 1 1 0 0 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 0 469
1 1 1 0 1 0 1 1 1 0 1 1 1 0 1 1 1 1 1 1 0 382
1 1 1 0 1 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 0 158
1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 114
1 1 1 0 0 0 1 1 1 1 1 1 1 0 0 1 1 1 0 1 0 102
1 1 1 0 0 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 0 92
1 1 1 0 1 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 0 89
1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 69
1 1 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 58
1 1 1 0 1 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 0 52
1 1 1 0 0 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 0 47
1 1 1 0 1 1 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 28
1 1 1 0 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 27
1 1 1 1 0 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 22
1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 0 1 1 20
1 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16
1 1 1 0 1 0 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 15
1 1 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 15
1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 14
1 1 1 0 0 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 11
1 1 1 0 0 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 10
1 1 1 0 1 0 1 1 1 0 1 1 1 0 0 1 1 1 1 1 1 8
1 1 1 1 0 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 6
1 1 1 0 1 0 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 5
1 1 1 0 1 0 1 1 1 0 1 1 1 0 1 1 1 1 0 1 1 5
1 1 1 0 0 0 1 1 1 0 1 1 1 0 0 1 1 1 1 1 1 5
1 1 1 1 0 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 4
1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 3
1 1 1 0 0 0 1 1 1 0 1 1 1 0 1 1 1 1 0 1 1 3
1 1 1 0 0 0 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 3
1 1 1 0 0 1 1 1 1 0 1 1 1 0 0 1 1 1 0 1 1 2
1 1 1 0 1 1 1 1 1 0 1 1 1 0 1 1 1 1 0 1 0 2
1 1 1 0 0 1 1 1 1 0 1 1 1 0 1 1 1 1 1 1 0 1
1 1 1 1 0 0 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 1

Table 3 PCNA Bax Bcl2 CD29 CD36 CD44 CD57 CD133 CD166 CEA CK19 CK20 CyclinA CyclinD1 DAPI EpCAM Ki67 Laminin Muc2 Muc1 NCAM Freq. Colour codes
1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 5012
1 0 1 0 0 1 1 0 0 0 0 0 1 1 0 0 1 1 0 0 0 2387
1 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 1 1 0 0 0 2187
1 1 1 0 0 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 0 2057
1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1787
1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 0 1738
1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1228
1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1189
1 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1075
1 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 1049
1 1 1 0 0 0 1 1 0 0 0 1 0 0 0 0 1 1 0 0 0 1049
1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 988
1 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 918
1 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 762
1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 728
1 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 1 1 0 0 0 705
1 0 1 0 0 0 1 0 1 0 0 0 0 0 1 0 1 1 0 0 0 658
1 1 1 0 0 0 1 0 0 0 0 1 0 0 1 0 1 1 0 0 0 529
1 0 1 0 0 0 1 1 0 0 0 1 0 0 0 0 1 1 0 0 0 468
1 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 0 459
1 1 1 0 0 0 1 0 1 0 0 1 0 0 0 0 1 1 0 0 0 561
1 0 1 0 0 0 1 1 0 0 0 0 0 0 1 0 1 1 0 0 0 417
1 1 1 0 0 0 1 1 1 0 0 1 0 0 0 0 1 1 0 0 0 405
1 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 1 0 0 0 396
1 0 1 0 0 0 1 1 0 0 0 1 0 0 1 0 1 1 0 0 0 392
Table 4 PCNA Bax Bcl2 CD29 CD36 CD44 CD57 CD133 CD166 CEA CK19 CK20 CyclinA CyclinD1 DAPI EpCAM Ki67 Laminin Muc2 Muc1 NCAM Freq. Colour Codes
1 1 1 0 0 0 1 1 1 1 1 1 0 0 0 1 1 1 1 1 0 1230
1 1 1 0 0 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 0 1200
0 1 1 0 0 0 1 1 1 1 1 1 0 0 0 1 1 1 1 1 0 492
0 1 1 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 1 1 0 479
1 1 1 0 0 0 1 0 0 1 1 1 0 0 0 1 1 1 1 1 0 469
1 1 1 1 0 0 1 0 1 1 0 1 1 1 0 1 1 1 1 1 1 446
1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 425
1 1 1 0 0 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 0 362
1 1 1 1 0 0 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 231
0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 1 1 0 1 0 0 209
1 1 1 0 0 0 1 0 1 1 1 1 0 0 0 1 1 1 0 1 0 192
1 1 1 0 0 0 1 1 1 1 1 1 0 0 0 1 1 1 0 1 0 183
1 1 1 0 0 0 1 0 0 1 1 1 0 0 0 1 1 1 0 1 0 182
0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 1 1 0 0 1 0 139
1 1 1 0 0 0 1 0 0 1 0 1 0 0 0 1 1 1 0 1 0 130
1 1 1 0 0 0 1 1 1 1 1 1 1 0 0 1 1 1 0 1 0 117
0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 1 1 0 0 1 0 114
1 1 1 0 0 0 1 0 1 1 0 1 0 0 0 1 1 1 0 1 0 113
0 0 0 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 0 110
1 1 1 0 0 0 1 1 1 1 1 1 0 0 0 1 1 1 0 0 0 104
1 1 1 0 0 0 1 0 1 1 1 1 0 0 0 1 1 1 0 0 0 104
0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 1 1 0 0 0 0 102
0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 1 1 0 0 0 0 101
0 0 1 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 0 101
0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 1 1 0 0 0 0 92
0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 1 1 1 0 0 0 92
0 0 1 0 0 0 1 0 1 1 1 1 0 0 0 1 1 1 0 0 0 92
0 0 0 0 0 0 1 0 1 1 1 1 0 0 0 1 1 0 0 0 0 89
0 1 0 0 0 0 0 1 1 1 1 1 0 0 0 1 1 0 0 0 0 86
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